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To accommodate the semi-allogeneic fetus, a state of maternal immune tolerance to paternally-derived 
conceptus alloantigens is required. Tolerance is initially established when the same antigens are 
contacted following seminal fluid exposure, and increases in tolerogenic CD4+Foxp3+ T regulatory 
(Treg) cells are elicited. Clinical studies demonstrate the importance of seminal fluid contact in human 
pregnancy, where pathologies of pregnancy including preeclampsia are more likely with a short period 
of sexual cohabitation. Despite the pivotal role of Treg cells in pregnancy, the factors which regulate 
their response are yet to be fully understood. In this thesis, we describe experiments using mouse 
models that investigate regulators of the Treg cell pool and their impact on pregnancy success.  
Initially, we examined the contribution of number of seminal fluid exposures to Treg cell generation. Our 
data demonstrate that repeated exposure to the same male alloantigens strengthens the Treg cell pool, 
and increases its stability. These changes were not observed after repeated mating to syngeneic males 
or following switching from syngeneic to allogeneic partners. Changes to the Treg cell population was 
also linked with greater resistance to inflammatory challenge in mid-gestation. These findings may 
provide a mechanistic explanation for clinical observations linking long-term seminal fluid exposure in 
women with improved outcomes of pregnancy.   
We then assessed the contribution of a number of key immune regulatory factors on the female Treg 
cell response in early pregnancy. Prominent among the tolerance-inducing cytokines is IL10, which 
protects against fetal loss and alters key immune cells in early gestation including Treg cells. In this 
study we demonstrate that maternal as opposed to fetal IL10 deficiency causes increases susceptibility 
to fetal loss following inflammatory challenge in mid-gestation. The transcriptome of Treg cells is altered 
in IL10 deficiency with increased Ctse (cathepsin E), Il1r1, Il12rb2 and Ifng. These findings highlight the 
pivotal contribution of maternal IL10 in facilitating robust Treg cell generation and immune protection of 
the fetus from inflammatory challenge. 
Recent studies demonstrate that microRNAs (miRNA) also play a role in Treg cell generation. miR-155 
and miR-223 are both regulated by seminal fluid following coitus and are postulated to play important 
roles in the peri-conception immune environment. Using mir-155 null mutant mice, we demonstrate that 
miR-155 deficiency substantially alters the local Treg cell and antigen presenting cell populations after 
mating. Using mir-223 null mice, we demonstrate that miR-223 also contributes to the peri-conception 
immune environment with alterations to the Treg cell and antigen presenting cell populations after 
mating. Furthermore, deficiency in either miR-155 or miR-223 increases susceptibility to fetal loss 
following pro-inflammatory challenge in mid-gestation. These findings indicate that both miR-155 and 
 
XI 
miR-223 have pivotal roles in establishing the appropriate maternal immune environment during the 
peri-conception period, and in activating sufficient immune tolerance to protect against inflammatory 
challenge in later gestation. 
Collectively, these data build understanding of key factors contributing to Treg cell generation and 
function in the peri-conception environment. The findings may be beneficial in informing new 
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conception” and “miRNA Regulation of Immune Tolerance in Early Pregnancy”. For full detail of the 
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1.1 Introduction 
Preeclampsia and related hypertensive disorders of pregnancy are major contributors to fetal and 
maternal morbidity and mortality in the world (Steegers et al., 2010). Preeclampsia affects 5-8% of all 
pregnancies and leads to approximately 60,000 maternal deaths and 500,000 perinatal deaths annually 
(WHO, 2005). The pathophysiological origin of preeclampsia remains unclear, but it is suggested that 
the peri-conception phase of pregnancy is important, particularly for the early onset category of 
preeclampsia. Implantation is the time when maternal immune disturbances can contribute to disruption 
of placental development (Redman and Sargent, 2010). Compromised placental development is 
characterised by insufficient remodelling of spiral arteries and defects of maternal uterine blood flow 
(Huppertz, 2008, Redman and Sargent, 2010, Steegers et al., 2010). Inadequate immune adaptation for 
gestation also contributes to the inflammatory responses characteristic of preeclampsia (Redman and 
Sargent, 2010, Sibai et al., 2005).  
As half of the fetal genes are derived from the father, the fetus is considered as semi-allogeneic and so 
can be recognised by maternal immune system as ‘non-self’. The maternal immune system clearly 
recognises and responses to fetal antigens, and adaptive immune tolerance towards paternally-derived 
transplantation antigens must be induced for protection from gestational disorders (Aluvihare et al., 
2004, Trowsdale and Betz, 2006). A key element of maternal immune adaptation for pregnancy is the T 
regulatory (Treg) cell population, which supports embryo implantation (Aluvihare et al., 2004, Robertson 
et al., 2009a). Treg cells prevent rejection of the fetus, suppress detrimental inflammation and facilitate 
matermal vessel remodelling to allow sufficient trophoblast invasion and access to maternal blood 
supply (Nevers et al., 2011). Therefore, it is critical to identify the factors that determine the quality of 
the Treg cell response, including activation and expansion of the Treg cell pool, and Treg cell stability 
and suppressive function, are these will be crucial for pregnancy success.  
The mechanisms regulating the Treg cell responses are not fully understood. It is known that the 
cytokine milieu is critical for Treg cell activation, differentiation and proliferation. Various cytokines are 
implicated in promoting Treg cells and suppressing generation of Th1 immune responses to limit 
inflammation in the gestational tissues (Lin et al., 1993, Munoz-Suano et al., 2011, Szekeres-Bartho et 
al., 2009). Amongst these cytokines, interleukin 10 (IL10) has potent anti-inflammatory properties. IL10 
is produced by a range of different types of cells, including T cells, B cells, macrophages, dendritic cells 
(DCs) as well as Treg cells (Annacker et al., 2001).  
Previous studies in mice have demonstrated that the seminal fluid delivered at mating influences the 
immune environment to promote expansion of the Treg cell pool before implantation (Robertson et al., 
2009a). It has been identified that seminal fluid provides antigens and cytokines that act to influence the 
phenotypes of antigen presenting cells, stimulate Treg cell populations, and to induce chemokines that 
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recruit Treg cells into the endometrium. Clinical observations have revealed that seminal fluid contact 
may protect women from developing preeclampsia. Studies by Dekker and Robillard (Dekker et al., 
1998) and several others (Kho et al., 2009, Einarsson et al., 2003, Klonoff-Cohen et al., 1989) have 
reported that preeclampsia is more common in nulliparous women, women who have a new male 
partner, or when there has been lack of exposure to the conceiving partner’s seminal fluid before 
conception. The increased incidence of preeclampsia is linked with short duration of sexual cohabitation 
with the conceiving partner, the use of barrier methods of contraception, or when donor gametes are 
used in in vitro fertilisation treatment (Dekker et al., 1998, Einarsson et al., 2003, Kho et al., 2009, 
Klonoff-Cohen et al., 1989, Salha et al., 1999). These observations raise the question of how the male 
partner contributes to preeclampsia and whether Treg cells and seminal fluid are involved.  
There is growing evidence showing that microRNAs (miRNAs) play important roles in the immune 
response, which suggests they may contribute to immune adaptation to pregnancy. Two miRNAs that 
appear to regulate Treg cell response are miR-155 and miR-223. miR-155 has been shown to regulate 
Treg cell pool expansion (Kohlhaas et al., 2009, Stahl et al., 2009). While miRNAs act directly in Treg 
cells, they can also regulate the antigen-presenting cells that are required to generate Treg cells. In 
particular, miRNAs regulate the phenotype and function of DCs which play important roles in mediating 
tolerance through controlling Treg cell responses. miR-223 is also thought to be important in 
macrophage and DC function (Johnnidis et al., 2008). However, there are no studies focusing on the 
relationship between miR-155 or miR-223 and Treg cell responses during early pregnancy.  
This chapter will discuss the critical factors that facilitate generation of stable Treg cells in order to 
establish and maintain immune tolerance for embryo implantation and ongoing pregnancy success. This 
chapter will also summarise current understanding of the factors and cytokines that regulate the 
abundance and stability of Treg cells in early pregnancy in both human and mice.  
1.2 Maternal immune tolerance 
In 1953, Sir Peter Medawar questioned the paradoxical immunological relationship between the mother 
and the fetus. He asked “How does the pregnant mother contrive to nourish within itself, for many weeks 
or months, a fetus that is an antigenically foreign body?" (Medawar, 1953). He proposed three possible 
mechanisms by which maternal immune tolerance may be established: 1) the fetus is anatomically 
separated from the mother; 2) the fetus is antigenically immature; and 3) the mother is immunologically 
indolent or inert. These ideas have guided research in reproductive immunology for more than 50 years 
(Billington, 2003).  
Over more than 60 years of study, it has been revealed that Sir Medawar’s hypotheses are incorrect. 
Rather than being suppressed, the maternal immune system is activated during pregnancy - it 
recognises the fetal antigens with T and B cell responses, and when behaving correctly, it facilitates 
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pregnancy success (Chaouat, 2007, Zhou and Mellor, 1998, Chaouat and Kolb, 1985, Kiger et al., 1985, 
Tafuri et al., 1995). Fetal cells are found in the maternal circulation during the first and second trimester 
(Herzenberg et al., 1979, Walknowska et al., 1969), indicating that the fetus is not anatomically 
separated from the mother. The antigenicity of placental trophoblast is reduced, with attenuated 
expression of major histocompatibility complex (MHC) genes, however transplantation antigens are 
clearly expressed (Fernandez et al., 1999). In addition, women can produce antibodies, as well as 
lymphocytes which react against fetal human leukocyte antigens (HLA) (Hunt et al., 2003, Van Rood et 
al., 1958, Tilburgs et al., 2009), indicating that the maternal immune system is not indolent or inert, but 
is actively responsive to the presence of fetal alloantigens.  
Recent studies have confirmed that activated T cells reactive with fetal HLA can be found in the 
peripheral blood and decidua of pregnant women (Tilburgs et al., 2009, van Kampen et al., 2001). 
Studies in mice with transgenic T cells that specifically recognise fetal antigens also indicate that the 
maternal immune system is aware of conceptus antigens from the time of conception (Moldenhauer et 
al., 2010). It is clear that maternal T cell-mediated immune responses to the semi-allogeneic fetus are 
activated in pregnancy. Skewing the T cell response from effector-mediated rejection towards Treg  
cell-mediated tolerance, is critical for the fetus to survive. The quality of the T cell response is most 
important at implantation when the conceptus first encounters maternal immune cells at implantation 
(Trowsdale and Betz, 2006).  
Seminal fluid is involved in the initial activation phase of the maternal immune adaptation for pregnancy, 
by providing paternal alloantigens and cytokines to drive the expansion of a T cell response that 
includes Treg cells (Robertson et al., 2009a, Robertson et al., 2009b) which are crucial in establishing 
maternal immune tolerance in readiness for implantation (Aluvihare et al., 2004, Shima et al., 2010). 
The importance of seminal fluid will be discussed in 1.3.  
1.2.1 T helper cell paradigms  
To address how T cell activation can support embryo implantation and maintain the progress of 
placental development, it is important to understand the different phenotypes of T cells. Generally, T 
helper cells (Th cells) are characterised as Th1, Th2, Th17 effector cells, or Treg cells. Th1 cells are 
identified by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, 
and can produce pro-inflammatory cytokines including interferon-γ (IFN-γ) and tumour necrosis factor 
(TNF). In contrast, Th2 cells are characterised by the transcription factor GATA-3 and STAT6 and also 
the production of anti-inflammatory cytokines such as IL4, IL5 and IL13. Th17 cells are also  
pro-inflammatory and play a pivotal role in autoimmune disease pathogenesis and allograft rejection 
(Crome et al., 2010, Peck and Mellins, 2010).  
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Treg cells are generally defined as CD4+CD25+ T cells expressing the unique intracellular marker, 
Forkhead box P3 (Foxp3). Treg cells regulate the generation and effector function of Th1, Th2 and Th17 
cells (Rudensky, 2011). The differentiation of Th1 and Th2 cells are generally considered as irreversible, 
but in contrast, Th17 and Treg cells exhibit phenotypic plasticity and can switch between the two 
phenotypes when micro-environmental conditions change (Zhou et al., 2009).   
1.2.2 Regulatory T cells  
Treg cells are 5-10% of peripheral blood CD4+ T cells in rodents and only 1-3% of CD4+ T cells in 
humans (Sakaguchi, 2000, Shevach, 2002). Sakaguchi and colleagues were the first to identify Treg 
cells as a unique subtype of T lymphocytes (Sakaguchi et al., 1995). Treg cells suppress autoreactive 
immune responses to prevent autoimmune diseases and are involved in suppression of allograft 
rejection (Sakaguchi et al., 1995). Null mutation in the master Treg cell transcription factor Foxp3 results 
in a fatal lymphoproliferative disorder in mice, which indicates the pivotal role of Treg cells in the 
regulation of inflammation and immune tolerance (Brunkow et al., 2001). In the last 10 years, Treg cells 
have been shown to be crucial in the establishment and maintenance of maternal immune tolerance in 
both human and mice (Aluvihare et al., 2004, Zenclussen et al., 2005, Heikkinen et al., 2004, Saito et al., 
2005).   
There are two distinct pathways by which Treg cells are generated. Treg cells can differentiate in the 
thymus in response to self-antigens, or in the periphery in response to various antigens including foreign, 
exogenously-derived antigens, or developmental or tissue-specific antigens not expressed in the 
thymus (See section 1.2.2.1). 
1.2.2.1 Treg cell ontogeny 
Two distinct origins and pathways of generation of Treg cells exist, based on the tissue in which they 
originate, their target antigens and their suppressive functions. Both are crucial in mediating tolerance 
towards endogenous non-pathogenic antigens and foreign but benign antigens normally in contact with 
the body. Firstly thymic Treg cells (tTreg cells) differentiate in the thymus via a selective process based 
on expression of specific T cell receptors (TCRs) (Fontenot et al., 2005). Secondly, Treg cells can be 
induced from the peripheral T cell pool (so-called ‘peripheral’ or ‘inducible’ Treg cells) which are 
generated in the periphery (Lee et al., 2011).   
1.2.2.1.1 Treg cell differentiation in the thymus 
The development of T cells in the thymus is determined by different avidities for self-antigens of TCRs. 
The thymus is the organ that ‘educates’ immature T cell populations before their release into the 
periphery. A serial selection sequence involving neglect, positive and negative selection and processes 
based on interactions between naïve T cells and the thymic epithelial cells, results in a pool of surviving 
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T cells. Failure to interact with self-antigens presented by MHC molecules on the thymic epithelial cells 
results in apoptosis of T cells (neglect). T cells with a high avidity between their TCR and MHC are 
positively selected and these T cells with excess reactivity to self-antigens undergo apoptosis (negative 
selection) (McCaughtry and Hogquist, 2008, Palmer and Naeher, 2009, Siggs et al., 2006).   
The generation of tTreg cells is believed to be the result of T cells that ‘escape’ from negative selection. 
When the TCR/MHC affinity of the naive T cells is just weaker than the threshold to induce negative 
selection and also with a relatively high affinity for self-antigen amongst cells that pass positive selection, 
Treg cells differentiate (Jordan et al., 2001). As tTreg cells are generated largely based on their 
reactivity to self-antigen, tTreg cells are considered to exert protection from a range of autoimmune 
diseases (Sakaguchi, 2005).  
1.2.2.1.2 Treg cell generation in the periphery 
Treg cells can also differentiate from pathways independent of the thymus. Studies have revealed that 
peripheral Treg cells (pTreg cells) are generated in the periphery to maintain the Treg cell population 
(Cozzo et al., 2005, Seddon and Mason, 1999). Recent studies clearly demonstrate the requirement of 
pTreg cells in maintaining immune tolerance. By using a TCR transgenic mouse model, oral 
administration of antigens results in induction of antigen specific Treg cells, which protect mice from 
experimental asthma (Mucida et al., 2005). These pTreg cells are anergic and suppressive both in vivo 
and in vitro (Mucida et al., 2005). Neonatal adoptive transfer of splenocytes containing tTreg cells can 
successfully rescue Foxp3-deficient mice (Haribhai et al., 2011). Supplementation by either tTreg cells 
or pTreg cells alone fails to rescue Foxp3 deficient mice, however, Foxp3-deficient mice receiving both 
tTreg and pTreg cells in combination exhibit a less severe inflammatory bowel disease and lower serum 
concentrations of TNF-α, IFN-γ and IL17 (Haribhai et al., 2011). Acute depletion of pTreg cells in the 
rescued mice results in inflammation and weight loss (Haribhai et al., 2011). These data suggest that 
pTreg cells are necessary to establish tolerance to the full range of self-antigens in the periphery. 
pTreg cells generated with affinities for antigens not expressed in the thymus expand TCR diversity 
specific for peripheral tissue antigens. Thus, the immune system can regulate responses against 
antigens that are foreign to self, and protect the body from aggressive or inappropriate responses. In the 
reproductive setting, pTreg cells with affinities for paternal alloantigens allow the maternal immune 
system to tolerate antigens absent from the thymus but associated with the developing fetus. It is also 
possible that tTreg cells contribute, as many T cells generated in the thymus have responsiveness to 
alloantigens (Sakaguchi et al., 2008) 
1.2.2.2 Interactions between dendritic cells and Treg cells  
Like other types of T cells, Treg cells require interaction with antigens to achieve proliferation and full 
suppressive activity (Samy et al., 2006). Antigen presenting cells, such as DCs, are required to convert 
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naïve CD4+ T cells to Treg cells and are also involved in the regulation of expansion and activation of 
resting Treg cells (Rutella et al., 2006). This is also the case in pregnancy. Local depletion of uterine 
DCs on gestational day 3.5 in mice results in a reduced implantation rate, suggesting that dendritic cell 
functions taking place before implantation are crucial to enable successful placental development (Plaks 
et al., 2008).  
The outcome of T cell and DC interaction is determined by the functional phenotype of DCs, reflected in 
the surface expression of CD80/86 and the specific DC cytokine profile. To convert naïve CD4+ T cells 
and expand pre-existing Treg cells, antigens must be presented by specific subsets of dendritic cells 
with tolerogenic properties (tDCs) (Manicassamy and Pulendran, 2011, Sharma et al., 2007b, Steinman 
et al., 2003). tDCs arise when DCs are differentiated in a cytokine milieu dominated by  granulocyte 
macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), 
transforming growth factor-β (TGF-β), IL10 and IL4 (Rutella et al., 2006, Steinman et al., 2003). tDCs 
are characterized as immature or semi-mature DC which do not express IL12 and express limited levels 
of co-stimulatory molecules CD80 and CD86 as well as pro-tolerogenic molecules programmed death 
ligand-1, immunoglobulin-like transcript 3, immunoglobulin-like transcript 4 and indoleamine  
2,3-dioxygenase (IDO) (Cella et al., 1997, Probst et al., 2005, Smits et al., 2005, Steinman et al., 2003). 
Treg cell generation relies on the presentation of cognate antigens by tDCs, and therefore, Treg cell 
generation, proliferation and differentiation is clonally specific to the antigens presented (Yamazaki et al., 
2006). These antigens may include paternal alloantigens, or minor histocompatibility antigens from the 
fetus or placenta.  
Treg cells can be converted from naïve CD4+ T cells, or activated from pre-existing Treg cells by tDCs 
(Munn et al., 2002, Steinman et al., 2003). It has been shown that IDO activates mature Treg cells in 
tumour-draining lymph nodes in mice (Sharma et al., 2007b). After adoptive transfer of IDO+ DCs into 
non-tumour bearing mice, resting Treg cells in the host were activated, in an IDO-dependent manner 
(Sharma et al., 2007b). Further evidence for the importance of IDO can be seen with an 8-fold increase 
in Foxp3 mRNA in murine CD4+ T cells co-cultured with IDO+ DCs at 3-6 days (Fallarino et al., 2006), 
indicating that IDO+ DCs are capable of converting CD4+ T cells into Treg cells. TGF-β is  
anti-inflammatory (Gorelik and Flavell, 2002, Sakaguchi, 2000, Shevach, 2002) and appears to be 
essential for the generation of Treg cells via indirect effects on DCs (Ghiringhelli et al., 2005b) and direct 
effect on expression of the signature transcription factor Foxp3 in Treg cells (Chen et al., 2003).  
Anti-inflammatory cytokine conditions are essential in converting naive T cells into Treg cells, rather 
than Th1, Th2 or Th17 cells. The activated Treg cells secrete TGF-β and IL10, which maintain the 
tolerogenic properties of tDCs (Sharma et al., 2007b), and suppress detrimental immune responses 
from being induced. This reactive loop between Treg cells and tDCs can be altered by infection or 
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inflammation, when pro-inflammatory cytokines, bacterial lipopolysaccharide (LPS) or other Toll-like 
receptor (TLR) ligands induce DC maturation, skewing the phenotypes of Treg cells into Th1 and Th17 
immunity (Manicassamy and Pulendran, 2011).  
1.2.2.3 Mechanisms of Treg cell-mediated suppression 
There are a number of ways that Treg cells act to suppress the immune system. Treg cell-mediated 
suppression can be via cell-cell contact (direct) or modulating the maturation and function of DCs 
(indirect), or in a contact-independent manner (Shevach, 2009). 
The best-defined mechanism by which Treg cells exert suppression is to inhibit IL2 production by other 
types of T lymphocytes. Once CD4+ T effector cells are activated via TCR, IL2 and other pro-
inflammatory cytokines are rapidly produced. The proliferation activity of CD4+CD25- T cells is 
significantly reduced after co-culture with CD4+CD25+ T cells via inhibiting IL2 production in 
CD4+CD25- T cells (Takahashi et al., 1998, Thornton and Shevach, 1998). As IL2 is critical for survival 
and activation of T cells, by limiting production of IL2, Treg cells can suppress the proliferation of T 
effector cells.  
Other studies have revealed that IL2 is also critical in maintaining Treg cell function, as IL2 deficient and 
IL2 receptor deficient mice develop systemic and lethal autoimmune disease (Sadlack et al., 1993, 
Schorle et al., 1991, Suzuki et al., 1997, Willerford et al., 1995). As Treg cells constitutively express 
CD25 (IL2 receptor), therefore, another proposed mechanism of Treg cell suppression is to compete 
with other T cells for IL2 and limit the availability of the cytokine (Pandiyan et al., 2007). The T effector 
cells are deprived of IL2 and undergo apoptosis in a Bim-dependent manner (Pandiyan et al., 2007). 
Whether Treg cells in gestational tissues inhibit IL2 production of T effector cells or compete with local T 
cells for IL2 requires more studies to clarify.  
Treg cells also modify the function of antigen presenting cells, including macrophages and DCs (Misra 
et al., 2004, Taams et al., 2005). The core Treg cell suppressive function is mediated via expression of 
cytotoxic T lymphocyte–associated molecule 4 (CTLA-4). The critical role of CTLA-4 in Treg cell 
suppressive function has been demonstrated using CTLA-4 specific blocking antibody and Treg-specific 
Ctla-4 deficient mice (Liu et al., 2001, Wing et al., 2008). Ctla-4 deficient mice show spontaneous 
lymphoproliferation including an elevated Treg cell proportion amongst CD4+ T cells, increased Treg 
cell numbers. Despite this, fetal autoimmune disease was observed (Wing et al., 2008). Binding of 
CTLA-4 results in the down-regulation of costimulatory molecules CD80 and CD86 on antigen 
presenting cells (Cederbom et al., 2000, Sakaguchi et al., 2009b, Oderup et al., 2006), which remain 
down-regulated even in the presence of stimuli which would normally elevate CD80/86 expression 
(Cederbom et al., 2000). In addition, binding of CTLA-4 to CD80/86 results in upregulation of IDO 
(Belladonna et al., 2007), which provokes the development of Treg cells.  
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In addition to modification of CD80/86 expression on antigen presenting cells, Treg cells may modify the 
capacity of DC to induce pro-inflammatory responses. Lymphocyte activation gene-3 (LAG-3) expressed 
by Treg cells binds to MHCII on antigen presenting cells which inhibits DC activation during Treg:DC 
interactions (Liang et al., 2008), and therefore suppresses pro-inflammatory responses. LAG-3 depletion 
by antibody administration diminishes the suppressive function of Treg cells in vitro and in vivo, and 
Treg cells from LAG-3 deficient mice exhibit reduced suppressive capacity (Huang et al., 2004). Taken 
together, these observations show a reciprocal interaction between tDCs and Treg cells; Specific tDC 
surface markers regulate Treg cell generation, while Treg cells can suppress pro-inflammatory immune 
responses via regulating antigen presenting cell phenotypes and maturation.  
As well as the cell-cell contact mechanisms mediating suppression, a contact-independent suppression 
can be achieved by Treg cell release of inhibitory cytokines such as TGF-β and IL10 as well as IL35 
(Collison et al., 2009, Collison et al., 2007, Sakaguchi et al., 2009a). TGF-β deficient mice develop 
autoimmune disease and also have a diminished number of Treg cells (Huber et al., 2004, Kulkarni et 
al., 1993, Shull et al., 1992). Administration of neutralising antibody against TGF-β results in attenuated 
suppressive activity in both human and mice (Strauss et al., 2007, Fahlen et al., 2005). TGF-β is 
expressed in a transmembrane form that is important for Treg cell suppressive activity in both human 
and mice (Ghiringhelli et al., 2005a, Nakamura et al., 2004). The transmembrane form of TGF-β may be 
involved in the regulation of differentiation of other T cells into Treg-like cells (Fahlen et al., 2005, 
Andersson et al., 2008). 
The immune-inhibitory function of IL10 has been well studied. IL10 deficient mice develop autoimmune 
disease, in particular colitis (Berg et al., 1996, Kuhn et al., 1993a). In an adoptive transfer model, 
administration of neutralising antibody against IL10 resulted in rejection of allografts (Hara et al., 2001, 
Kingsley et al., 2002). The relationship between IL10 and Treg cells is discussed further in section 1.6.  
IL35, the new member of the IL12 family, has also been shown to be inhibitory and required for the 
maximal suppressive activity (Collison et al., 2007). Ectopic expression of IL35 induced regulatory 
activity on naïve T cells, and recombinant IL35 treatment suppresses T-cell proliferation in vitro (Collison 
et al., 2007). 
1.2.3 Treg cell response during normal pregnancy 
1.2.3.1 Treg cell responses in human pregnancy 
Several studies have focused on lymphocyte subpopulations during pregnancy in humans. Sasaki and 
colleagues have shown that CD4+CD25+ Treg cells are increased in both decidua and peripheral blood 
during early pregnancy (Sasaki et al., 2004). Other studies also demonstrate this systemic elevation of 
Treg cells in the first trimester, with a peak in the second trimester followed by a reduction in the third 
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trimester and further decline after successful labour in normal pregnant women (Saito et al., 2005, 
Heikkinen et al., 2004, Tilburgs et al., 2006, Xiong et al., 2013).  
In addition, the suppressive function of the Treg cell population in pregnancy has been demonstrated in 
vitro. Isolated peripheral CD4+CD25+ T cells from normal pregnant women are enriched with a higher 
expression of Foxp3 mRNA, compared with CD4+CD25- T cells (Somerset et al., 2004). These Treg 
cells suppress the proliferation of autologous CD4+CD25- T cells in response to dendritic cells 
(Somerset et al., 2004). Moreover, the densities of Treg cells were greater in the decidua compared with 
peripheral blood, indicating the importance of not only expansion of Treg cells in the periphery, but also 
their recruitment to the uterus (Sasaki et al., 2004, Tilburgs et al., 2006).  
Furthermore, the reduction of Treg cells in the third trimester suggests that Treg cell loss might be 
involved in the process of parturition at term. Women who undergo a spontaneous vaginal delivery have 
a lower proportion of decidual CD4+CD25+ T cells, compared with those who undergo a caesarean 
section (Sindram-Trujillo et al., 2004). In women, the percentage of peripheral Treg cells declines 
towards the end of pregnancy, accompanied by an elevation of activated T cells, and a sharp increase 
of activated T cells in term labour (Zhao et al., 2007). A recent study also demonstrated that the 
suppressive activity of Treg cells is diminished towards the end of pregnancy in both term and pre-term 
labour (Kisielewicz et al., 2010), indicating that Treg cell demise or conversion to T effector cells may be 
involved in the initiation of labour.  
1.2.3.2 Treg cell responses in rodent pregnancy 
Similar changes in the immune cell profile are observed in rodent pregnancies with system expansion of 
Treg cells (Aluvihare et al., 2004, Zhao et al., 2007). Treg cells are expanded in spleen, inguinal lymph 
nodes, iliac lymph nodes and blood of female mice on gestational day 10.5 after allogeneic mating 
(female mated to MHC disparate males) (Aluvihare et al., 2004). Treg cells increase systemically on day 
7.5 postcoitum (DPC), and in the peripheral blood reached a peak on DPC 7.5, followed by a reduction 
to non-pregnant levels just before labour (Zhao et al., 2007). Expansion of the Treg cell compartment 
has been observed on DPC 3.5 in the uterus draining lymph nodes (PALN) of female mice after 
allogeneic mating (Robertson et al., 2009a). An increase Treg cell number is also seen in the mouse 
uterus on DPC 3.5 where Treg cells are required to exert suppressive function at implantation (Guerin et 
al., 2011).  
Using rodent models, the importance of Treg cells in regulating the maternal immune environment in 
pregnancy has been addressed. By using an adoptive transfer model, the crucial role of Treg cells was 
identified in mice. T cells depleted of CD4+CD25+ Treg cells or complete T cells from normal pregnant 
mice were adoptively transferred into pregnant T cell deficient mice. The allogeneic fetuses were 
completely rejected in the absence of Treg cells amongst the transferred population, however, no fetal 
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rejection was found in syngeneic pregnancies (no MHC disparity between male and female mice) 
(Aluvihare et al., 2004). In vivo depletion of CD25+ cells resulted in a similar fetal rejection in mice 
(Darrasse-Jeze et al., 2006). When anti-CD25 monoclonal antibody PC61 was administrated to deplete 
CD25+ cells from female mice after allogeneic mating, fewer fetuses survived to term, while in 
syngeneic mating, there was no change in reduced fetal survival rate (Darrasse-Jeze et al., 2006).  
Other studies have utilised anti-CD25 monoclonal antibody to deplete CD25+ cells at or prior to 
implantation, and confirm that this results in a pregnancy failure in allogeneic pregnancy but not 
syngeneic pregnancy in mice (Zenclussen et al., 2005, Shima et al., 2010), indicating that paternal 
alloantigen specific Treg cells are pivotal for successful implantation. In the abortion-prone CBA/J x 
DBA/2 mouse model, adoptive transfer of Treg cells from CBA/J females mated with Balb/c males into 
CBA/J female mice mated with DBA/2 males before implantation (between DPC 0 to DPC 2) caused a 
reduction in fetal loss as well as increased expression of decidual Foxp3. Treg cells must be previously 
exposed to antigen to exert suppressive function, as donor Treg cells from virgin mice are ineffective. 
Moreover, Treg cells transfer after the day of implantation is ineffective (Zenclussen et al., 2005), 
indicating that sufficient Treg cells must be present at the time of implantation in order to protect the 
embryo as trophoblast cells first commence invasion (Zenclussen et al., 2005), indicating that sufficient 
Treg cells are most important prior to and at the time of implantation. Depletion of Treg cells in the  
pre-implantation period caused failure of implantation in all allogeneically-mated female mice, but did 
not interfere with pregnancy when treatment occurred in mid- or late-gestation (Shima et al., 2010). 
Taken together, these studies indicate that paternal antigen-specific Treg cells are crucial in supporting 
fetal implantation. Therefore, it is essential to define the factors that regulate the size of the Treg cell 
population or Treg cell suppressive function or stability during pregnancy.  
1.3 Role of seminal fluid in immune priming for pregnancy 
1.3.1 Composition of seminal fluid  
Seminal fluid is a complex biological fluid that contains spermatozoa, seminal plasma, male alloantigens 
and soluble factors with immune-regulatory functions. Male alloantigens, such as MHC are expressed 
on human sperm cell precursors and mature gametes, and also can be found in seminal plasma in 
soluble form. Experiments in mice show male alloantigens can be presented by antigen presenting cells 
recruited to the female uterine endometrium after insemination (Robertson et al., 1996).  
One of the soluble factors in seminal fluid is TGF-β. High amounts of TGF-β1 and TGF-β3 are found in 
seminal plasma of mouse, human and many mammalian species, with a lower amount of TGF-β2 
(Lokeshwar and Block, 1992, Nocera and Chu, 1993, O'Leary et al., 2011, Srivastava et al., 1996, 
Tremellen et al., 1998). Another highly abundant immune-regulatory factor, prostaglandin, is detected in 
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humans (Templeton et al., 1978), other primates (Kelly et al., 1976) and some mammalian species 
(Claus et al., 1992, Oliw et al., 1986, Rego et al., 2014) but not in rodents and pigs (Schjenken and 
Robertson, 2014). Among these prostaglandins, 19-hydroxy prostaglandin E (19-OH PGE) with 
immunosuppressive activity which regulates female tract responses to seminal fluid (James and 
Hargreave, 1984). In addition, in the presence of TGF-β and PGE2, macrophages and DCs are 
differentiated to mediate tolerogenic immune responses (Blois et al., 2007, Jaiswal et al., 2012).  
1.3.2 Seminal fluid and the inflammatory response 
A pregnant mother is initially exposed to paternal alloantigens in seminal fluid at or prior to conception 
(Hutter and Dohr, 1998), and secondly when trophoblast cells invade during implantation (Holland et al., 
2012). Both MHCI and MHCII molecules are carried in the ejaculate, either on sperm or within seminal 
plasma (Fernandez et al., 1999, Hutter and Dohr, 1998), to provide the first exposure of the female 
reproductive tract to paternal antigens. In human, this will generally also be a regular exposure to the 
conceiving partner before conception occurs. TGF-β, and 19-OH PGE2 are two abundant factors 
implicated as immune regulatory agents acting to initiate the Treg cell response (Kelly and Critchley, 
1997a, Robertson et al., 1997), and these may interact with additional, less well defined pro-tolerance 
factors in seminal fluid. Exposure to seminal fluid elicits maternal tolerance to paternal alloantigen by 
increasing the CD4+CD25+ T cell population (Robertson et al., 2009a) and CD4+ Treg cells (Guerin et 
al., 2011) in the PALN on DPC 3.5, as well as in the mouse uterus (Guerin et al., 2011). In mouse 
models where either the plasma or sperm fractions of the ejaculate are removed by surgical excision of 
the male seminal vesicles or vasectomy respectively, the expected increase in the Treg cell pool is 
diminished, showing both the sperm and/or epididymal secretions, as well as secretions from the 
seminal vesicles, are importance in female Treg cell induction (Guerin et al., 2011, Robertson et al., 
2009a). The induction of Treg cells, is associated with a state of transient, antigen specific  
hypo-responsiveness to male partner transplantation antigens, as demonstrated in a tumour challenge 
model (Robertson et al., 2009a). 
1.3.2.1 Seminal fluid induced immune response 
At coitus, seminal fluid interacts with epithelial cells lining the cervix and female reproductive tract to 
induce several cytokine and chemokines. In mice, cytokines and chemokines including GM-CSF,  
G-CSF, IL6, C-X-C motif chemokine ligand 1(CXCL-1) and CXCL-2 and C-C motif chemokine ligand-3 
(CCL-3) are elevated in the endometrial tissues after insemination (Johansson et al., 2004, Pollard et al., 
1998, Sanford et al., 1992, Schjenken et al., 2015, Robertson et al., 1998, Robertson et al., 1996). The 
requirement for seminal plasma for this female cytokine response is demonstrated in mice where males 
where the seminal vesicles are surgically excised, which results in no or only low induction of cytokine 
expression after mating (Schjenken et al., 2015).  
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In humans, similar cytokine responses are observed in the cervix after coitus. In vitro and in vivo studies 
have revealed an induction of GM-CSF, IL1A, IL6, IL8, CCL-2 and CCL-20 in the cervix after seminal 
fluid contact (Sharkey et al., 2012a, Sharkey et al., 2012b, Sharkey et al., 2007). When barrier 
contraception (a condom) is used to prevent seminal fluid contact, no cytokine response is seen in 
cervix tissue, showing seminal fluid plays a pivotal role in initiating this inflammation-like response 
(Sharkey et al., 2012b). Significant cytokine induction can also be demonstrated in human ectocervical 
epithelial cells exposed to seminal fluid in vitro (Sharkey et al., 2007). 
The change in cytokines and chemokines induced by seminal fluid in the female reproductive tract 
results in an influx of immune cells including macrophages, granulocytes, neutrophils and DCs into 
subepithelial stromal region in mice (De et al., 1991, McMaster et al., 1992, Robertson et al., 1998, 
Robertson et al., 1996, Robertson et al., 1992). Similar leukocyte recruitment can be observed in the 
human cervix, where macrophages, DCs and memory T cells are found to accumulate in the epithelial 
layer and deeper stromal tissues (Sharkey et al., 2012b).  
1.3.2.2 Male alloantigen recognition and presentation 
Female macrophages and DCs recruited to the endometrium, and possibly male DCs carried in the 
ejaculate, are potentially responsible for presenting male alloantigens deposited by seminal fluid at 
coitus (Robertson et al., 1996, McMaster et al., 1992). These antigen presenting cells pick up male 
alloantigens and traffic to the PALN to drive the proliferation and differentiation of Treg cells or interact 
locally with uterine residing T cells (Robertson et al., 2009a).   
The presentation of male alloantigens could thus be mediated either by maternal antigen presenting 
cells or paternal antigen presenting cells. The appearance of male alloantigens has been demonstrated 
by mating wild-type (WT) female mice to male mice expressing green fluorescent protein (GFP) 
ubiquitously under the beta actin promoter. GFP+ cells (paternal cells) could be found in the uterus, 
decidua and lymph nodes on DPC 0.5 (Zenclussen et al., 2010) showing that male alloantigens might 
be presented by paternal antigen presenting cells immediately after insemination. In addition, some of 
the GFP+ cells were positive for the DC marker CD11C and also expressed MHCII, indicating that DCs 
in seminal fluid may be recognised by maternal T cells (Zenclussen et al., 2010).  
In addition, Moldenhauer et al demonstrated that male alloantigens are cross-presented by maternal 
antigen presenting cells (Moldenhauer et al., 2009). Using an OT-I and OT-II transgenic mouse model, 
antigen presentation pathways were addressed. Female mice were administered ovalbumin-specific 
OT-I T cells after mating to male mice expressing ovalbumin. Ovalbumin-specific T cells were found 
locally in the PALN with high proliferative activity. When ovalbumin was presented by maternal antigen 
presenting cells, the CD8+ T cells were activated, but male partner antigen presenting cells presenting 
ovalbumin failed to induce similar responses (Moldenhauer et al., 2009).   
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1.3.3 Seminal fluid contributes to Treg cell responses 
There are several studies demonstrating the contribution of seminal fluid to the Treg cell response in 
pregnancy. Both seminal plasma and sperm are required for expansion of the Treg cell pool in the  
peri-implantation period as demonstrated by experiments investigating effects of mating with seminal 
vesicle deficient and vasectomised mice. The Treg cells in both the PALN and the uterus were 
increased after exposure to intact seminal fluid, compared with virgin oestrus female mice, but exposure 
to sperm alone in the absence of seminal plasma failed to induce any elevation (Guerin et al., 2011, 
Robertson et al., 2009a). However, exposure to seminal plasma of vasectomised males induced similar 
expansion of Treg cells in both PALN and uterus, compared with females exposed to intact seminal fluid 
(Guerin et al., 2011). However, the absence of either sperm or seminal plasma caused the expression 
of Foxp3 mRNA in the uterus to be reduced, compared with females exposed to intact seminal fluid, 
suggesting both elements are needed for the full Foxp3 response (Guerin et al., 2011). Mating to 
seminal vesicle deficient and vasectomised male mice also failed to expand the uterine Treg cell pool 
and the elevation of Foxp3 mRNA level (Guerin et al., 2011). Mechanical stimulation failed to alter Treg 
cell proliferation, which demonstrates hormonal changes elicited by cervical stimulation are not sufficient, 
and reinforces the importance of seminal fluid exposure (Schumacher et al., 2007). More recent studies 
also confirm the expansion of Treg cells in PALN by exposure to intact seminal fluid, as well as the 
presence of seminal plasma (Teles et al., 2013, Shima et al., 2015). In addition, in vitro exposure to 
different concentrations of seminal plasma induced Treg cell populations to expand, but not 
conventional T cells (Teles et al., 2013). Taken together, these studies confirm that seminal fluid 
provokes the expansion of Treg cells in lymph nodes and uterus the early pregnancy.   
Seminal fluid may be involved in expanding Treg cells indirectly via regulation of the phenotype of 
uterine antigen presenting cells. Seminal plasma has been shown to promote a tolerogenic phenotype 
in DCs in vitro (Remes Lenicov et al., 2012). Human monocytes co-cultured with a high dilution of 
seminal plasma were differentiated to DCs but failed to develop a mature phenotype in the presence of 
LPS (Remes Lenicov et al., 2012). Once these DCs were activated, they secreted high levels of  
anti-inflammatory cytokines, such as IL10 and TGF-β, and low level of pro-inflammatory cytokines, and 
a tolerogenic phenotype in DCs is found which indicates that seminal plasma may be involved in the 
regulation of Treg cell responses by promoting tolerogenic DCs. (Remes Lenicov et al., 2012),  
1.3.4 microRNAs in the seminal fluid 
As detailed above, seminal fluid regulates the female tract immune environment and contributes to the 
establishment of maternal immune tolerance through expansion of the Treg cell pool. Recently,  
non-coding RNAs, including miRNAs have been identified to be involved in the regulation of immunity 
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(Baltimore et al., 2008). Thus, we postulate that miRNA carried by seminal fluid or induced in females by 
seminal fluid are involved in the female immune response following coitus.  
miRNAs are short non-coding RNAs, usually 22-25 nucleotides long, which undergo a series of 
maturation steps using endonucleases (Dorsha and Dicer), to attain functional competence. Once 
miRNAs are mature, they are incorporated into the RNA-induced silencing complex and then transport 
to the target site (Taganov et al., 2007). The most well-studied functions of miRNAs are the degradation 
of target mRNA (Dong et al., 2013) or the inhibition of translation process of target transcripts (Olsen 
and Ambros, 1999).  
Interestingly, seminal fluid contains a large number of miRNAs (Krawetz et al., 2011). These are carried 
by sperm and also are present in exosomes in the plasma fraction of seminal fluid (Vojtech et al., 2014). 
Sperm miRNAs are delivered to the oocyte at fertilisation where they impact on embryo development 
and transgenerational inheritance of paternal epigenetic exposures (Fullston et al., 2013, Liu et al., 2012, 
Rodgers et al., 2015). Some immune-regulating miRNAs have been identified to be carried by sperm, 
such as miR-17, miR-19, miR-23b, miR-146a, miR-155, miR-223 and let-7c (Amanai et al., 2006, Nixon 
et al., 2015). This raises the question of whether miRNAs carried by sperm may target female immune 
pathways in the peri-conception period. The role of miRNAs in the regulation of immune responses and 
key miRNAs will be discussed in section 1.5. 
1.4 miRNAs involved in the regulation of immune cells in the peri-conception 
period 
There is growing evidence that specific miRNAs are involved in the regulation of functional capacity of 
immune cells (Baltimore et al., 2008). Using Dicer null mice, altered innate and adaptive immune 
responses could be observed when miRNAs are absent, with a systemic compromise in T cells 
(Taganov et al., 2007). Conditional depletion of Dicer in T cells causes reduced T cells in both the 
thymus and periphery (Cobb et al., 2006, Muljo et al., 2005). Ablation of Dicer in B cells resulted in a 
diminished B cell pool and compromised antibody-producing capacity (Koralov et al., 2008). Taken 
together, these observations show miRNAs are essential in various leukocytes that are crucial for 
regulation of the immune response. 
There is evidence that endogenous miRNAs could be involved in the regulation of endometrial immune 
environment, but this has not been examined directly. Women who had altered immune-regulatory 
miRNA expression in the first trimester and pre-conception immune-regulatory miRNAs appear more 
likely to experience development of immune-associated pregnancy complications, such as preeclampsia 
and miscarriage (Winger et al., 2015).  
miRNAs regulate genes and factors involved in the process of maternal immune tolerance (Schjenken 
et al., 2016). miRNAs such as miR-152 and miR-148a regulate HLA expression (Manaster et al., 2012). 
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Given the evidence showing that miRNAs differentially regulate immune responses, and since immune 
tolerance is critical in pregnancy success, it is possible that some specific miRNAs carried by seminal 
fluid or induced by seminal fluid in female tissues regulate the female immune environment in the  
peri-conception period, either directly in T cells or via regulating of antigen presenting cell phenotypes. 
1.4.1 miRNAs and antigen presenting cells 
As discussed in section 1.3.2.3, DCs are involved in the process of Treg cell proliferation and 
differentiation, and the phenotype of DCs is critical in the induction of Treg cell differentiation. miRNAs 
are known to regulate the function and phenotype of DCs and so could contribute to Treg cell pool 
expansion. 
Specific miRNAs are involved in the differentiation of DCs from monocytes. Twenty miRNAs have been 
identified as differentially expressed in human monocyte-derived dendritic cells over a course of 5 days 
in culture (Hashimi et al., 2009). Amongst these 20 miRNAs, miR-21 and miR-34 were identified as the 
key to monocyte-derived dendritic cell differentiation via regulating the target gene Wnt1 and Jag1 
(Hashimi et al., 2009). Inhibition of miR-21 and miR-34 or supplementation of exogenous Wnt-1 and 
Jagged-1 resulted in the dysregulation of DC-specific intercellular adhesion molecule-3 grabbing  
non-integrin /CD14 expression ratio, and disrupted endocytic function of immature DCs (Hashimi et al., 
2009). Since endocytosis is critical in antigen presenting cell function (Burgdorf and Kurts, 2008), 
dysregulation of these miRNAs may disrupt the capacity of antigen presenting cells to take up male 
alloantigens and expression of co-stimulatory molecules which may in turn impact on the establishment 
of immune tolerance following coitus.  
miR-155 is reported to play a critical role in maintaining optimal function of DCs (Rodriguez et al., 2007).  
miR-155 deficiency does not alter DC maturation as MHCII and co-stimulatory molecule expression was 
comparable in miR-155 deficient DCs, compared with WT DCs (Rodriguez et al., 2007). However, the 
antigen presenting capacity of miR-155 deficient DCs was approximately 2.5-fold lower compared to WT 
DCs, as the DC-specific intercellular adhesion molecule-3 grabbing non-integrin expression level was 
suppressed by PU.1, and these miR-155 deficient DCs failed to activate T cells effectively (Rodriguez et 
al., 2007). In vitro studies suggest miR-155 is also involved in DC maturation. miR-155 was consistently 
overexpressed in activated DCs after 6 hrs and 24 hrs of maturation (Stumpfova et al., 2014). Increased 
levels of miR-155 were correlated with accumulation of the key cell cycle inhibitor (p27kip1) in DCs, and 
overexpression of miR-155 in DCs resulted in p27kip1 elevation and DC apoptosis (Lu et al., 2011). In 
addition, miR-155 was induced in DCs after microbial stimulation, where it down-regulates the 
production of pro-inflammatory cytokines (Ceppi et al., 2009). Taken together, these data show that 
miR-155 plays an important role in the regulation of DC function in both innate and adaptive immunity.  
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miRNAs that promote a tolerogenic phenotype in DCs may also contribute to the establishment of 
maternal immune tolerance. Studies have identified specific miRNA profiles that distinguish immature, 
activated and tolerogenic DCs in humans, and show that miR-17, miR-133b, miR-203 and the miR-23b 
cluster are uniquely expressed in tDCs (Stumpfova et al., 2014). miR-23b has been demonstrated to 
function as a tolerogenic agent. miR-23b over-expressing mice showed delayed onset of  
collagen-induced arthritis and experimental autoimmune encephalomyelitis, as well as lower clinical 
score and incidence of collagen-induced arthritis and experimental autoimmune encephalomyelitis, 
compared with WT mice (Zhu et al., 2012). By suppressing IL17, TNF-α or IL1β-induced NF-κB 
activation and cytokine expression, miR-23b represses autoimmune inflammation (Zhu et al., 2012). In 
addition, an in vitro study revealed transfection of miR-23b into mouse DCs promoted a tolerogenic 
phenotype via targeting Notch 1 and the NF-κB pathway, with elevated IL10 production and the capacity 
to induce CD4+Foxp3+ Treg cell differentiation (Zheng et al., 2012).  
miRNAs which regulate macrophage polarisation could be important for the success of pregnancy, as 
macrophage polarisation has a clear effect on inflammation (Liu and Abraham, 2013). Macrophages can 
be classified as M1-like macrophages (pro-inflammatory) or M2-like macrophages (anti-inflammatory). 
Between these two phenotypes, 109 miRNAs have been identified as being differentially expressed 
(Graff et al., 2012, Zhang et al., 2013). miR-155 expression is upregulated in M1 macrophages 
compared to M2 (Graff et al., 2012, Zhang et al., 2013), and promotes M1-like polarisation via 
suppressing suppressor of cytokine signalling 1 (Wang et al., 2010a). miR-223 deficient mice exhibit the 
pro-inflammatory M1 phenotype in macrophages (Zhang et al., 2013) while M2 polarisation can be 
promoted by let-7c (Zhuang et al., 2012), indicating that miR-223 and let-7c may promote M2 
polarisation.  
Considering the critical role of antigen presenting cell throughout gestation to support the success of 
pregnancy, it is clear that miRNAs with potential to induce an appropriate phenotype and polarisation of 
antigen presenting cells in early pregnancy need further investigation.  
1.4.2 miRNA and Treg cells 
To identify miRNAs that contribute to Treg cells that are critical in supporting gestation, the miRNA 
profile of Treg cells and conventional CD4+ T cells has been investigated (Cobb et al., 2006). Treg cells 
appear to have a miRNA profile distinct to conventional CD4+ T cells, with 35 miRNAs (including  
miR-146a, miR-155 and miR-223) being preferentially expressed and 33 miRNAs being down-regulated 
in Treg cells (Cobb et al., 2006). Interestingly, miR-223 was identified as the most upregulated miRNA in 
Treg cells, compared with conventional CD4+ T cells (Cobb et al., 2006). The relationship between  
miR-223 and Treg cells remains to be investigated as only one study has examined miR-223 expression 
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in Treg cells and showed a correlation with a reduced Treg cell population in pregnant women (Herberth 
et al., 2014).  
One of the most well-studied miRNAs in Treg cells is miR-155. It has been revealed that miR-155 is a 
target of Foxp3, as Foxp3 binds to an intron in the DNA sequence encoding the miR-155 precursor 
mRNA BIC (Marson et al., 2007). During Foxp3+ thymocyte differentiation, the expression level of  
miR-155 is upregulated by Foxp3 (Lu et al., 2009b). In isolated Foxp3+ and Foxp3- thymocytes,  
miR-155 expression levels were found to be approximately 20-fold higher in Foxp3+ CD4+ single 
positive thymocytes compared to Foxp3- thymocytes. Additionally, disruption of Foxp3 expression in 
peripheral Treg cells leads to down-regulation of miR-155 as well as BIC mRNA (Lu et al., 2009b). 
Compared to the miR-155 sufficient controls, absence of miR-155 caused a decrease of Treg cell 
proliferative activity in the periphery (Lu et al., 2009b). When T cell depleted bone marrow was 
transferred into miR-155-deficient mice, a reduction in the proportion of Treg cells was observed on day 
100 post bone marrow transfer, suggesting miR-155 is crucial in maintaining competitive fitness in 
lympho-replete mice (Lu et al., 2009b).  
Unlike miR-155, miR-146a is reported to be indispensable for Treg cell-mediated suppression. In order 
to evaluate the role of miR-146a in Treg cell suppressive function, Mirn-146a-/-/Foxp3KO mice with  
miR-146a null mutation specific to Foxp3+ Treg cells were generated. These mice developed  
immune-mediated pathologies, such as conjunctivitis, blepharitis and dermatitis. Interestingly, the Treg 
cell populations in these Mirn-146a-/-/Foxp3KO mice were increased compared to  
Mirn-146a+/+/Foxp3KO mice (Lu et al., 2010). Moreover, an increased Treg cell population was also 
observed in Mirn-146a-/-/B6 mice, suggesting that miR-146a deficiency increases the Treg cell 
population. However, miR-146a deficient Treg cells failed to restrain activation of miR-146a sufficient T 
effector cells (Lu et al., 2010). Taken together, these data indicate miR-146a is important for Treg cells 
to maintain their suppressive function. Moreover, in human monocytes, it has been shown that  
miR-146a and miR-146b were both upregulated in a NF-κB dependent manner after challenge with LPS 
(Taganov et al., 2006).  
Considering the essential role of seminal fluid in expanding the Treg cell pool in early gestation, more 
studies are required to address how specific miRNAs contribute to Treg cell responses during the  
peri-conception period.  
1.5 IL10 
Cytokines secreted by placental trophoblast and uterine cells are involved in the regulation of Th1 
immune responses and act to limit inflammation in local tissues (Lin et al., 1993, Munoz-Suano et al., 
2011, Szekeres-Bartho et al., 2009). Amongst these cytokines, IL10 has potent anti-inflammatory 
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properties. IL10 is produced by a range of different types of cells, including T cells, B cells, 
macrophages, DCs and Treg cells (Annacker et al., 2001).  
IL10 stimulates and regulates a diverse range of cells, including DCs, natural killer (NK) cells, 
macrophages and T cells (Fiorentino et al., 1991a, Fiorentino et al., 1991b, Maynard and Weaver, 2008). 
IL10 inhibits antigen presentation, as well as the expression of MHCII and costimulatory molecules 
CD80/CD86 in DCs and the modification of DC phenotype ultimately regulates the activation of T cells 
(Mosser and Zhang, 2008). In addition, IL10 can induce the differentiation of Treg cells from naïve T 
cells (Nevers et al., 2011). IL10 may then be one important factor that regulates the response and 
phenotype of Treg cells during early pregnancy. 
1.5.1 IL10 and Treg cells 
 IL10 is highly expressed in CD4+CD25+ T cells from 7-day-old mice, indicating that CD4+CD25+ T 
cells can secret IL10 (Asano et al., 1996). IL10 inhibited the production of pro-inflammatory cytokines 
such as IL17, IFN-γ, IL2 and TNF-α (Gu et al., 2008, Lochner et al., 2008), and also promoted T cell 
Foxp3 expression in vitro (Heo et al., 2010).  
The feedback loop between IL10 and Treg cells is crucial in maintaining the Treg cell population. After 
repetitive stimulation with immature DCs, naïve CD4+ T cells differentiated to non-proliferating IL10 
producing T cells, with upregulated expression of CTLA-4 (Jonuleit et al., 2000). When colitis was 
induced in IL10 and recombination-activating gene 1 (Rag1) double deficient mice, Treg cells failed to 
maintain their regulatory activity due to loss of Foxp3 expression (Murai et al., 2009), indicating IL10 is 
required in the presence of inflammation. In addition, IL10 receptor deficient mice also failed to maintain 
Foxp3 expression in Treg cells, indicating that IL10 acts directly on the Treg cells (Murai et al., 2009). 
Treg cells can partially develop pro-tolerance functions independently of IL10 (Maynard et al., 2007, 
Pillai et al., 2011, Rowe et al., 2011), indicating other tolerogenic mechanisms exist in addition to IL10 
secretion. The effect of IL10 deficiency on Treg cells in pregnancy therefore warrants further 
investigation.  
1.5.2 IL10 and pregnancy 
The importance of IL10 during pregnancy has been addressed in several studies using murine models. 
Studies have revealed that absence of maternal IL10 did not impact on either syngeneic or allogeneic 
pregnancy progression (Rowe et al., 2011, Svensson et al., 2001, White et al., 2004). However, 
administration of low dose of LPS or other TLR ligands to IL10 null mice caused a greater degree of 
fetal loss, indicating that IL10 null mice are highly sensitive to inflammatory challenge (Murphy et al., 
2005, Robertson et al., 2007). In addition, the importance of IL10 in gestation was addressed by the 
CBA/J x DBA/2 abortion-prone murine model. After transferring protective Treg cells into abortion-prone 
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mice, administration of neutralising IL10 antibody resulted in abrogating the protection from Treg cells, 
again indicating the pivotal role of IL10 for pregnancy tolerance (Schumacher et al., 2007).  
As discussed earlier, an inappropriate amount or type of leukocytes and pro-inflammatory cytokines in 
the tissues at the maternal-fetal interface may result in preeclampsia. IL10, as a pivotal  
anti-inflammatory cytokine, has been studied for its role in normal pregnancy and preeclampsia. In IL10 
null mice, exposure to 9.5% oxygen from DPC 7.5 until DPC 17 in a hypoxia-induced preeclampsia 
model resulted in preeclampsia-like symptoms, including hypertension, proteinuria and reduced fetal 
weights, compared with WT mice (Lai et al., 2011). In the hypoxia-induced preeclampsia model, IL10 
null mice also appeared to have elevated soluble fms-like tyrosine kinase 1, compared with WT mice 
(Lai et al., 2011). Administration of recombinant IL10 from DPC 8 to DPC 16 resulted increased fetal 
weight, elevated blood pressure and restored proteinuria to normal levels, as well as reducing excess 
levels of soluble fms-like tyrosine kinase 1 (Lai et al., 2011). TLR-3 induced preeclampsia-like features 
were exacerbated in IL10 null mice and administration of exogenous IL10 showed beneficial effects on 
endothelial function (Chatterjee et al., 2011). Similar observations are found in pregnant hypertensive 
rats, where administration of IL10 can reverse hypertension and endothelial dysfunction (Tinsley et al., 
2010). Taken together these studies suggest that IL10 could be one key target in preeclampsia 
diagnostics or for therapeutic treatment. 
A reduced level of IL10 has been observed in preeclamptic women. Women experiencing preeclampsia 
showed a significant skewing from type 2 cytokines towards type 1 cytokines, and in particular a 
significant reduction in IL10 was observed in serum at the time of delivery (Borekci et al., 2007, Sharma 
et al., 2007a).  
1.6 Peri-conception origin of preeclampsia 
Altered maternal immune responses are associated with several pregnancy complications, such as 
recurrent pregnancy loss, infertility and preeclampsia. In particular, the origin of preeclampsia is not fully 
understood, and different types of preeclampsia may be caused by different factors. It is hypothesised 
that the peri-conception phase is critical in the origin of early onset preeclampsia (the most severe form 
of the syndrome) as compromised placental development is associated with preeclampsia development 
(Huppertz, 2008, Redman and Sargent, 2010, Steegers et al., 2010).  
1.6.1 Immune responses during trophoblast cell invasion in normal pregnancies 
In human pregnancy, appropriate placentation requires appropriate maternal decidual adaptation 
including adequate remodelling of uterine spiral arteries. Cells of the maternal immune system operate 
in a delicate balance to regulate the events of placental trophoblast invasion and uterine vascular 
remodelling (Lala and Chakraborty, 2003, Wells, 2007). T cells, Treg cells, macrophages, DCs, uterine 
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NK cells and other leukocytes presented in the decidua facilitate trophoblast cell migration and invasion 
(King, 2000, Trundley and Moffett, 2004, Williams et al., 2009).  By controlling removal of native cells 
from the spiral artery, these leukocytes allow trophoblast cells to reach the endometrium (Lash et al., 
2010, Nagamatsu and Schust, 2010). Treg cells and their secreted cytokines promote maternal immune 
adaption towards the semi-allogeneic fetus and prevent development of detrimental Th1 and Th17 
immunity (Robertson, 2010). Treg cells also suppress pro-inflammatory cells to ensure the proper 
invasion (Williams et al., 2009, Somerset et al., 2004, Tilburgs et al., 2008). Together, the immune cells 
present in the decidua during early pregnancy regulate the immune response to ensure proper vascular 
remodelling (Amsalem et al., 2014, Jasper et al., 2011, Klauber et al., 1997, Woidacki et al., 2015) and 
trophoblast invasion (Lala and Chakraborty, 2003, Wells, 2007). The appropriate type and proper 
amount of facilitating immune cells are therefore key to healthy pregnancy, and disturbances in the 
immune response may result in compromised placental development. Compromised or incomplete 
placental development is believed to result in pregnancy complications, such as preeclampsia or 
miscarriage (Redman and Sargent, 2010, Veenstra van Nieuwenhoven et al., 2003).  
1.6.2 Altered immune responses in women with preeclampsia 
Disruption of placenta formation is generally characterised by inadequate remodel spiral arteries and 
failure to achieve high capacity maternal blood flow (Huppertz, 2008, Redman and Sargent, 2010, 
Steegers et al., 2010). In addition, placentas from women experiencing preeclampsia showed altered 
vasculature and excess inflammation, compared with placentas from healthy individuals (Roberts and 
Post, 2008, Roberts and Escudero, 2012). Some serum makers, such as placenta protein 13, long 
pentraxin 3 and pregnancy associated plasma protein-A, have been reported to be different in the first 
trimester of pregnancy (Burger et al., 2004, Cetin et al., 2006, Rovere-Querini et al., 2006, Spencer et 
al., 2007), and altered serum placenta protein 13 level was found as early as 7 to 8 weeks of gestation 
in women experiencing preeclampsia (Huppertz et al., 2008), which suggests preeclampsia (at least the 
early onset form) may develop during the earliest steps of development of the placenta.  
Unlike normal pregnancy, women with preeclampsia show evidence of inappropriate immune responses 
and alternatively activated immune cells and cytokines (Freeman et al., 2004, LaMarca et al., 2013). An 
emerging consensus view is that insufficient trophoblast invasion resulting in placental ischemia is 
accompanied by, and probably secondary to imbalanced immune cell activation, in turn resulting in 
placental damage and excessive and chronic inflammation (Redman and Sargent, 2010, Cornelius et al., 
2013, Irani et al., 2010). The chronic inflammation is caused by increased pro-inflammatory responses 
and cytokines, as well as diminished Treg cells and anti-inflammatory cytokines (LaMarca et al., 2013, 
Santner-Nanan et al., 2009, Prins et al., 2009, Wallace et al., 2011). These altered immune responses 
are increasingly viewed as causal, at least in a proportion of preeclampsia and related pregnancy 
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complications. Therefore, in order to understand the mechanisms of how preeclampsia is developed, it 
is important to understand how these immune cells are regulated in normal gestation and particularly 
the factors that regulate their origin and proliferation at the outset of pregnancy.  
The role of prior contact with the conceiving partner’s seminal fluid in reducing the incidence of 
preeclampsia has been observed in several clinical cohort studies. Preeclampsia is generally regarded 
as a disease of primiparous women, with second and subsequent pregnancies less susceptible than 
first pregnancies, while women who have a new conceiving partner have increased risk of  
pregnancy-induced hypertensive disorders, indicating that the benefit from prior seminal fluid contact is 
partner-specific (Dekker et al., 1998). In addition, the incidence of pregnancy-induced hypertension is 
inversely related to the duration of exposure to partner’s seminal fluid (Dekker et al., 1998), which 
suggests that a sufficient peroid of sexual cohabitation and seminal fluid contact may be required to 
protect women from developing PE. An increased incidence of preeclampsia was also found in women 
who received donor gametes where prior exposure to gamete antigens in the context of seminal fluid 
did not occur (Salha et al., 1999), again consistent with seminal fluid exposure potentially providing 
protection in women from preeclampsia development. In the mouse model, seminal fluid is prominent in 
expanding Treg cell populations in early pregnancy, however, the benefit from repeated seminal fluid 
exposure and the mechanisms of partner-specificity have not yet been well investigated in mouse 
models. 
1.6.3 Treg cells are deficient in preeclampsia 
In women with preeclampsia, the Treg cell population is reduced in the peripheral blood and decidual 
tissues as compared to normal pregnant women, when evaluated before the onset of labour or 
caesarean section (Quinn et al., 2011, Santner-Nanan et al., 2009, Sasaki et al., 2007, Prins et al., 
2009).  These reduced Treg cells appeared to also have altered suppressive activities and phenotypes 
(Steinborn et al., 2008, Steinborn et al., 2012). The decidual Treg cell population is reduced in  
late-onset severe preeclampsia and further decreased in patients with early-onset severe preeclampsia 
(Quinn et al., 2011). In preeclamptic women, the Treg cell population in peripheral blood is reported to 
be even lower than non-pregnant women, and with a shift towards IL17 expressing phenotypes 
(Santner-Nanan et al., 2009, Tian et al., 2016). In addition, decreased decidual Treg cells were found to 
promote apoptosis in trophoblast cells which resulted in compromised trophoblast cell invasion into the 
decidua, which may increase the incidence of preeclampsia (Munoz-Suano et al., 2011).  
The imbalance between Treg and Th17 cells associated with preeclampsia has been investigated. T cell 
dysfunction can trigger the development of preeclampsia, as the reduced placental blood flow, 
inadequate uterine spiral arterial modification and compromised fetal growth is observed in T cell 
deficient mice (Croy et al., 2011). In addition, in the reduced uterine perfusion pressure rat model of 
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preeclampsia, adoptive transfer of Treg cells from normal pregnant rats reversed preeclampsia-like 
symptoms via attenuating circulating pro-inflammatory cytokines IL17 and TNF (Cornelius et al., 2015).  
1.7 Summary  
There is growing evidence showing the importance of Treg cells in the establishment and maintenance 
of maternal immune tolerance towards the semi-allogeneic fetus to support pregnancy success. Clinical 
studies as well as experimental mouse models have demonstrated that an insufficient number of stable 
functional Treg cells is associated with pregnancy complications, such as preeclampsia. However, 
factors that govern the appropriate Treg cell responses remain poorly understood. In particular, how 
male alloantigens, the major anti-inflammatory cytokine IL10, and key microRNAs miR-155 and miR-223 
impact on Treg cells, is of considerable interest.  
The hypothesis to be investigated in this research thesis is that male alloantigens, miR-155, miR-223, 
and IL10 all regulate Treg cell expansion and stability directly or via regulating the functions and 
phenotypes of antigen presenting cells in the peri-conception period (Figure 1.1).  
The experiments described in this thesis will address the involvement of male alloantigens and miR-155 
and miR-223 in the regulation of Treg cell expansion and stability in early gestation. The role of IL10 in 
regulating Treg cell pool expansion, phenotype and pregnancy outcomes will be addressed in mid and 
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Figure 1.1 Current working model of Treg cell expansion post coitus. 1. Residential antigen presenting cells 
process male alloantigens carried by seminal fluid, and present antigens to resting Treg cells or naïve CD4+ T 
cells in the PALN. miRNAs carried by seminal fluid or induced by seminal fluid in the female reproductive tract 
may regulate the phenotype of antigen presenting cells or directly regulate Treg cell population. 2. Treg cells are 
activated and undergo proliferation and differentiation in the PALN, in the appropriate cytokine and miRNA 
environment. 3. The key cytokine IL10 is involved in regulating the size of the Treg cell pool, and Treg cell 
stability and phenotype. 4. The activated functional Treg cells are recruited to the uterus to inhibit Th1 and Th17 
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1.8 Hypotheses  
This study will address the following hypotheses: 
1. IL10 is critical for regulating the Treg cell pool and absence of IL10 can alter Treg cell 
phenotype in pregnancy; 
2. Repeated exposure to seminal fluid acts to boost the Treg cell pool, progressively strengthening 
immune competence to sustain pregnancy, and 
3. miR-155 and miR-223 induced by seminal fluid are additional regulators of the quality and 
strength of the Treg cell response in early pregnancy. 
1.9 Research aims 
The experiments in this study will utilise mouse models to address the following Aims: 
1. To investigate the effect of IL10 on Treg cell number and phenotype in mid-gestation, using Il10 
null mutant mice;  
2. To investigate whether repeated prior contact with the same male transplantation antigens 
impacts on the Treg cell population and stability in early pregnancy, and 
3. To determine whether miR-155 and miR-223 influence Treg cell number and phenotype in early 
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2.1 Animals and treatments 
2.1.1 Mice 
All animal experiments were approved by the University of Adelaide Animal Ethics Committee and were 
conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes (7th ed., 2004). All mice were maintained in specific pathogen-free conditions with 
controlled light (12 hours (hr) light, 12 hr dark cycle) and constant temperature (24 oC) at the Laboratory 
Animal Services Medical School facility. Food and water were provided ad libitum. All female mice 
utilised in these studies were 10-20 weeks old, and the male mice utilised as studs were between 10 
weeks and 24 months old.  
2.1.1.1 C57Bl/6 mice 
For chapter 3 and 4, C57Bl/6 (B6) female mice (Harlan sub-strain) were purchased from Laboratory 
Animal Services at the University of Adelaide, South Australia. For chapter 5 and 6, B6 mice (Jackson 
sub-strain) were purchased from Animal Resource Centre, Western Australia.  
2.1.1.2 Il10 null mice 
Mice with genetic deficiency in IL10 were previously generated by targeted mutation of the Il10 gene in 
129/Ola embryonic stem cells, and then propagated on a B6 background and injection into B6 
blastocysts (Kuhn et al., 1993b). Il10 null mice were bred in-house at Laboratory Animal Services as 
homozygous breeding pairs and received broad-spectrum antibiotics (Oxymav 100: 100 g/kg 
oxytetracycline hydrochloride; Mavlab, Queensland, Australia) in autoclaved drinking water twice weekly 
at a concentration of 2 mg/mL to prevent auto-immune colitis. 
2.1.1.3 miR-155 null mice 
miR-155 null mutant mice were purchased from Jackson Laboratory (Bar Habour, ME, USA, Stock 
No: 007745 | bic/miR-155) and bred in-house at Laboratory Animal Services as homozygous breeding 
pairs. These mice were previously generated by replacing bic/mir-155 gene with an in-frame  
β-galactosidase reporter gene (with polyA sequence and followed by a loxP-flanked neomycin 
resistance cassette) in F1H4 embryonic stem cells (derived from B6:129 hybrid mice), and chimeras 
were bred to B6 to establish miR-155 null mice (Thai et al., 2007). LoxP-flanked selection cassettes 
were removed by crossing these mice with a cre-deleter strain (congenic B6 background), resulting in 
bic/mir-155 mutant mice. These miR-155 mutant mice were backcrossed to B6 for at least five 
generations.  
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2.1.1.4 miR-223 null mice   
miR-223 null mice were purchased from Jackson Laboratory (Bar Habour, ME, USA, Stock 
No: 013198 | miR-223) and bred in-house at Laboratory Animal Services as homozygous breeding pairs. 
These mice were originally generated using a targeting vector designed to replace the entire coding 
region of the microRNA-223 (mir-223) gene with an frt-flanked neomycin resistance cassette. The 
construct was electroporated into (B6 x 129S4Sv/Jae) F1-derived V6. ES cells. Correctly targeted ES 
cells were injected into B6 blastocysts and the resulting chimeric males were bred to C57Bl/6 females to 
generate a colony of miR-223 mice. These mice were backcrossed for at least 5 generations to B6. 
SJL-Ptprca Pepcb/BoyJ and thus also harbor the CD45.1 (Ly5.1 or Ptprca) allele. 
2.1.1.5 Balb/c mice 
For chapter 3, 4, 5 and 6, Balb/c male mice were purchased from Laboratory Animal Services at The 
University of Adelaide, South Australia.  
2.1.1.6 Balb/b mice 
For chapter 4, Balb/b male mice were kindly provided by Rachel Kuns, QIMR Berghofer Medical 
Research Institute, Queensland.  
2.1.2 Mating 
Adult naturally cycling female mice were housed with a proven-fertile stud male. Female mice were 
checked each morning between 0900 h and 1100 h for the presence of a vaginal copulatory plug. The 
day a plug was observed was considered day 0.5 postcoitum (DPC), and female mice were separated 
from the studs. 
2.1.3 RU486 treatment  
Plugged B6 mice were given RU486 (Mifepristone, Sigma-Aldrich, Missouri, USA) to prevent embryo 
implantation in the multiple-mating study (Chapter 4). RU486 stock (8 mg/kg of RU486) was prepared in 
methanol and stored for a maximum of 1 week at -20 oC. On DPC 3.5, between 0900 h and 1100 h, 
female mice were injected subcutaneously with 8 mg/kg RU486 in sesame oil. The female mice were 
rested for at least 2 days after RU486 injection before being housed with stud males for further mating.  
2.1.4 Estrus Cycle Tracking  
In some experimental mice, the stage of the oestrus cycle was determined by analysis of wet mounts of 
vaginal lavage cells (‘vaginal smears’) as described previously (Byers et al., 2012). Vaginal smears 
were performed between 0830h and 1100h by lavage of the vagina with 20 µl sterile phosphate 
buffered saline (PBS). Smears were deposited on SuperFrost glass slides (HD Scientific Supplies Pty 
Ltd, NSW, Australia) and coverslipped. The cellular contents were analysed under a phase contrast 
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microscope (Olympus, Edwardstown, SA, Australia) to determine the stage of the oestrus cycle (Table 
2.1). The oestrous cycle of all female mice was tracked for 7 days before mice were utilised in 
experiments.  
Table 2.1 Oestrus stage determination by vaginal smears 
Stage of the oestrus cycle Cytology of cells in vaginal smears Length of each stage 
Proestrus E or EC 24 h 
Oestrus EC+ or C+ 12 h 
Metestrus C++ clumps or C+E L++ 36 to 48 h 
Diestrus Low number of cells C-- L-- 36 h 
 
E= epithelial cells, C= cornified epithelial cells, L= leukocytes, + indicates normal level of cells, ++ 
indicates many cells  
2.2 Microarray and real time PCR 
2.2.1 Microarray 
2.2.1.1 RNA Extraction 
The gene expression profile of Treg cells from Il10+/+ or Il10-/- mice was determined by microarray. 
Treg cells from DPC 8.5-10.5 female mice were previously isolated from para-aortic lymph nodes (PALN) 
by MACS CD4+CD25+ Regulatory T cell Isolation Kit for mice (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instruction. Then cells were spun down to harvest cell pellets 
and then stored at -80 oC. 
Treg cell RNA extraction was performed by using miRNeasy Mini Kits (Qiagen Inc., Valencia, CA, USA) 
according to the manufacturer’s instruction with minor amendments. After adding QiAzol lysis regent  
(700 µl), tubes were shaken vigorously for 10 seconds (s) to homogenise CD4+CD25+ T lymphocytes. 
The tubes containing homogenate were left on the bench top for 5 minutes (min) at room temperature 
(RT). Then chloroform (0.2 volumes) was added to the homogenate and shaken vigorously for 15 s. The 
tubes were incubated for 3 min at RT before centrifuging at 12,000 x g for 15 min at 4 oC. The upper 
aqueous phase was collected and 1.5 volume of 100% ethanol was added and samples were mixed 
thoroughly. The sample was then transferred into an RNeasy Mini spin column, centrifuged at  
10,000 x g for 15 s, and the flow-through was discarded. Buffer RWT (500 µl) was added into the spin 
column, centrifuged at 10,000 x g for 15 s and the flow-through was discarded. This step was then 
repeated before the spin column was dried by centrifugation at 10,000 x g for 2 min. Treg cell RNA was 
then eluted with 30 µl of RNase free water.  
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The concentration and purity of each RNA sample was determined using a Nanodrop 
Spectrophotometer (ND-1000, Nanodrop Technologies Inc., Wilmington, DE). RNA quality was 
determined using an RNA 6000 Pico Total RNA Kit (Agilent Technologies, Santa Clara CA) at Adelaide 
Microarray Centre prior to use in microarray experiments. RNA with a RNA Integrity Number (RIN) >7 
was used in this study. 
2.2.1.2 Microarray analysis  
For microarray analysis, RNA was pooled (from 2-4 mice per pool) resulting in four biological replicates 
of CD4+CD25+ T cells from both Il10-/- and Il10+/+ mice. Microarray analysis was performed using 
Affymetrix Mouse Gene 2.0 ST Arrays at the Adelaide Microarray Centre. Total RNA (1 ng) was 
amplified using the Ovation PicoSL WTA System V2 (Nugen Inc., San Carlos, CA, USA) and MinElute 
Reaction Cleanup Kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer’s instructions, to 
provide 5 μg of cRNA for each microarray. 
The microarray data were normalised and analysed using Partek Genomics Suite (Partek, Inc.). Raw 
data from the Affymetrix platform (cel files) were imported and normalised using RMA background 
correction, Partek's own guanine-cytosine content correction, and mean probe summarization. A 
threshold of either a greater than 1.4-fold change (low stringency) or a greater than 2.0-fold change 
(high stringency) was used to identify differentially expressed genes, with a false-discovery rate of 
p<0.05. 
2.2.1.3 Reverse Transcription 
Total cellular RNA (25 ng to 327 ng) was reverse transcribed from 125 ng random hexamer primed RNA 
from each of 8-12 individual Il10-/- and Il10+/+ mice employing a Superscript-III Reverse Transcriptase 




2.2.1.4 Quantitative Real-Time PCR 
Quantitative real-time PCR (qPCR) was used to confirm microarray data. qPCR was performed using  
1 ng of cDNA, supplemented with 0.1-0.5 μM 5’ and 3’ primers (Table 2.2) and 1 x Power SYBR Green 
PCR Master Mix (Life Technologies, Applied Biosystems, CA, USA). The negative control included in 
each reaction contained H2O substituted for cDNA. qPCR amplification was performed using an ABI 
Prism 7000 Sequence Detection System (Life Technologies, Applied Biosystems, CA, USA) using 
reaction conditions of 95 oC for 10 min, then 40 cycles of 95 oC for 15 s and 60 oC for 1 min. Target 
gene abundance was calculated using the Delta C(t) method normalizing target gene expression to the 
 
ZHANG                                                           Chapter 2                                                              31 
Gmpr reference gene (Livak and Schmittgen, 2001). Gmpr was selected from a list of candidate 
reference genes (Gmpr, Gapdh, Gm6578) that were shown to be stable based on microarray data. 
These candidates were then assessed for their suitability using Normfinder (MOMA, Aarhus N, 
Denmark). From this, Gmpr was selected as the most stable reference gene. 
2.2.1.5 Primer Design 
2.2.1.5.1 Primers designed by Primer Express 
Primer pairs specific for mRNA expression were designed using Primer Express version 2 software (Life 
Technologies, Applied Biosystems, CA, USA). Messenger RNA sequences were downloaded from the 
Entrez nucleotide database, accessible from the National Centre for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov). All primers were purchased from Geneworks (Adelaide, SA, Australia). A 
list of all primer sequences for target genes analysed, including product size and Genbank accession 
number are provided in Table 2.2.  
2.2.1.5.2 Primer specificity and efficiency  
Prior to using the primers to confirm microarray data, primer specificity was determined by gel 
electrophoresis (2% agarose gel; Promega, Madison, USA) of products generated by qPCR (see 2.2.1.4) 
and pUC 19 DNA/Hpa II DNA ladder (500 ng/µL, GeneWorks, Thebarton, SA, Australia) to confirm the 
correct product size. Analysis of the dissociation curve and gel electrophoresis was used to exclude the 
formation of primer dimers or non-specific products. PCR products were excised from the gel and 
purified using UltraClean® 15 DNA Purification Kit (MoBio, Carlsbad, CA, USA) according to the 
manufacturer’s instruction (https://mobio.com/media/wysiwyg/pdfs/protocols/12100-300.pdf). The 
purified DNA samples were then sent to Australian Genome Research Facility for Sanger Sequencing 
(Adelaide, SA, Australia). The returned sequence result of each primer pair was confirmed with NCBI 
BLAST database.  
Once it was determined that the primers were specific for the gene of interest, assay optimisation and 
validation experiments were performed to determine the amplification efficiency of each primer pair. 
Primer efficiency was determined by performing qPCR with a serial dilution (neat, 1/8, 1/64, 1/512 and 
1/4096) of cDNA from murine PALN tissue. Then the amplification efficiency was calculated based on 
the equation: E = (10^ (-1/slope)-1) *100, where the slope was the standard curve of log10 of dilutions 
and corresponding CT value from each qPCR result. All primers were determined to have a correlation 
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Table 2.2 Primers designed by Primer Express for qRT-PCR 







Ctla2a 5' CAGGAAGGAAAAGGCGGAG 0.25 51 NM_007796 
  3' GGCTGGTGGTACTTGAGGAGAG     
Ctse 5' TGACCGTGGAAATAACCAAGTG 0.10 51 NM_007799 
  3' CCTCTTTAGGGAACTGCGGG     
Gmpr 5' CAAAGTGGGAGTCGGACCAG 0.50 51 NM_025508 
  3' CCTGTCTTGGTTCGGGTGG     
Ifng 5' GCGTCATTGAATCACACCTG 0.25 129 NM_008337.3 
  3' TGAGCTCATTGAATGCTTGG     
Il1r1 5' CCCTGGCTTGTGTTACAGCA 0.25 52 NM_008362 
  3' AATGTGGAGCCGCTGTGG     
Il12rb2 5' CTCTTTCCATTTTTGCATCAAGTTC 0.10 51 NM_008354 
 3' CACCACCGAAGATGAGTGGG     
Il17a 5' CTGAGAGCTGCCCCTTCACT 0.25 51 NM_010552 
  3' CCACACCCACCAGCATCTTC     
Gapdh 5’ AGAGGCCCTATCCCAACTCG 
3’ TCCCTAGGCCCCTCCTGTTA 
0.25 91 XM_017321385 
Gm6578 5’ AAAGGGCCTTCCTCCATGTG 
3’ TGGTTCCTTGCCTAGGGCTT 
0.25 122 NR_003631  
 
 
2.3 Fetal outcome assessment 
Mated Il10+/+ and Il10-/- (chapter 3), B6 (chapter 4), miR-155+/+ and miR-155-/- (chapter 5) and  
miR-223+/+ and miR-223-/- (chapter 6) female mice were killed between 1100 h and 1400 h on  
DPC 17.5 by cervical dislocation. Uteri were examined for the presence of viable fetuses and females 
were classified as having ‘viable pregnancy’ (at least one viable fetus), or not. The whole uterus of each 
female was dissected and the total number, and number of viable and resorbing implantation sites were 
recorded. Each viable fetus was dissected from the amniotic sac and umbilical cord and fetuses and 
placentae were weighed.  
2.3.1 Lipopolysaccharide (LPS) treatment  
Female mice were weighed on DPC 0.5 and DPC 9.5 to determine whether they were pregnant. 
Females that had gained more than 2 grams on DPC 9.5, compared with DPC 0.5 weight, were 
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considered to be pregnant. Il10-/- and Il10+/+ females were administered with LPS (Salmonella 
typhimurium; 0.25 μg in 200 μl PBS with 0.1% bovine serum albumin (BSA); intra-peritoneally (i.p), 
Sigma-Aldrich) on DPC 9.5 to evaluate the impact of inflammatory challenge on pregnancy outcomes. 
miR-155-/-, miR-155+/+, miR-223-/- and miR-223+/+ females were administered with LPS from E. coli 
(Escherichia coli; 1.0 μg in 200 μl PBS with 0.1% BSA; i.p, Sigma-Aldrich) on DPC 9.5. For all 
experiments, the vehicle control was an equivalent volume of PBS with 0.1% BSA.  
2.4 Flow Cytometry Analysis  
Mesenteric lymph nodes (mLN), spleen, blood, PALN were collected from B6 (chapter 4), and mLN, 
spleen, blood, PALN and uterus were collected from miR-155+/+ and miR-155-/- (chapter 5) or  
miR-223+/+ and miR-223-/- (chapter 6) female mice on DPC 3.5 or at oestrus for flow cytometry 
analysis.  
2.4.1 Blood collection 
For anaesthesia, mice received an i.p. injection of 15 μl/g body weight of 2% Avertin (tribromoethanol; 
Sigma-Aldrich, St. Louis, USA). Blood was collected by cardiac puncture from the female mice after 
anaesthesia, and then lymphocytes were separated using Lympholyte®-Mammal Separation media 
(Cedarlane, Ontario, Canada). Blood was diluted with 1.5 mL RPMI 1640 (no phenol red) (Gibco®, Life 
Technologies, Scoresby, VIC, Australia), supplemented with 10% fetal bovine serum (FBS) (Gibco®, 
Life Technologies) and 1% penicillin/streptomycin (10,000 U/mL) (Gibco®, Life Technologies) (cRPMI) 
prior to underlying Lympholyte separation media (3 mL). Blood was centrifuged at 800 x g for 20 min at 
RT without brake. The well-defined lymphocyte layer (middle layer) was collected after centrifugation, 
and then washed in cRPMI for 800 x g for 10 min before flow cytometry staining.  
2.4.2 Spleen collection 
Spleens were harvested and homogenised by gently pressing the splenic tissue through a 70 µm nylon 
cell strainer (BD Falcon, Bedford, USA) using a 5 mL syringe plunger (BD, Bedford, USA). Cells were 
then filtered through the 70 µm nylon cell strainer and washed in cRPMI. Red blood cells (RBC) were 
lysed in 1x RBC lysis buffer (2 mL, 0.155 M NH4Cl, 10 mM KHCO3, 99.2 µM EDTA disodium salt in RO 
water) at RT for 15 s, and washed in cRPMI at 400 x g for 5 min before flow cytometry staining. 
2.4.3 mLN and PALN collection 
mLN and PALN were collected and homogenised by gently grinding the tissues between the frosted 
ends of two SuperFrost glass slides (HD Scientific Supplies Pty Ltd, NSW, Australia) in a 35 mm petri 
dish (BD Falcon, Bedford, USA).  Cells were then filtered through a 70 µm nylon cell strainer and 
washed in cRPMI at 400 x g for 5 min before flow cytometry staining.  
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2.4.4 Uterus collection  
Uterine tissue was harvested, placed in PBS and trimmed of fat, mesentery, and blood vessels under a 
dissection microscope (Olympus, New York, NY). Uterine horns were then finely chopped in 2 mL of 
RPMI 1640 supplemented with 2% FBS (Gibco, Life Technologies), 1 mg/mL collagenase (Clostridium 
histolyticum, Sigma-Aldrich) and amplification grade DNase I (4 unit/mL). Fragmented uterine tissues 
were incubated with regular shaking for 30 min at 37 oC. Digested cells were passed through a 70 µm 
cell strainer. Undigested tissues were ground between the frosted ends of two SuperFrosted glass 
slides (HD Scientific Supplies Pty Ltd, NSW, Australia), washed with RPMI 1640 supplemented with 10% 
FBS and passed through a 70 µm nylon cell strainer. To remove non-viable cells, FBS (2 mL) was 
carefully deposited in the bottom of the tube, and viable cells were collected as the pellet after 
centrifugation at 400 x g for 5 min without brake, before flow cytometry staining.  
2.4.5 Cell count 
For chapter 4, the total cell numbers from PALN, mLN spleen and blood were determined by using 
CountBrightTM Absolute Counting Beads, for flow cytometry according to the manufacturer’s instruction 
(https://tools.thermofisher.com/content/sfs/manuals/mp36950.pdf). For chapter 5 and 6, the total cell 
numbers from PALN, uterus, mLN, spleen and blood were determined by using a haemocytometer. 
2.4.6 Cytokine stimulation assay 
Half of the cells isolated from mLN, spleen, blood and PALN for experiments in chapter 4 were used for 
in vitro cytokine stimulation assays. The other half of the cells were stained for flow cytometry 
(described in 2.4.7). Cells for in vitro cytokine stimulation assays were initially resuspended in cRPMI, 
diluted in 0.4% trypan blue (Sigma-Aldrich, MO, USA) and counted using a haemocytometer. Viable 
cells were resuspended at 1.0 x 107 cells/mL, and incubated with stimulation media (cRPMI with phornp; 
12-myristate 13-acetate (PMA) (final concentration 0.1 μg/mL), ionomycin (final concentration  
1.0 μg/mL), and monensin (eBioscience, final concentration 2 µM) at 37 oC with 5% CO2 for 4 h. Then 
cells were harvested and washed in cRPMI at 400 x g for 5 min before flow cytometry staining.  
2.4.7 Labelling of Single Cell Suspensions for Flow Cytometry 
In this section, all centrifuge steps were at 300 x g for 5 mins at 4 oC unless otherwise stated. Single cell 
suspensions from mLN, spleen, blood, PALN and uterus were washed with 2 mL of  
fluorescence-activating cell sorting (FACS) buffer (0.1% BSA/0.5% Sodium Azide in 1 x PBS) and 
centrifuged. Cell viability was determined by adding 100 µL of 1/1000 fixable viability dye FSV620 (BD 
Pharmingen™, BD Biosciences, San Diego, USA) for 15 min at RT. Cells were then washed in 3 mL of 
PBS. Fc Receptors were blocked by resuspending cells in 50 µl of 1/100 anti-Fc-γIIR antibody (FcBlock, 
BD Pharmingen™) in FACS buffer for 10 min at 4 oC.  
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For Treg cell labelling, surface markers were labelled by adding 50 µl of an antibody master mix 
(Fluorescein isothiocyanate (FITC) conjugated anti-CD3 antibody (BD Pharmingen™); Phycoerythrin 
(PE) conjugated anti-CD4 antibody (BD Pharmingen™) and PE-Cyanine 7 conjugated anti-CD25 
antibody (eBioscience, San Diego, USA)) (all antibodies diluted 1/100 in FACS buffer) for 15 min at RT 
(Table 2.3). Cells were then washed with 3 mL of FACS buffer and PBS followed by centrifugation. 
Following surface staining, the intracellular Treg cell marker Foxp3 was stained using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Cells were initially permeabilised with 500 
µl permeabilisation solution at 4 oC for 30 min and washed in permeabilisation buffer. To detect Treg 
cells, the cells were then incubated with Allophycocyanin (APC) conjugated anti-Foxp3 antibody 
(eBioscience) at 1/100 dilution in permeabilisation buffer for 30 min (Table 2.3). Cells were then washed 
in permeabilisation buffer (3 mL) and resuspended in PBS (300 mL) before FACS analysis.  
For APC labelling, surface markers were labelled by adding 50 µl of an antibody master mix (APC-Cy7 
conjugated anti-CD11b antibody (BD Pharmingen™); BV510 conjugated anti-CD11c antibody (BD 
Pharmingen™); PE conjugated anti-F4/80 antibody (BD Pharmingen™); Alex488 conjugated anti-I-A/I-E 
antibody (BD Pharmingen™); PE-Cyanine 7 conjugated anti-CD80 antibody (eBiosciences) and APC 
conjugated anti-CD86 antibody (eBiosciences)) (all antibodies diluted 1/100 in FACS buffer, except 1/50 
dilution for F4/80) for 15 min at RT (Table 2.4). Cells were then washed in FACS buffer (3 mL) and 
resuspend in PBS (300 µL) before FACS analysis.  
For cytokine stimulation assay, surface and intracellular markers for both unstimulated cells and 
stimulated cells were shown in Table 2.5. Surface markers were labelled by adding 50 µl of an antibody 
master mix (FITC conjugated anti-CD4 antibody (BD Pharmingen™) and PE-Cyanine 7 conjugated  
anti-CD25 antibody (eBioscience, San Diego, USA)) (all antibodies diluted 1/100 in FACS buffer) for 15 
min at RT (Table 2.5). Cells were then washed with 3 mL of FACS buffer and PBS followed by 
centrifugation. For unstimulated cells, following surface staining, the intracellular Treg cell marker Foxp3 
was stained using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Cells were initially 
permeabilised with 500 µl permeabilisation solution at 4 oC for 30 min and washed in permeabilisation 
buffer. To detect Treg cells, the cells were then incubated with APC conjugated anti-Foxp3 antibody 
(eBioscience) at 1/100 dilution in permeabilisation buffer for 30 min (Table 2.5). Cells were then washed 
in permeabilisation buffer (3 mL) and resuspended in PBS (300 mL) before FACS analysis. For 
stimulated cells, following surface staining, cells were incubated in 50 µl of an antibody master mix to 
detect intracellular cell marker Foxp3 and Il17 (APC conjugated anti-Foxp3 antibody (eBioscience) and 
PE conjugated anti-IL17A antibody) (all antibodies diluted 1/100 in permeabilisation buffer). Then cells 
were washed and resuspended in PBS (300 µl) before FACS analysis.  
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Data were analysed using a FACS Canto II analyser (BD Biosciences, San Jose, USA) and FACS Diva 
software (version 6.0, BD Biosciences). Gates were applied to the forward scatter/side scatter dot plots 
to exclude cell debris from analysis. The FACS gating strategies are described in each results chapter. 
 
Table 2.3 Monoclonal antibodies used in flow cytometric analysis of Treg cells 
mAb  Conjugate Clone Source 
CD3 FITC 17A2 BD Pharmingen™ 
CD4 PE H129.19 BD Pharmingen™ 
CD25 PE-Cy7 PC61.5 eBioscience 
FOXP3 APC FJK-16S  eBioscience 
 
 
Table 2.4 Monoclonal antibodies used in flow cytometric analysis of antigen presenting cells 
mAb  Conjugate Clone Source 
CD11b APC-Cy7 M1/70 BD Pharmingen™ 
CD11c BV510 HL3 BD Pharmingen™ 
F4/80 PE T45-2342 BD Pharmingen™ 
I-A I-E (MHC II) ALEX488 M5/144.15.2 BD Pharmingen™ 
CD80 PE-CY7 16-10A1 eBioscience 
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Table 2.5 Monoclonal antibodies used before and after in vitro stimulation in flow cytometric analysis 
mAb  Conjugate Clone Source 
CD4 FITC GK 1.5 BD Pharmingen™ 
CD25 PE-Cyanine7 PC 61.5 BD Pharmingen™ 
FOXP3 APC FJK-16S eBioscience 
IL17A PE eBio17B7 eBioscience 
 
2.5 Statistical Analysis 
Data were assessed for normal distribution with a Shapiro-Wilk normality test using GraphPad Prism v6 
(GraphPad software Inc, San Diego, USA) or SPSS Statistics Version 20.0 (IBM Corporation, Armonk, 
NY, USA). The effect of maternal genotype on % viable pregnancy (number of females classified as 
‘viable pregnancy’, as percentage of total mated mice) was analysed by Chi-square analysis. The effect 
of maternal genotype on resorption rate and viable fetus per litter in chapter 3, 5 and 6 was analysed by 
unpaired T-test, or one-way ANOVA and Sidak T test. The effect of maternal genotype on fetal weight, 
placental weight and fetal:placental weight ratio in chapter 5 and 6 was analysed by mixed model 
analysis, with mother as subject, and litter size (total number of implantations) as covariate when 
identified as having a significant effect (as specified in Figure legends). If data were not normally 
distributed, data were analysed using Kruskal-Wallis H test and Mann-Whitney U test. Data are 
presented as the mean ± SEM (standard error of mean). The difference between groups was 
considered statistically significant if p<0.05. In some cases, superscript letters (a, b and c) were used to 
indicate differences between treatment groups. In other cases, an asterisk (*) identifies a treatment or 
















 An Altered T Regulatory Cell 
Gene Expression Profile is Associated 
with Lipopolysaccharide Induced Fetal 







The data in this chapter has contributed to a publication entitled “Unstable Foxp3+ regulatory T cells and 
altered dendritic cells are associated with lipopolysaccharide-induced fetal loss in pregnant  
interleukin 10-deficient mice”. For full detail of the publication, please see section 8.4.  
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3.1 Abstract 
Maternal immune tolerance of the semi-allogeneic fetus requires CD4+Foxp3+ T Regulatory (Treg) cells, 
which suppress inflammation and anti-fetal immunity. Prominent among the regulatory cytokines that 
contribute to the establishment of tolerance is interleukin-10 (IL10).  IL10 deficiency is known to elevate 
susceptibility to fetal loss in syngeneic and allogeneic pregnancies, but the mechanisms are not well 
elucidated. In this study, we assessed the specific contribution of maternal IL10 in the maintenance of a 
tolerogenic immune environment and examined the impact of IL10 deficiency on the Treg cell 
transcriptome. To evaluate the impact of maternal IL10 deficiency on susceptibility to fetal loss, Il10-/- or 
Il10+/+ females were mated with Balb/c males, pregnant females were administered LPS (0.25 µg) or 
PBS control on day 9.5 postcoitum (DPC), and pregnancy outcomes were determined on DPC 17.5.  
Il10-/- mice mated to Balb/c were more susceptible to fetal loss when challenged with LPS, with a lower 
proportion of Il10-/- mice carrying viable fetuses (33% in Il10-/- and 91% in Il10+/+ mice, p=0.019) and a 
higher rate of fetal resorption in Il10-/- mothers (68% in Il10-/- and 20% in Il10+/+ mice, p=0.03). In a 
separate cohort, Il10-/- or Il10+/+ CD4+CD25+ T cells were isolated from para-aortic lymph nodes 
(PALN) of pregnant mice on DPC 9.5-11.5, total RNA was extracted, and Affymetrix microarray and 
qPCR were conducted to evaluate the Treg cell gene expression profile. Affymetrix microarray revealed 
an altered transcriptional profile in Treg cells from pregnant Il10-/- mice, with elevated expression of the 
immune associated genes, cathepsin E (Ctse), Il1r1, Il12rb2 and Ifng. In conclusion, the absence of 
maternal IL10 plays a crucial role in protecting against inflammation induced fetal loss in pregnancy and 
further impacts the gene expression profile in Treg cells. These findings suggest a pivotal role for IL10 
in facilitating robust immune protection of the fetus from inflammatory challenge and suggest IL10 
deficiency could contribute to human gestational disorders where altered T cell responses are 
implicated.  
3.2 Introduction  
Inheritance by the conceptus of maternal and paternal transplantation antigens results in the fetus being 
a semi-allogeneic challenge to the mother. Substantial adaptations in the maternal immune system are 
required to tolerate the fetus and suppress deleterious inflammatory responses that cause gestational 
disorders and fetal demise. Secretion of immune-regulatory cytokines and hormones by placental 
trophoblasts and uterine cells (Lin et al., 1993, Munoz-Suano et al., 2011, Szekeres-Bartho et al., 2009) 
constrain inflammation and limit type 1 immunity, particularly in the gestational tissues and local lymph 
nodes. Prominent amongst these cytokines is IL10 (Lin et al., 1993, Thaxton and Sharma, 2010), a 
cytokine that stimulates and reinforces modifications to the innate and adaptive immune system, 
including induction of regulatory phenotypes in the dendritic cell (DC), macrophage and T lymphocyte 
compartments (Fiorentino et al., 1991a, Fiorentino et al., 1991b, Maynard and Weaver, 2008). 
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Experiments in Il10 null mutant (Il10-/-) mice demonstrate that in the absence of maternal IL10, neither 
allogeneic nor syngeneic pregnancies are compromised (Rowe et al., 2011, Svensson et al., 2001, 
White et al., 2004). However pregnant Il10-/- mice are highly vulnerable to inflammatory challenge, with 
administration of low dose LPS or other Toll-like receptor (TLR) ligands causing elevated rates of fetal 
resorption (miscarriage) (Murphy et al., 2005, Robertson et al., 2007) or preterm delivery (Robertson et 
al., 2006, Thaxton et al., 2009) in syngeneic matings, depending on gestational timing of the insult. 
The mechanisms through which IL10 controls inflammatory mediators have not been defined, although 
uterine natural killer (uNK) cells and tumour necrosis factor (TNF) appear to be involved in promoting 
fetal loss when pregnant Il10-/- mice are challenged (Murphy et al., 2005). We postulate that in the 
absence of IL10, anti-inflammatory mechanisms protecting the fetus are compromised. One of the key 
leukocyte populations likely to be affected by absence of IL10 is T regulatory (Treg) cells, a subset of 
anti-inflammatory and immune suppressive CD4+ T lymphocytes, defined by their expression of the 
transcription factor fork-head box P3 (Foxp3) (Fontenot et al., 2005, Fontenot et al., 2003). The critical 
role of Treg cells in limiting inflammation and mediating immune tolerance is demonstrated in Foxp3 null 
mutant mice (Scurfy mice) that develop a lethal multi-organ lymphoproliferative disorder (Brunkow et al., 
2001). IL10 is implicated in the generation of Treg cells and is prominent in aspects of their suppressive 
function (Maynard and Weaver, 2008, Shevach, 2009), including in pregnancy where neutralising IL10 
abrogates the protective effects of Treg cells in a murine abortion model (Schumacher et al., 2007). 
IL10 also influences macrophages and DCs, which have important roles in sustaining pregnancy 
independently of T cells (Erlebacher, 2013) as well as through specific antigen-presenting and  
immune-regulatory functions including control of the generation of induced Treg cells from naïve T 
lymphocyte precursors (Maynard and Weaver, 2008). During murine pregnancy, Treg cells are elevated 
in the gestational tissues and systemic circulation by approximately 50% in mid-gestation (Kallikourdis 
et al., 2007, Rowe et al., 2011) and similar changes are evident in pregnant women (Saito et al., 2005, 
Santner-Nanan et al., 2009). Experiments in Treg cell depleted mice (Aluvihare et al., 2004, Zhao et al., 
2007) and abortion-prone mice (Zenclussen et al., 2005) show these cells are essential for establishing 
allogeneic pregnancy. Their immune regulatory actions are most crucial around the time of embryo 
implantation, when their abundance is a limiting factor in implantation and placental development 
(Shima et al., 2010). Experiments using tetramers demonstrate the majority of the maternal Treg cells 
which expand in pregnancy are fetal antigen-specific (Rowe et al., 2011), and dependence on the CNS1 
regulatory region in the Foxp3 gene confirms this is at least partly the result of extrathymic generation of 
inducible (peripheral) Treg cells responding to fetal alloantigen (Samstein et al., 2012) after initial 
priming in response to paternal seminal fluid at conception (Robertson et al., 2009a). Treg cells have 
recently been shown to protect the fetus from preterm delivery induced by the Toll-like receptor (TLR) 4 
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ligand bacterial LPS (Bizargity and Bonney, 2009) and fetal loss induced by the TLR9 ligand DNA motif 
CpG (Lin et al., 2014). Although IL10 is important in Treg cell suppressive function, Treg cells can 
develop and execute at least some pro-tolerance functions independently of IL10 (Maynard et al., 2007, 
Pillai et al., 2011, Rowe et al., 2011). 
We have recently demonstrated that Il10-/- mice exhibit altered local T cells responses, with a 
pronounced hyperplasia in PALN draining the uterus and a greater than 6-fold increase in CD4+ and 
CD8+ T cells observed (Prins et al., 2015). Amongst the increased CD4+ T cells, Treg cells were found 
to be substantially enriched, with 11-fold higher numbers at DPC 9.5 in Il10-/- mice (Prins et al., 2015). 
Moreover, more activated phenotypes of DCs and macrophages were found in the Il10-/- mice during 
pregnancy (Prins et al., 2015). Despite the increased numbers of IL10-/- Treg cells, these cells 
expressed low Foxp3 and had impaired suppressive capacity (Prins et al., 2015). Given the significance 
of Foxp3 as a master regulator of Treg cell function (Yagi et al., 2004, Fontenot et al., 2003), this raises 
the question of whether IL10 deficiency may impact on the molecular composition of the Treg cells 
during pregnancy and contribute to facilitating robust immune protection of the fetus. In this study we 
utilised Il10 null mutated mice to address the role of IL10 in the protecting fetus from inflammatory 
insults and the gene expression profile in the Treg cell population.  
3.3 Results 
3.3.1 Effect Maternal IL10 Deficiency Elevates LPS-Induced Fetal Loss 
Previously, we reported that the Il10 null mutation causes elevated fetal loss when pregnant mice 
carrying syngeneic IL10-deficient fetuses are administered low-dose LPS (Robertson et al., 2007). To 
investigate the contribution of maternal IL10 to this increased susceptibility, Il10-/- and Il10+/+ B6 
females were mated with Il10+/+ Balb/c males to generate allogeneic pregnancies with maternal, but 
not fetal IL10 deficiency. On DPC 9.5, pregnant females were administered LPS at a low dose  
(0.25 µg/mouse) identified previously to induce fetal loss in pregnant Il10-/- mice but not in Il10+/+ 
controls (Robertson et al., 2007). In mice examined just before term on DPC 17.5, Il10-/- mice were 
more severely affected by LPS treatment than control mice, with a lower proportion of Il10-/- mice 
carrying viable fetuses at DPC 17.5 (33% in Il10-/- vs 91% in Il10+/+ mice, p=0.019) (Figure 3.1A). 
Furthermore, LPS caused a higher rate of fetal resorption in Il10-/- mothers (68% in Il10-/- vs. 20% in 
Il10+/+ mice, p=0.030) (Figure 3.1B), resulting in significantly fewer viable fetuses per mated females 
(2.57 viable fetuses in Il10-/- vs 5.91 fetuses in Il10+/+, p<0.05) (Figure 3.1C). No effects of genotype or 
LPS treatment on fetal weight, placental weight, or fetal weight: placental weight ratio were seen (Figure 
3.1D, E, and F). Thus, elevated fetal loss in Il10-/- mothers can be largely attributed to maternal, as 
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Figure 3.1 The effect of Il10 null mutation on pregnancy parameters after low-dose LPS challenge. Il10+/+ 
and Il10-/- B6 mice were mated with Balb/c males and injected i.p. with LPS (1µg) or control (PBS) on DPC 9.5, 
then autopsied on DPC 17.5. Data are the percentage of mated females pregnant with viable fetuses (A); the 
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percentage of total implantation sites per pregnant female undergoing resorption (individual data points with 
mean ± SEM; B), the number (mean ± SEM) of viable implantation sites per mated mouse (individual data points 
with mean value shown; C), the fetal weight (estimated marginal mean ± SEM; D), the placental weight 
(estimated marginal mean ± SEM; E), and the fetal: placental weight ratio (estimated marginal mean ± SEM; F). 
Numbers of mated mice are shown in parentheses. The effect of genotype was evaluated in (A) by Chi-square 
analysis and in (B) by ANOVA and Sidak t-test. The effect of genotype was evaluated in (D-F) by mixed model 
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3.3.2 IL10 Deficiency Alters Gene Expression Profile in Treg Cells 
Treg cells from Il10-/- mice exhibited reduced Foxp3 expression and functional capacity (Prins et al., 
2015) which raised the question of whether Treg cells have an altered genotype in pregnant Il10-/- mice. 
To examine this, we performed a microarray experiment using Affymetrix microarrays on CD4+CD25+ T 
cells isolated by magnetic cell sorting from PALN of Il10-/- and Il10+/+ mice on DPC 9.5. Four biological 
replicates of CD4+CD25+ T cell RNA (each pooled from two or three different mice) from each genotype 
were reverse transcribed into cDNA and hybridised to Affymetrix Mouse Gene 2.0 ST Arrays. Principal 
component analysis showed clustering of cDNAs according to genotype (Figure 3.3A). A total of 52 
probe sets were classified as highly differentially expressed with high-stringency criteria (fold 
change >2.0, P<0.05) between genotypes, with 45 genes upregulated and 7 genes downregulated 
(Figure 3.3B). Of the genes upregulated in Treg cells from Il10-/- mice, seven have potential relevance 
to Treg cell function, identified by Ingenuity Pathway Analysis and literature searches as linked with 
cytokine-cytokine receptor interactions (Il10; upregulated 2.1-fold), maintenance of Treg cell function 
(Ctse, Lilrb4, and Slpi; upregulated 7.2-, 2.1-, and 2.7-fold, respectively), and loss of Treg cell function 
(Cd24a, Ighm, and Igj; upregulated 2.0-, 10.1-, and 3.1-fold, respectively) (Table 3.1). Using a  
low-stringency analysis (fold-change >1.4, P<0.1), a total of 299 genes were classified as moderately 
differentially regulated by IL10 deficiency, including 247 that were upregulated and 52 that were 
downregulated in Il10-/- compared to Il10+/+ Treg cells. Of these, 47 were identified as associated with 
cytokine signalling or Treg cell stability and function, with a total of 42 upregulated and 5 downregulated 
in Il10-/- compared to Il10+/+ CD4+CD25+ T cells (Table 3.2). Several genes of interest were 
independently quantified by qPCR in CD4+CD25+ T cells from PALN of pregnant Il10+/+ and Il10-/- 
mice on DPC 9.5. In the absence of IL10, increases were detected in expression of Ctse encoding the 
intracellular proteinase cathepsin E (155-fold, P<0.0001) (Figure 3.3A), Ctla2 encoding the cytotoxic T 
lymphocyte associated protein 2 complex (CTLA2) (4.4-fold, P<0.01) (Figure 3.3B), Il1r1 encoding the 
IL1 receptor type 1 (10.4-fold, P<0.05) (Figure 3.3D), and Ifng encoding the Th1 cytokine IFNG (6.3-fold, 
P<0.05) (Figure 3.3E). A trend to increased expression was seen in Il12rb2 encoding the IL12 receptor 
beta 2 subunits (8.3-fold, P=0.076) (Figure 3.3F). No consistent change was seen in expression of other 
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Table 3.1 Genes of interest identified as highly differentially expressed using high-stringency criteria in Affymetrix microarray analysis of mRNA expression in 
purified Treg cells from Il10+/+ or Il10-/- mice. 
Accession # Gene Symbolǂ WT mean KO mean Difference Fold-change P value 
    
 
Cytokine - Cytokine Receptor Interactions 
   NM_010548 Il10* 275.21 575.51 300.30 2.09 0.0087 
       Maintenance of Treg function (immune tolerance) 
    NM_007799 Ctse 454.62 3256.71 2802.09 7.16 0.0000 
NM_013532 Lilrb4 396.62 849.90 453.28 2.14 0.0483 
NM_011414 Slpi 248.11 680.08 431.97 2.74 0.0463 
       Loss of Treg function (inflammation and apoptosis) 
    NM_009846 Cd24a 614.44 1772.60 1158.16 2.88 0.0302 
BC053409 Ighm 26.46 266.33 239.87 10.06 0.0239 
NM_152839 Igj 151.28 471.01 319.73 3.11 0.0191 
*High stringency criteria: Fold-change >2.0, p<0.05, Difference between means >100.  
ǂ All genes listed are upregulated in Il10-/- mice compared to Il10+/+ mice.  
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Table 3.2 Genes of interest identified as moderately differentially expressed using low stringency criteria in Affymetrix microarray analysis of mRNA expression 
in purified Treg cells from Il10 +/+ or Il10 -/- mice. 
Accession # Gene Symbol WT mean  KO mean Difference Fold-change P value 
Upregulated in Il10-/- compared to Il10+/+ 
      
Cytokine - Cytokine Receptor Interactions 
     ENSMUST00000168841 Ccr2 1140.44 1733.71 593.28 1.52 0.0027 
NM_008337 Ifng 161.95 228.54 66.59 1.41 0.0017 
NM_010548 Il10 275.21 575.51 300.30 2.09 0.0087 
NM_008354 Il12rb2 155.63 235.86 80.22 1.52 0.0049 
NM_010552 Il17a 112.80 167.19 54.39 1.48 0.0699 
NM_008362 Il1r1 445.15 834.33 389.18 1.87 0.0475 
NM_010555 Il1r2 616.30 865.09 248.79 1.40 0.0912 
       Maintenance of Treg function (immune tolerance) 
    NM_007796 Ctla2a 566.15 984.66 418.51 1.74 0.0065 
NM_001145801 Ctla2b 75.99 162.47 86.49 2.14 0.0114 
NM_007799 Ctse 454.62 3256.71 2802.09 7.16 0.0000 
ENSMUST00000102894 Gp49a 62.06 199.23 137.17 3.21 0.0727 
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NM_013532 Lilrb4 396.62 849.90 453.28 2.14 0.0483 
NM_134250 Havcr2 89.47 162.57 73.10 1.82 0.0460 
ENSMUST00000112063 Klrd1 134.36 226.54 92.18 1.69 0.0538 
ENSMUST00000040250 Kmo 125.79 192.92 67.13 1.53 0.0361 
NM_001168392 Ramp1 254.87 361.58 106.71 1.42 0.0047 
NM_011414 Slpi 248.11 680.08 431.97 2.74 0.0463 
       Loss of Treg function (Inflammation and Apoptosis) 
    ENSMUST00000071130 Alox5ap 103.56 162.98 59.42 1.57 0.0524 
NM_019735 Apip 197.34 300.70 103.36 1.52 0.0952 
NM_001081001 Brca2 150.40 212.02 61.62 1.41 0.0185 
NM_001167949 Atp2b4 346.07 521.67 175.60 1.51 0.0082 
NM_001113179 Bub1 217.26 359.51 142.25 1.65 0.0306 
ENSMUST00000040182 Ccdc88a 183.33 258.63 75.30 1.41 0.0388 
NM_009846 Cd24a 614.44 1772.60 1158.16 2.88 0.0302 
NM_023223 Cdc20 257.37 369.84 112.47 1.44 0.0792 
NM_007793 Cstb 800.50 1149.87 349.37 1.44 0.0099 
ENSMUST00000113480 Cysltr1 156.41 255.65 99.24 1.63 0.0132 
NM_133720 Cysltr2 442.39 630.91 188.52 1.43 0.0779 
NM_001172092 Depdc1a 87.18 181.70 94.52 2.08 0.0314 
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NM_013542 Gzmb 275.27 679.82 404.55 2.47 0.0955 
NM_008252 Hmgb2 1046.23 1474.18 427.95 1.41 0.0202 
NM_013552 Hmmr 165.16 265.01 99.85 1.60 0.0564 
NM_008287 Hrsp12 265.76 459.97 194.21 1.73 0.0516 
NM_008297 Hsf2 265.12 375.02 109.90 1.41 0.0011 
NM_028680 Ift57 253.93 392.46 138.53 1.55 0.0030 
BC053409 Ighm 26.46 266.33 239.87 10.06 0.0239 
NM_152839 Igj 151.28 471.01 319.73 3.11 0.0191 
NR_029853 Mir363 18.77 69.03 50.26 3.68 0.0669 
ENSMUST00000034065 Nek1 206.78 291.49 84.71 1.41 0.0304 
NM_016764 Prdx4 207.89 332.82 124.93 1.60 0.0140 
NM_009185 Stil 122.78 192.02 69.24 1.56 0.0369 
NM_011623 Top2a 994.79 1517.60 522.81 1.53 0.0166 
       Downregulated in Il10-/- compared to Il10+/+ 
 
Cytokine - Cytokine Receptor Interactions 
     NM_009835 Ccr6 738.72 517.30 -221.42 -1.43 0.0039 
NM_008348 Il10ra 579.48 391.00 -188.48 -1.48 0.0775 
NM_019583 Il17rb 508.26 317.06 -191.20 -1.60 0.0377 
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       Maintenance of Treg function (immune tolerance) 
    NM_011267 Rgs16 770.78 516.25 -254.53 -1.49 0.0749 
AK042280 Slamf6 428.06 266.81 -161.25 -1.60 0.0686 
 
Stringency criteria: Fold-change >1.4, p<0.1, Difference between means >50. 
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Figure 3.2 Microarray analysis showing the effect of Il10 null mutation on the gene expression profile in 
CD4+CD25+ Treg cells. Treg cells were isolated from PALN on day 9.5 pc from Il10+/+ and Il10-/- mice mated 
with Balb/c males. RNA was extracted and gene expression measured by Affymetrix Mouse Gene 2.0 ST arrays 
(n = 4 biological replicated pooled from n=2-4 mice from a total of 12 samples per genotype). Microarray data was 
analysed by Partek Genomics Suite to generate (A) principal component analysis, blue dots represents Il10-/- and 
red dots represent Il10+/+ cells, and (B) heat map data for a total of 52 probe sets classified as highly 
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Figure 3.3 The effect of Il10 null mutation on gene expression in Treg cells. CD4+CD25+lymphocytes were 
recovered from PALNs of Il10+/+ and Il10-/- B6 mice on DPC 9.5 after mating with Balb/c males. Gene 
expression was assessed by microarray and qPCR was used to confirm the expression of Ctse (A), Ctla2a (B), 
Il17a (C), Il1r1 (D), Ifng (E) and Il12rb2 (F) which were identified as being differentially regulated. Data are the 
expression (mean ± SEM), normalised to reference gene Gmpr, in Treg cells from Il10+/+ mice (n = 12) and  










ZHANG                                                        Chapter 3                                                           53 
3.4 Discussion  
Appropriate control of maternal inflammation is essential for optimal fetal growth and on-time birth. Treg 
cells are paramount among the immune-regulatory leukocytes operating to suppress inflammation and 
promote tolerance at the fetal-maternal interface in pregnant females (Aluvihare et al., 2004, Guerin et 
al., 2009). Currently, a lack of understanding of the maternal and fetal factors that control the generation 
and suppressive function of Treg cells is a limitation in our capacity to tackle human gestational 
disorders, including preeclampsia and preterm birth. These conditions result from excessive maternal 
inflammation and are associated with disturbances in the Treg cell populations (Guerin et al., 2009, 
Santner-Nanan et al., 2009).  
In the present study, we demonstrated that Il10-/- mice are more susceptible to fetal loss when 
challenged with LPS in allogeneic pregnancy, even when the foetuses are Il10+/- as a result of mating 
Il10-/- females with Il10+/+ males, and then demonstrated the Treg cells generated in PALN of pregnant 
Il10-/- mice display altered expression of Ctse and other genes linked with Treg function. This, coupled 
with the finding that IL10 deficient Treg cells have altered functional features indicating decreased 
stability (Prins et al., 2015) are likely to contribute to the elevated susceptibility of Il10-/- mice to 
inflammatory challenge and fetal loss (Murphy et al., 2005, Robertson et al., 2007, Robertson et al., 
2006). 
Altered T cell immunity in IL10-deficient mice appears not to affect tolerance of fetal alloantigens, 
because steady-state pregnancy progresses normally irrespective of the alloantigenic status of the fetus 
(White et al., 2004). The functional requirement for IL10 becomes apparent when pregnant Il10-/- mice 
are administered low-dose LPS to induce a systemic inflammatory response, revealing a key role for 
IL10 in protecting the fetal-placental tissues from uncontrolled inflammatory cytokines and natural killer 
cell cytotoxicity causing fetal death and/or preterm labour (Murphy et al., 2005, Robertson et al., 2007, 
Robertson et al., 2006). Thus, it seems that a major function of the copious IL10 produced by 
leukocytes, placental trophoblasts, and other cell lineages in gestational tissues (Thaxton and Sharma, 
2010) is to buffer pregnancy in the event of an inflammatory insult. 
These experiments show that IL10 in the maternal compartment, as opposed to the fetal or placental 
tissues, is most crucial for protecting pregnancy. This implies a pivotal role for endogenous IL10 in 
supporting anti-inflammatory and protolerance mechanisms in the mother. IL10 has key actions in Treg 
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cell biology (Asseman et al., 1999, Rubtsov et al., 2008) with our studies demonstrating that when 
maternal IL10 synthesis is disrupted, the generation of Treg cells is disturbed (Prins et al., 2015).   
It is important to consider that in the present study, because fetuses were heterozygous for the Il10 
gene, the maternal compartment is not entirely IL10 deficient. IL10 derived from the fetus and placenta 
can enter the maternal system. This fetal-derived IL10 would be highest through the second half of 
gestation, when maternal blood enters the placental labyrinth. Paracrine effects of fetal IL10 on 
maternal immune cells could reasonably explain the resolution of lymph node hypertrophy by DPC 12.5 
observed in Prins et al., 2015 (Prins et al., 2015). This may also explain why the fetal growth impairment 
seen previously after mid-gestation LPS administration when IL10 is absent from both maternal and 
fetal tissues (Robertson et al., 2007) was not recapitulated in the Prins study (Prins et al., 2015). 
Affymetrix microarray analysis indicated an altered pattern of gene expression in Treg cells in pregnant 
Il10-/- mice. This may be a compensatory response to lack of autocrine IL10 signalling. Production of 
IL10 by Treg cells is one of the central pathways mediating suppressive function, and IL10 deficiency 
constrains Treg cell function to differing extents depending on the tissue (Izcue et al., 2006, Rubtsov et 
al., 2008). This fits with an emerging picture of unique, nonredundant, and specialized roles for 
individual suppressive mediators in Treg cells that are exploited in different physiological and 
pathophysiological settings (Rubtsov et al., 2008). Cell lineage-restricted Il10 null mutation in Foxp3+ 
cells shows a dominant, nonredundant role for Treg cell-derived IL10 in maintaining immune 
homeostasis at environmental surfaces, including the colon, lung, and skin (Rubtsov et al., 2008).  
T cell-specific blockade of IL10 signalling shows that IL10 production from CD4+Foxp3+ Treg cells is 
important for Treg cell suppression of Th17 and Th1 cells (Huber et al., 2011). 
Among the most strongly upregulated genes in Treg cells from Il10-/- mice was Ctse, encoding the 
endolysosomal aspartic proteinase, cathepsin E. Cathepsin E is implicated as a key factor contributing 
to adaptive Treg suppressive mechanisms that are independent of IL10. Elevated Ctse was previously 
reported in Treg cells engineered for deficiency in both IL10 and IL35, where it promotes TNF-related 
apoptosis inducing ligand (TRAIL)-mediated suppression, to compensate for loss of IL10 and IL35 (Pillai 
et al., 2011). Cathepsin E is also associated with increased turnover of IL1B and IL18 through 
degradation of the protein sequestering molecule a2-macroglobulin (Shibata et al., 2003). Ctse is 
induced in inflammation (Nakanishi et al., 1993) in response to cytokines, including IL17 (McAllister et 
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al., 2014) and IFNG (Tsukuba et al., 2003). A previous study found elevated Ctse expression in Il10-/- 
mice after ozone-induced inflammation in the lung (Backus et al., 2010). 
Other differentially regulated genes were detected in Treg cells from Il10-/- mice, with upregulated Ifng 
and a trend to elevated Il17 expression. This shift in disposition to Th1 and Th17 gene expression may 
contribute to the instability of Il10-/- Treg cells we observed after pro-inflammatory stimulation. Genes 
encoding cytokine receptors IL1r1 and IL12rb2 were elevated, as was the T cell marker Ctla2. IL12rb2 is 
required for TGFB-dependent stimulation of Treg cell development, and signalling via this receptor is 
thought to regulate the number and functional maturity of Treg cells (Zhao et al., 2008). 
In summary, we have demonstrated that in pregnancy, maternal IL10 is a key determinant of protection 
from inflammatory challenges. Treg cells generated in the absence of IL10 remain competent to sustain 
allogeneic pregnancy under steady-state conditions, but in the event of inflammatory challenge their 
compromised stability would be a factor in the uNK cell activation and shift to Th1 immunity that causes 
fetal loss. These findings are relevant to understanding the role of IL10 in the immune response to 
pregnancy and may ultimately contribute to elucidating the pathology of preeclampsia and related 
complications of human pregnancy, where a less robust Treg cell response (Santner-Nanan et al., 2009) 
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4.1 Abstract 
Immune adaptation to accommodate pregnancy requires sufficient T regulatory (Treg) cells in the 
endometrium to suppress inflammation, prevent maternal immune rejection and promote maternal 
vascular changes during the critical peri-implantation period. Previously we have demonstrated that 
seminal fluid exposure stimulates the proliferation of Treg cells in mouse lymph nodes and reproductive 
tract tissues. In this study, we aimed to determine the contribution of male major histocompatibility 
complex (MHC) molecules and repeated exposure to seminal fluid in determining the strength of the 
Treg cell response. 
Female C57Bl/6 (B6) female mice were mated either once or four times to syngeneic males (Balb/b 
males; H-2b, no MHC disparity) or allogeneic males (Balb/c males; H-2d, MHC disparity), or three times 
to syngeneic Balb/b then one time to allogeneic Balb/c males (partner-switching model). Progression to 
pregnancy between matings was prevented by administration of RU486 on day 3.5 postcoitum (DPC). 
Virgin oestrous females were used as non-mated controls when required. The population characteristics 
and stability of para-aortic lymph node (PALN) Treg cells were determined on DPC 3.5 after the final 
mating using flow cytometry and cell culture methods. In an additional cohort, pregnancy outcomes 
were assessed through administration of LPS (1.0 µg) or vehicle to pregnant B6 females on DPC 9.5 of 
the final mating. Females were then sacrificed on DPC 17.5 to assess pregnancy outcome parameters 
including percentage of viable pups, resorption rate, fetal weight, placental weight and fetal: placental 
weight ratio. 
A significant expansion in the size of the Treg cell population in the PALN was observed in female mice 
mated four times to Balb/c (19.6-fold, p<0.001), compared with females mated only once to Balb/c. 
Although increases were also seen in females mated four times to Balb/b (7.4-fold, p<0.001) or three 
times to Balb/b and one time to Balb/c (2.6-fold, p<0.01) compared to oestrus controls, the population 
was not greater than in females mated only once, and was less than that in females mated four times to 
Balb/c (p<0.01).   
Repeated mating with Balb/c males also resulted in a more stable Treg cell population in the PALN, 
compared with females mated four times with Balb/b (45% decrease in the Th17/Treg ratio, p<0.05). In 
the steady state, females mated either syngeneically or allogeneically were similarly capable of 
sustaining pregnancy, as no significant difference in the number of viable pups or resorption rate was 
seen. However, LPS injection resulted in a reduced number of viable pups per litter (47%, p<0.05) and 
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an elevated resorption rate (1.72-fold, p=0.07) in repeated syngeneic mating compared to repeated 
allogeneic mating groups.  
Collectively, these data provide evidence that repeated exposure to seminal fluid acts to expand the 
Treg cell pool and increase the stability of Treg cells in the female reproductive tract during early 
pregnancy. These data also demonstrate that MHC alloantigens play a crucial role in the expansion of a 
stable Treg cell population, as repeated mating with syngeneic males was not capable of eliciting the 
same Treg cell response. Interestingly, the robust response observed after repeated mating in 
allogeneic males led to increased protection against inflammatory challenge in mid-gestation. These 
findings may provide a mechanistic explanation linking clinical observations that prior contact with the 
conceiving partner’s seminal fluid is associated with reduced pregnancy complications in women.   
4.2 Introduction  
A variety of adaptions within the maternal immune system are required to establish a tolerogenic 
immune environment during the peri-conception period and to maintain it through gestation (Trowsdale 
and Betz, 2006). Key to these adaptions is the expansion of regulatory CD4+CD25+ Treg cells (Guerin 
et al., 2009, Shima et al., 2010, Shevach, 2009). These cells compromise 5-10% of CD4+ T cells in 
rodents and 1-3% of CD4+ T cells in humans (Sakaguchi, 2000, Shevach, 2002) and are defined as 
having constitutive expression of CD25 (IL-2 receptor α chain) (Sakaguchi et al., 1995) and expression 
of the unique marker Foxp3 (Fontenot et al., 2005, Fontenot et al., 2003).  
In pregnancy, Treg cells support implantation and subsequent fetal development by suppressing 
proliferation and function of CD4+ and CD8+ T cells, B cell and NK cells, as well as impacting DC and 
macrophage maturation and function (Guerin et al., 2009, Shevach, 2002). The expansion of the Treg 
cell pool plays an important role in preparing the uterus for implantation as Treg cell depletion prior to 
implantation results in pregnancy loss in allogeneic matings (Shima et al., 2010, Aluvihare et al., 2004). 
Treg cells can be generated within the thymus (Shevach, 2002) or in the periphery, where local naïve 
CD4+ T cells convert to Treg cells (Akbar et al., 2003). Like other T cells, their suppressive and 
proliferative capacity depends on interaction with cognate antigen presented by antigen presenting cells 
(Thornton and Shevach, 1998, Walker et al., 2003). In the context of pregnancy, the relevant antigens 
are paternal MHC antigens, which are present in seminal fluid and also expressed by conceptus tissue. 
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There is strong clinical and experimental evidence demonstrating that Treg cells contribute to 
maintenance of normal pregnancy in humans. In pregnant women, Treg cells are increased in both 
peripheral blood and decidua in the first and second trimester, followed by a subsequent decline in the 
third trimester and postpartum (Saito et al., 2005, Heikkinen et al., 2004, Tilburgs et al., 2006, Xiong et 
al., 2013). Altered Treg cell populations and compromised Treg cell function are associated with multiple 
pregnancy complications, such as preeclampsia, and recurrent miscarriage. Elevated Th17 and reduced 
Treg cell populations are found in the peripheral blood from preeclamptic women, compared with normal 
pregnant women (Santner-Nanan et al., 2009). In addition, low expression of the Treg cell marker Foxp3 
in the endometrium in non-pregnant cycles is also associated with unexplained infertility (Jasper et al., 
2006).  
Over recent years, studies have begun to highlight that T-cell subsets are not as stable as previously 
assumed and under certain conditions can exhibit plasticity and covert into another T-cell subtype. Treg 
cells can lose Foxp3 expression and convert to IL-17 producing or Th17 cells in a pro-inflammatory 
environment (Osorio et al., 2008, Yang et al., 2008). Treg cells can switch to a Th17 phenotype 
following co-culture with DCs activated by the fungal recognition receptor, dectin-1 (Osorio et al., 2008). 
In addition, TGF-β producing thymic derived Treg cells activated by CD4+CD24- T cells can 
differentiation to Th17 cells in the presence of IL-6 in vitro (Xu et al., 2007). Given the plasticity between 
Treg cells and Th17 cells, studies are required to explore the importance of Treg cell stability in 
supporting pregnancy success.  
Seminal fluid plays an important role in the expansion of Treg cells at the outset of pregnancy 
(Robertson et al., 2009a). Initially, seminal fluid exposure leads to a transient inflammatory response 
coupled with an infiltration of inflammatory cells. This occurs in the ectocervix in humans (Sharkey et al., 
2007, Pandya and Cohen, 1985) and the uterus in mice (Johansson et al., 2004). The presence of 
tolerogenic molecules in seminal fluid, including HLA-G, TGF-β and 19-OH PGE are required to drive 
Treg cell expansion through converting DCs into tolerogenic DCs (Kelly and Critchley, 1997b, Hutter 
and Dohr, 1998, Robertson et al., 2002). The pivotal role of seminal fluid in the expansion of Treg cells 
has been elegantly demonstrated in mice, where the absence of seminal fluid in a vasectomised and 
surgical excision of seminal vesicle male mice failed to expansion Treg cell population in the PALN and 
uterus (Guerin et al., 2011).  
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In addition to the provision of pro-tolerogenic immune regulatory molecules, seminal fluid also provides 
paternal antigens which are an important component for eliciting the female response (Holland et al., 
2012). Paternal alloantigens, particularly MHC, are expressed at low or undetectable levels on sperm 
cells but are present in seminal plasma in a soluble form. These MHC and also minor histocompatibility 
complex antigens are also expressed by the conceptus, including subsets of placental trophoblasts, on 
specific lineages that differ between mice and human. Paternal antigens have been demonstrated to 
activate CD4+ and CD8+ T cells following seminal fluid exposure at conception (Moldenhauer et al., 
2009) indicating that paternal antigens presented by maternal antigen presenting cells may be involved 
in the regulation of Treg cells and their function. Additionally, elevated paternal-specific Treg cells can 
be found in the PALN in female mice on DPC 3.5 and 5.5 following allogeneic matings compared with 
unmated oestrus females (Shima et al., 2015).  
Given the link between Treg cells and pregnancy pathologies, it is interesting that the duration of prior 
exposure to the conceiving partner’s seminal fluid is associated with some pregnancy pathologies in 
humans. Clinical studies demonstrate that women who have had limited exposure to a partner’s seminal 
fluid through use of barrier contraception or short period of cohabitation (<6 months) are more likely to 
develop preeclampsia (Kho et al., 2009, Einarsson et al., 2003, Klonoff-Cohen et al., 1989) than 
individuals who have had a longer period of seminal fluid exposure (Kho et al., 2009), indicating that 
longer term exposure to a specific partner’s seminal fluid exposure may be protective for women from 
preeclampsia development. These findings suggest that the immunological tolerance developed 
following seminal fluid exposure is partner specific and longer periods of exposure to seminal fluid 
strengthens the tolerogenic response leading to better outcomes in pregnancy. The question beyond 
this observation is whether repeated exposure to partner’s seminal fluid strengthens the Treg cell pool, 
and whether this benefit is partner-specific; and whether partner alloantigens, in particular MHC 
antigens are important in Treg cell expansion. Given the pivotal role Treg cells play in establishing 
maternal immune adaption and the contribution of seminal fluid to this response, we hypothesised that 
male alloantigens strengthen the Treg cell response in a partner-specific manner in early pregnancy.  
The experiments described in this chapter aim to assess the influence of repeated exposure to male 
alloantigens on Treg cell expansion in the local PALN, distal secondary lymph tissues and in the 
peripheral blood. In these experiments, a mouse model was utilised where female mice were exposed 
to either syngeneic (Balb/b males) or allogeneic (Balb/c males) male ejaculates once or four times, or 
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exposed to syngeneic ejaculate three times followed by allogeneic ejaculate once. Treg cell number and 
stability were analysed by FACS and pregnancy outcomes were analysed on DPC 17.5.   
4.3 Results 
4.3.1 Expansion of Treg cells pool after repeated exposure to seminal fluid 
Previously, we demonstrated that exposure to male seminal fluid drives the expansion of the Treg cell 
pool on DPC 3.5 in the mouse uterus and PALN (Guerin et al., 2011). To investigate whether repeated 
exposure to seminal fluid further expands the Treg cell population, and whether this expansion is in a 
partner-specific manner, female C57Bl/6 (B6) female mice were mated either once or four times with 
Balb/c (H-2d; allogeneic mating - MHC disparate), Balb/b (H-2b; syngeneic mating - same MHC), or 
three times with Balb/b and one time with Balb/c males (partner switching model). As a mating control, 
oestrous B6 females were utilised. Between each mating, pregnancies were prevented by RU486 as 
described in 2.1.3 and PALN were collected on DPC 3.5. The percentage and total number of Treg cells 
were quantified by FACS. mLN, spleen and blood were also assessed with the data presented in the 
Appendix (see chapter 8, section 8.1.1). 
In order to understand the impact of repeated mating on the Treg cell pool, we compared Treg cell 
populations between repeated matings and a single mating. Despite a 1.1-fold and a 2.9-fold increase in 
Treg cell numbers in the PALN following 1 x mating with Balb/c males and 1x mating with Balb/b males, 
compared to the unmated oestrus control (Figure 4.1A), these differences were not statistically 
significant. No significant change in Treg cell numbers were observed following 1 x mating with Balb/b 
males compared to the 1 x Balb/c mating group.  
We then explored the impact of repeated mating (4 x mating) on the expansion of Treg cells on DPC 3.5 
in the PALN. Repeated mating with allogenic Balb/c males resulted in a significant increase in Treg cell 
numbers compared to both the oestrus control (19.6-fold, p<0.001) and the 1 x Balb/c mating group  
(17.2-fold, p<0.001) (Figure 4.1A). Interestingly, while repeated mating with syngeneic Balb/b males did 
result in an increased Treg cell population compared to the oestrus control (7.5-fold, p<0.001), there 
was no significant expansion observed between females mated 1x with Balb/b males and 4x with Balb/b 
males (Figure 4.1A).  Most notably, repeated mating (4 x mating) to Balb/c males resulted in a 
significant increase in the number of Treg cells compared to 4 x Balb/b mating (2.6-fold increase, 
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p<0.01) showing that repeated exposure to MHC disparate seminal fluid resulted in a more robust Treg 
cell response (Figure 4.1A).  
We then assessed the impact of repeated mating using the partner switching model (3 x Balb/b matings 
and 1 x Balb/c mating) and demonstrated that while switching partners following repeated mating also 
resulted in a significant increase in Treg cell number compared to oestrous females (6.6-fold, p<0.01), 
these numbers were significantly lower than repeated mating with Balb/c males (82%, p<0.0001) and 
equivalent to a single mating with a Balb/b male. Further, while not significant, switching partners 
resulted in a lower number of Treg cells compared to repeated mating to Balb/b males (Figure 4.1A).  
4.3.2 Stability of Treg cells  
In addition to the number of Treg cells, the stability and function of these cells also play an important 
role in regulating the female immune environment during gestation. In this study, Treg cell stability was 
assessed in cells collected from the PALN by flow cytometry following 4h in vitro stimulation using PMA 
(final concentration 0.1 μg/mL) and ionomycin (final concentration 1.0 μg/mL). In all groups, stimulation 
of these cells resulted in a significant reduction in the proportion of Treg cells (Figure 4.1B) and an 
increase in the proportion of Th17 T cells (Figure 4.1C).  
We then compared the impact of stimulation on the ratio of CD4+IL17A+ cells to CD4+CD25+Foxp3+ 
cells in all groups. An increase in the ratio of Th17/Treg cells indicates lower stability in the Treg cell 
phenotype. Stimulation of total cells did not significantly alter the Th17/Treg ratio in most comparisons 
with the exception of a significant decrease in the Th17/Treg ratio in the 4x Balb/c repeated mating 
group compared to the 4x Balb/b mating group (45%, p<0.05, Figure 4.1D). Further, a trend towards an 
increase in the Th17/Treg ratio was observed in females mated 4x with Balb/b, compared with females 
mated 1x with Balb/b (p=0.057, Figure 4.1D). This increase was not observed after repeated mating in 
Balb/c males. Therefore, optimal Treg cell stability requires repeated exposure to seminal fluid from the 
same MHC dissimilar male haplotype. 
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Figure 4.1 The effect of repeated exposure to male alloantigens on the number of Treg cells and stability 
of Foxp3 expression in CD4+ T cells from PALN. B6 females were left unmated, mated 1x with Balb/c, 4x with 
Balb/c, 1x with Balb/b, 4x with Balb/b or 3x with Balb/b and 1x with Balb/c, and on DPC 3.5, PALN was analysed 
by flow cytometry for Treg cell parameters. Data presented as mean ± SEM and are the total cell number of 
CD4+CD25+ Foxp3+Treg cells in the PALN (A), the expression of Foxp3 immediately after cell collection or 4h 
after strong polyclonal PMA/ionomycin stimulation in vitro (B), the expression of IL17A immediately after cell 
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collection or 4h after strong polyclonal PMA/ionomycin stimulation in vitro (C), and the ratio of CD4+IL17+ to 
CD4+CD25+Foxp3+ cells from PALN after stimulation (D). The effect of PMA stimulation was evaluated using a 
paired T test in B and C, and the effect of mating was evaluated using Kruskall-Wallis and Mann-Whitney test in A 
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4.3.3 Repeated exposure to male alloantigens reduced susceptibility of fetal loss post LPS 
challenge in mid-gestation 
Clinical observations suggest that shorter sexual cohabitation is associated with elevated risk of 
pregnancy pathologies such as preeclampsia (Kho et al., 2009). In addition, women who have a new 
conceiving partner are more likely to develop preeclampsia (Klonoff-Cohen et al., 1989, Einarsson et al., 
2003) suggesting that the protective effects following longer periods of cohabitation are partner specific. 
To determine whether the alterations in Treg cell number and stability following repeated mating with 
allogeneic or syngeneic males, or partner switching in males have an impact on pregnancy outcomes a 
cohort of B6 females were assessed for pregnancy outcomes Females were mated either once or four 
times with Balb/c males, Balb/b males or three times with Balb/b and one time with Balb/c males. As 
before, RU486 was administered on DPC 3.5 between each mating to prevent pregnancy, and on  
DPC 9.5 of the final mating, a low dose inflammatory challenge (LPS; 1.0 µg) or vehicle control (PBS) 
was administered to pregnant females, then outcomes were assessed on DPC 17.5.  
Using a low dose inflammatory challenge, there was no impact of LPS on the proportion of mated 
females with a viable pregnancy in all groups compared to the equivalent vehicle control. However, 
females mated 1x or 4x to Balb/b males or mated 3 x Balb/b and 1x Balb/c had a lower proportion of 
viable implants compared to the vehicle control, although the difference failed to reach significance 
(Figure 4.2A). Of those groups, consistent with the Treg cell profiles, females given LPS after mating 4x 
to Balb/b males also had an 36% reduction in females carrying viable implants compared to the 4x 
Balb/c group (p=0.08, Figure 4.2A).  
LPS injection resulted in a reduction in the number of viable pups per mother in all groups except 4x 
matings to Balb/c, and an elevation in the resorption rate in all groups except 3x to Balb/b and 1x to 
Balb/c, compared to mating matched PBS controls (Figure 4.2B and C). Interestingly, following LPS 
treatment, a significantly lower number of viable fetuses was observed in females mated 1x (42%, 
p<0.01, Figure 4.2B) and 4x to Balb/b (47%, p<0.05, Figure 4.2B), compared to females mated 1x or 4x 
to Balb/c males on DPC 17.5. Associated with the reduction in viable fetuses, LPS administration also 
resulted in a trend towards a higher rate of fetal resorption in females mated 4x to Balb/b (1.7-fold, 
p=0.07, Figure 4.2C).  
We then examined the impact of LPS exposure following repeated mating with Balb/c, Balb/b or  
Balb/c + Balb/b on fetal weight, placental weight and fetal: placental weight ratios. As can be seen in 
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Figure 4.2D-F, LPS treatment in different mating groups had no major impact on these parameters, 
although there was a 4.8% decrease in fetal weight in the 1x Balb/c group compared to the equivalent 
PBS control (Fig 4.2D, p=0.042).  
Overall, these data suggest that repeated exposure to seminal fluid from allogeneic males results in a 
greater expansion and more stable population of Treg cells in the uterine draining lymph nodes in early 
pregnancy in a partner specific manner. Further, this mating protocol resulted in greater protection from 
inflammatory challenge in mid-gestation, suggesting that the more robust population of Treg cells 
provided by repeated seminal fluid exposure contributes to the mechanism for better protection against 
inflammatory insult in later gestation.  
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Figure 4.2 The effect of repeated exposure to male syngeneic or allogeneic antigens on pregnancy 
parameters after low-dose LPS challenge. B6 mice were mated either once or four times to Balb/c, Balb/b or 
mated three time to Balb/b and one time to Balb/c and injected i.p. with LPS (1µg) or control (PBS) on DPC 9.5, 
then autopsied on DPC 17.5. Data are the percentage of mated females pregnant with viable fetuses (A), the 
number (mean ± SEM) of viable implantation sites per mated mouse (individual data points with mean value 
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shown; B), the percentage of total implantation sites per pregnant female undergoing resorption (individual data 
points with mean ± SEM; C), the fetal weight (estimated marginal mean ± SEM; D), the placental weight 
(estimated marginal mean ± SEM; E), and the fetal: placental weight ratio (estimated marginal mean ± SEM; F). 
The effect of genotype was evaluated in A by chi-square analysis and in B by ANOVA and Sidak t-test. The effect 
of genotype was evaluated in D-F by mixed model analysis. *p<0.05, #p<0.1, compared with mating groups at 
same LPS dose; a, b, c, d indicates p<0.05, comparing between LPS or vehicle control administration within the 
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4.4 Discussion 
A sufficient number and function of Treg cells is crucial to establishing maternal immune tolerance for 
successful pregnancy. Treg cells suppress inflammation and promote immune adaption at the  
maternal-fetal interface (Aluvihare et al., 2004, Guerin et al., 2009). Understanding the regulation and 
function of Treg cells is crucial to develop treatments for human gestational complications, such as 
preeclampsia and recurrent miscarriage (Guerin et al., 2009), where altered Treg cells are implicated. 
Seminal fluid contributes to Treg cell expansion in early gestation, with contributions from both sperm 
and seminal plasma (Guerin et al., 2011, Robertson et al., 2009a). The role of previous seminal fluid 
contact in protecting women from developing preeclampsia has been observed in clinical studies, and is 
the most reasonable explanation for observations that nulliparous women, women who have a new 
conceiving partner and pregnancies initiated with donor gametes are associated with higher incidence 
of preeclampsia (Salha et al., 1999, Dekker et al., 1998). These observations also suggest that the 
benefit of prior seminal fluid contact is partner-specific. However, to date there has not been direct 
evidence to demonstrate that this protection comes from a more robust and suppressive Treg cell pool. 
The current study was undertaken to evaluate the impact of repeated female reproductive tract contact 
with seminal fluid on Treg cell number and function in the PALN, other distal lymphoid organs and also 
peripheral blood during the peri-implantation period of pregnancy. Our data demonstrates that the Treg 
cell pool is further expanded after repeated mating particularly in the uterine draining lymph nodes, and 
to a greater extent after mating with allogeneic males. In addition to an increase in the Treg cell 
population, this study also demonstrates that repeated allogeneic mating leads to a more stable Treg 
cell population compared to mating with syngeneic males. The changes to the Treg cell population have 
a functional consequence, leading to an increased resilience to inflammatory insult in mid-gestation 
following repeated mating to allogeneic males. This result is consistent with an important role for Treg 
cells in protecting fetuses from inflammatory insults throughout gestation. Strikingly, these changes are 
not observed following repeated mating with syngeneic males or following male partner switching, 
highlighting the importance of consistent exposure to the same disparate MHC antigens in establishing 
a tolerogenic maternal immune environment.  
Changes in the Treg cell population in the peri-implantation period has previously been examined in 
mice, where an increase in the percentage of CD4+CD25+ T cells was observed on DPC 3.5 in a range 
of lymphoid organs (Aluvihare et al., 2004, Guerin et al., 2011). This Treg cell expansion has been 
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attributed to seminal fluid as females mated to seminal plasma deficient and vasectomised males fail to 
expand the Treg cell pool (Guerin et al., 2011).  Surprisingly, in the current study unlike previous studies 
the number of Treg cells in the PALN after a single mating to Balb/c was increased compared to oestrus 
females, but the increase did not reach statistical significance. This deviance from previous studies is 
likely to be due to the smaller number of mice in the current study.  In addition, the methodology for 
quantifying absolute Treg cell populations was not identical between the previous and current study, 
which may potentially resulted in this deviance.  
Treg cells are known to play a crucial role in maintaining an appropriate immune environment in 
pregnancy. In the mouse model, T cells depleted of CD4+CD25+ Treg cells or unsorted T cells from 
normal pregnant mice were adoptively transferred into pregnant T cell deficient mice. The allogeneic 
fetuses were completely rejected in the absence of Treg cells amongst the transferred population, 
however, no fetal rejection was found in syngeneic pregnancies (Aluvihare et al., 2004). In vivo 
depletion of CD25+ cells resulted in a similar fetal rejection in mice (Darrasse-Jeze et al., 2006). When 
anti-CD25 monoclonal antibody PC61 was administrated to deplete CD25+ cells from female mice after 
allogeneic mating, fewer fetuses survived to term, while in syngeneic mating, there was no change in 
reduced fetal survival rate (Darrasse-Jeze et al., 2006). Clinically, changes in the maternal immune 
environment in pregnancy, including increases in pro-inflammatory responses and decreases in the 
Treg cell population are associated with pregnancy complications such as preeclampsia, and an 
increased length of exposure to a specific partner’s seminal fluid reduces our risk (Kho et al., 2009). 
Altogether, these studies suggest that repeat exposure to seminal fluid may strengthen the Treg cell 
pool. In the current study, we demonstrate that repeated exposure to male alloantigens expands the 
Treg cell population in the PALN, compared with oestrus controls and females mated once to allogeneic 
males, indicating a pivotal role of repeated seminal fluid exposure in progressively expanding Treg cells 
in the peri-conception period. It is notable that Treg cell expansion is less apparent following mating with 
syngeneic males, with no change in the Treg cell pool following repeated exposure to syngeneic 
seminal fluid. Taken together, these data suggest that both male major and minor antigens can initiate 
Treg cell proliferation, but major antigens are more capable to stimulate Treg cell expansion.  
The findings presented in this chapter provide a mechanism to explain why women who have a short 
period of cohabitation prior to falling pregnant, or primiparous women, have greater susceptibility to 
obstetric disorders associated with inflammation and dysfunction of the maternal immune response 
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(Dekker et al., 1998). In patients with preeclampsia, reduced Treg cell population (Sasaki et al., 2007, 
Prins et al., 2009, Santner-Nanan et al., 2009, Quinn et al., 2011) and a shift towards Th17 phenotypes 
in Treg cells are observed (Santner-Nanan et al., 2009, Tian et al., 2016), indicating that the importance 
of robust Treg cell population in protecting women from developing preeclampsia. In the current study, 
the importance of repeated exposure to male alloantigens in the induction of stable Treg cells on  
DPC 3.5 was demonstrated in mice, as a female mice mated 4x to Balb/c exhibit the largest expansion 
of Treg cells. In this study, we also assessed the stability of these cells following polycloncal stimulation 
in vitro. Strikingly, Treg cells in PALN from females repeatedly mated to allogeneic males exhibited 
increased stability compared to females repeatedly mated to syngeneic males or females in the partner 
switching group, indicating that exposure to MHC disparate seminal fluid can progressively strengthen 
as well as expand the Treg cell pool. This is the first mouse study which has demonstrated that the 
benefit from seminal fluid contacting benefits from an extended period of seminal fluid exposure and is 
partner-specific, and repeated exposure to male alloantigens can further expand Treg cell population 
and also stabilise Treg cell phenotype. Taken together, the data reinforce growing evidence that male 
alloantigens are essential for the expansion of a robust Treg cell population in early pregnancy. 
Apart from the number of Treg cells and their stability, the suppressive activity of Treg cells is also 
associated with normal pregnancy (Somerset et al., 2004). Treg cells suppress autoreactive immune 
responses to prevent autoimmune diseases, inhibit inflammation and are involved in suppression of 
allograft rejection (Sakaguchi et al., 1995). In order to accommodate the semi-allogeneic fetus, Treg 
cells with appropriate suppressive activity are required. In women experiencing recurrent miscarriage, 
the suppressive activity of Treg cell are diminished, as an increased number of Treg cells are required 
to exert suppression when compared to fertile women (Arruvito et al., 2007, Wang et al., 2010b). While 
the current study does not quantify Treg cell suppressive activity, our unpublished data demonstrates 
that repeated exposure to allogeneic male seminal fluid enhances suppressive activity in Treg cells, 
compared to the Treg cells in females that have single seminal fluid exposure (Moldenhauer, 
unpublished).  
It is interesting to note that despite the clear differences in Treg cell number and stability following 
mating with allogeneic Balb/c compared to syngeneic Balb/b males, there is no change in their capacity 
to sustain pregnancy under normal physiological conditions. This can be observed in PBS injected 
females where no change in the capacity to sustain pregnancy, the number of viable pups or the 
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resorption rate is observed. However, the importance of these changes became apparent when 
pregnant females were administrated a low dose of LPS to result in inflammatory challenge, where a 
reduction in viable fetuses and an elevated resorption rate were observed in females mated 4x to Balb/b, 
compared to females mated 4x to Balb/c. The adverse outcome after LPS treatment is likely to be due 
to the reduced Treg cell population and impaired stability observed in early pregnancy, resulting in a 
Treg population unable to suppress the systemic inflammation. These findings suggest that the 
decrease in Treg cell number, stability and potentially suppressive function in females mated 4x to 
Balb/b compared to 4 x Balb/c may impact their capacity to withstand an inflammatory challenge and 
reinforces the importance of seminal fluid exposure in the induction of protective Treg cells prior to 
implantation.  
Further studies are required to better quantify the mechanisms underlying the adverse pregnancy 
outcomes after inflammatory challenge in these repeated mated female mice. The Treg cell proportion 
and number, as well as stability and suppression could be addressed after the inflammatory challenge 
and also in the late gestation period to further investigate how impaired Treg cell population leads to 
adverse pregnancy outcomes. It would also be of value to consider Treg cell transfer experiments, to 
determine whether the increased susceptibility to inflammatory challenge can be mitigated by 
supplementation of paternal antigen-reactive Treg cells.  
Taken together, this study demonstrates that repeated allogeneic matings results in further expanded 
and more stable Treg cell population in the PALN in mice on DPC 3.5. This elevation is not observed in 
repeated syngeneic matings, highlighting the pivotal role of MHC disparity in the expansion of Treg cells. 
In addition, this study also reveals that Treg cells following multiple matings with allogeneic males  
(4x Balb/c) are more stable than those Treg cells from females mated repeatedly to syngeneic males  
(4x Balb/b) and while females are able to sustain pregnancy, they are more susceptible to inflammatory 
challenge in the mid-gestation. These findings provide compelling proof-of-concept in the mouse model 
of a benefit of long term seminal fluid exposure and the importance of male alloantigens for the 
expansion of stable Treg cells. The observations may be ultimately beneficial in understanding the 
factors contributing to immune-associated pregnancy complications, such as recurrent miscarriage and 
preeclampsia in women. 
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5.1 Abstract  
Maternal immune tolerance of the semi-allogeneic fetus requires CD4+Foxp3+ T-regulatory (Treg) cells, 
which suppress inflammation and anti-fetal immunity. In pregnant mice, expansion of the Treg cell pool 
is initiated by seminal fluid contact at coitus. Recent studies have demonstrated that microRNAs 
(miRNA) play a role in Treg cell generation, with miR-155 established as a key Treg cell miRNA. 
Seminal fluid has recently been found to induce female reproductive tract miRNAs following coitus. 
However, the contribution of miR-155 to in early pregnancy is yet to be assessed. To assess the 
contribution of miR-155 to Treg expansion in early pregnancy, miR-155-/- or miR-155+/+ (C57Bl/6) 
females (n=10-15) were mated with Balb/c males. T cell and antigen presenting cell profiles from the 
uterus and para-aortic lymph nodes (PALN) which drain the uterus were assessed using flow cytometry 
3.5 day postcoitum (DPC). Virgin oestrous miR-155-/- and miR-155+/+ females were used as no mating 
controls. To investigate the impact of miR-155 deficiency on susceptibility to a pro-inflammatory 
challenge, a second cohort of pregnant females was administered LPS (1.0 µg) or PBS control on  
DPC 9.5, and pregnancy outcomes were determined on DPC 17.5. 
miR-155 deficiency resulted in significant alterations to the Treg cell profile in early pregnancy with the 
most striking changes being observed in the PALN on DPC 3.5, where a 53%, a 69% and a 35% 
reduction was observed in Treg proportion, Treg number and Foxp3 expression, respectively.  
In the absence of miR-155, fewer macrophages in the PALN expressed CD80 and CD86 (reduced by 
31% and 43% respectively). Fewer DCs expressed MHCII+ in the PALN on DPC 3.5 (reduced by 69%) 
in the absence of miR-155. miR-155 deficiency also resulted in a 69% reduction in the number of 
CD86+ DCs in the PALN.  
miR-155 deficiency altered the outcomes of pregnancy challenged with LPS, with an 8.3% reduction in 
fetal weight and a 14% reduction in the fetal: placental ratio in late gestation. A 19-fold higher resorption 
rate was observed in miR-155-/- females after LPS treatment, compared with miR-155+/+ females 
treated with LPS.  
In conclusion, the absence of miR-155 alters the maternal immune profile in early pregnancy and this 
may be a determinant of increased susceptibility to inflammation-induced fetal loss later in gestation. 
These findings suggest that miR-155 has a pivotal role in establishing the appropriate maternal immune 
environment during the peri-conception period that facilitates appropriate protection against 
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inflammatory challenge and may be relevant to understanding how Treg-associated pregnancy 
pathologies arise in women.  
5.2 Introduction  
The fetus inherits paternal alloantigens, which results in a semi-allogeneic challenge to the maternal 
immune system. Immune adaptions towards the semi-allogeneic fetus are required to establish a 
tolerogenic immune milieu and suppress excessive inflammatory responses that can contribute to 
gestational disorders. Maternal immune tolerance is medicated by Treg (CD4+ CD25+ Foxp3+) cells 
(Aluvihare et al., 2004), which are potent suppressors of the generation and function of Th1 and Th17 
immune responses. Treg cells are a unique subtype of T cells, compromising approximately 5-10% of 
CD4+ T cells in mice. Treg cells also influence the function and maturation of DCs and macrophages 
(Shevach, 2009, Guerin et al., 2009), and conversely altered presenting capacity and maturation of 
antigen presenting cells can lead to impaired T cell responses. Depletion of Treg cells results in loss of 
the ability to maintain allogeneic pregnancy in mice (Aluvihare et al., 2004, Shima et al., 2010) and 
impaired Treg function is implicated in human gestational disorders (Jasper et al., 2006).  
Seminal fluid deposition in the female reproductive tract results in a transient inflammatory response 
and initiates immune changes in human (Pandiyan et al., 2007, Sharkey et al., 2007), mice (Johansson 
et al., 2004) and all other mammalian species studied thus far (Schjenken and Robertson, 2014). At 
coitus, interactions between seminal fluid and epithelial cells in the reproductive tract induce elevated 
synthesis of cytokines and chemokines (Sharkey et al., 2012a, Sharkey et al., 2012b, Sharkey et al., 
2007) which results in an influx of antigen presenting cells in both human (Sharkey et al., 2012b) and 
mice (De et al., 1991, McMaster et al., 1992, Robertson et al., 1998, Robertson et al., 1996, Robertson 
et al., 1992).  
In pregnancy, Treg cells are initially expanded following seminal fluid contact at coitus (Guerin et al., 
2011, Robertson et al., 2009a). There is accumulating evidence to suggest that seminal fluid is involved 
in facilitating establishment of immune tolerance (Robertson, 2005). An elevated Treg cell population 
was observed in mice exposed to intact seminal fluid (Guerin et al., 2011), but exposure to sperm alone 
(Guerin et al., 2011) or mechanical stimuli to mimic copulation (Schumacher et al., 2007) failed to 
induce Treg cell population. In addition, a recent study revealed that uterine DCs cross-present male 
alloantigens to activate maternal T cells (Moldenhauer et al., 2009) to contribute to Treg cell expansion. 
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Thus, to address how Treg cells are regulated, it is essential to investigate both DCs and Treg cell 
responses. 
A reduced number of Treg cells with less suppressive activity has been observed in abortion-prone 
murine models (Zenclussen et al., 2005, Zenclussen, 2005). Depletion of CD4+CD25+ T cells lead to 
gestation failure in mice, indicating that Treg cells are crucial to sustain pregnancy.  In addition, reduced 
Treg cells with less suppressive capacity and with a shift towards an IL-17 expressing phenotype were 
observed in preeclampsia (Quinn et al., 2011, Santner-Nanan et al., 2009, Sasaki et al., 2007, Prins et 
al., 2009, Tian et al., 2016). Amongst the factors that contribute to Treg cell responses and functions, 
miRNAs are well established immunological regulators. As the functions of individual miRNAs are highly 
redundant, and each miRNA can target more than 100 genes (Lu and Clark, 2012), miRNAs are 
involved in nearly all developmental, homeostatic and pathological processes (Griffiths-Jones et al., 
2008) and act to regulate  immune cells (Mehta and Baltimore, 2016) and pregnancy (Bidarimath et al., 
2014).  
miR-155 is a key immune regulatory miRNA. It regulates multiple immune cells, including B cells, T cells, 
and antigen presenting cells. Several studies have shown that miR-155 regulates T cell differentiation 
into Th1, Th2 and Th17 subtypes (O'Connell et al., 2007, Rodriguez et al., 2007, Vigorito et al., 2007), 
as well as controlling Treg cell development (Lu et al., 2009a, Kohlhaas et al., 2009). In addition,  
miR-155 is induced in DC after inflammatory stimulation (Baltimore et al., 2008), and also regulates 
antigen presenting capacity in DCs (Rodriguez et al., 2007). In addition, miR-155 expression is altered 
in women with recurrent pregnancy loss (Tang et al., 2016, Winger et al., 2015) and also preeclampsia 
(Pineles et al., 2007). However, the role of miR-155 in early pregnancy is yet to be addressed.  
In the experiments described in this chapter, we utilised miR-155-/- mice to investigate the role of  
miR-155 in the regulation of the peri-conception immune milieu and the role of miR-155 in Treg cell, 
macrophages and DC regulation. 
5.3 Results 
5.3.1 miR-155 deficiency results in a systemic change to the maternal T cell profile in early 
pregnancy  
To determine the impact of miR-155 deficiency on the T cell profile in early pregnancy, miR-155-/- and 
miR-155+/+ female mice were mated to Balb/c males. The PALN, mesenteric lymph nodes (mLN), 
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spleen and blood were collected from females on DPC 3.5 for T cell quantification. Virgin oestrous 
females were used as an unmated control.  In this chapter, the T cell population was characterised 
using antibodies against CD3, CD4, CD25 and Foxp3. Figure 5.1 depicts the flow cytometry gating 
strategy, where lymphocytes were initially gated among total cells in each tissue. CD4+ T cells were 
then gated within the lymphocyte population by CD3 and CD4 positive staining. Finally, Treg cells were 
gated by assessing the CD3+CD4+ T cell population for CD25 and Foxp3 expression. Data for PALN 
are described in detail in this chapter, while the results for mLN, spleen and blood are presented in 
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Figure 5.1 T cell flow cytometry gating strategy. Total lymphocytes were initially gated using SSC and FSC. 
From within the lymphocyte population, the expression of firstly CD3 and then CD4 (from within the CD3+ 
population) was utilized to define the CD4+ T cell population (CD3+CD4+ T cells). The Treg cell population was 
defined on the basis of expression of CD25 and then Foxp3 (from within the CD25 population) (CD25+Foxp3+ 
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5.3.1.1 Total cell expansion in female reproductive tissues 
To assess the impact of miR-155 deficiency on immune cell population expansion in early pregnancy, 
we firstly examined the total cell number in the PALN on DPC 3.5. While the total cell number in the 
PALN increased by 1.3-fold (p<0.05) in the miR-155+/+ females after mating, this elevation was not 
observed in the absence of miR-155 (Figure 5.2), and miR-155 mice were also relatively 
lymphocytopaenic at oestrus. miR-155 deficiency resulted in a 31% and 42% reduction in the total cell 




Figure 5.2 The effect of miR-155 deficiency on populations of total cells in the PALN. miR-155+/+ and  
miR-155-/- mice were mated with Balb/c males, and on DPC 3.5, total cells from the PALN were quantified by 
counting using a haemocytometer. Unmated virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are number of total cells x106 in the PALN. Differences between groups were 
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5.3.1.2 T cell profile in female reproductive tract lymph nodes  
To assess the impact of miR-155 deficiency on the establishment of a tolerogenic immune environment 
in early pregnancy, we firstly examined the T cell profile in the PALN. Within the CD3+ population, while 
no change was observed in the proportion of CD4+ T cells amongst total lymph node cells (Figure 5.3A), 
the increase in total CD4+ cell number seen following mating in miR-155+/+ mice (2.0-fold, p<0.0001) 
was not observed in miR-155-/- females. In addition, miR-155 deficiency resulted in a reduction in the 
number of T cells both at oestrus (39%, p<0.05) and on DPC 3.5 (53%, p<0.0001), compared to  
miR-155+/+ females (Figure 5.3B). Interestingly, miR-155 deficiency also altered the level of CD4 
expression within T cells, with the increase in CD4 MFI observed after mating in miR-155+/+ females  
(1.6-fold, p<0.0001) not observed in miR-155-/- females. Furthermore, miR-155 deficiency resulted in a 
reduction in the CD4 MFI both at oestrus (19%, p<0.001) and on DPC 3.5 (46%, p<0.0001), compared 
to WT controls (Figure 5.3C). This data indicates that in early pregnancy, miR-155 deficiency alters 
CD4+ T cell populations.  
Given the importance of Treg cells in the establishment of a tolerogenic immune environment in early 
pregnancy, we then assessed the Treg cell population within the PALNs. No change in the proportion of 
Treg cells within the T cell population was observed following mating in miR-155+/+ or miR-155-/- mice, 
compared to the genotype-matched oestrus controls. miR-155 deficiency resulted in a lower proportion 
of Treg cells, both at oestrus (52%, p<0.0001) and on DPC 3.5 (53%, p<0.0001), compared to WT mice 
(Figure 5.3D). Consistent with our previous observations (Guerin et al., 2011) the total number of Treg 
cells was increased in miR-155+/+ following mating (2.1-fold, p<0.0001). Treg cell number was also 
expanded (1.7-fold, p<0.05) following mating in miR-155 deficient mice, but not to the same extent as 
WT controls. Overall, miR-155 deficiency resulted in a reduction in PALN Treg cells at oestrus (69%, 
p<0.05) and DPC 3.5 (76%, p<0.0001) (Figure 5.3E).  
The level of Foxp3 expression as measured by MFI in Treg cells is associated with Treg suppressive 
capacity (Chauhan et al., 2009). Foxp3 MFI is induced after mating in miR-155+/+ mice (1.3-fold, 
p<0.05). In contrast, no change in Foxp3 MFI was observed following mating in miR-155-/- mice, with 
miR-155-/- mice having a significantly lower Foxp3 MFI on DPC 3.5 compared to miR-155+/+ mice 
(35%, p<0.0001) (Figure 5.3F).  
Altogether, these data show that the absence of miR-155 alters the maternal immune response in early 
pregnancy, reducing total CD4+ T cells and in particular reducing the CD4+ Treg cell population in the 
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Figure 5.3 The effect of miR-155 deficiency on populations of T cells in the PALN. miR-155+/+ and  
miR-155-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the 
PALN were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. 
Data are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the 
total number of CD4+ T cells x106 (B),the CD4 MFI (C), the percentage of Treg cells (D), the total number of Treg 
cells x106 (E), and the MFI of Foxp3 (F). Differences between groups were evaluated using Kruskal-Wallis test 
and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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5.3.2 Effect of miR-155 deficiency on the macrophage and dendritic cell profile during early 
pregnancy 
Given the importance of antigen presenting cells in the peri-conception immune environment and in 
generating the T cell response, we then assessed the impact of miR-155 deficiency on the profile of 
macrophages and DCs in early pregnancy. At oestrus and on DPC 3.5, cells from the mLN, spleen, 
PALN and uterus were collected for analysis by flow cytometry.  
Macrophages were assessed by examining populations of total macrophages (CD11B+ F4/80+ cells), 
activated macrophages (MHCII+ CD11B+ F4/80+ cells), and macrophages expressing the  
co-stimulatory molecules CD80 (CD80+ CD11B+ F4/80+ cells) and CD86 (CD86+ CD11B+ F4/80+ 
cells). Figure 5.4 depicts the flow cytometry gating strategy, where leukocytes were initially gated based 
on size and complexity among total cells in each tissue. Macrophages were then identified on the basis 
of F4/80 and CD11B positive staining. Specific subsets of macrophages were then determined based 
on MHCII, CD80 and CD86 expression from within the CD11B+F4/80+ cell population (Figure 5.4). 
DCs were assessed by examining populations of total dendritic cells (CD11C+ F4/80- cells), activated 
DCs (MHCII+ CD11C+ F4/80- cells), and DCs expressing the co-stimulatory molecules CD80  
(CD80+ CD11C+ F4/80- cells) and CD86 (CD86+ CD11C+ F4/80- cells). Figure 5.5 depicts the flow 
cytometry gating strategy, where leukocytes were initially gated based on size and complexity among 
total cells in each tissue. DCs were then identified on the basis of F4/80 negative staining and CD11C+ 
positive staining. Specific subsets of DCs were then determined based on MHCII, CD80 and CD86 
expression from within the CD11C+ F4/80- cell population (Figure 5.5). Data for uterus and PALN are 
described in detail in this chapter, while the results of mLN and spleen are presented in chapter 8, 
section 8.2.2 and section 8.2.3. 
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Figure 5.4 Macrophage flow cytometry gating strategy. Total leukocytes were initially gated using SSC and 
FSC. From within the leukocyte population, cells were assessed for the expression of firstly F4/80+, and then 
CD11B+ (from within the F4/80+ population) to define the total macrophage population (CD11B+ F4/80+ cells). 
Activated macrophages were then defined by examining MHCII+ cells from within the macrophage population 
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(MHCII+ CD11B+ F4/80+ cells). Finally, macrophages expressing the co-stimulatory molecules CD80 (CD80+ 
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Figure 5.5 Dendritic cell flow cytometry gating strategy. Total leukocytes were initially gated using SSC and 
FSC. From within the leukocyte population, cells were assessed for expression of CD11C+ (from within the 
F4/80- population) to define the total dendritic cell population (CD11C+ F4/80- cells). Activated dendritic cells 
were then defined by examining MHCII+ cells from within the dendritic cell population (MHCII+ CD11C+ F4/80- 
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cells). Finally, DCs expressing the co-stimulatory molecules CD80 (CD80+ CD11C+ F4/80- cells) and CD86 
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5.3.2.1 Macrophage profile in female reproductive tract tissues and associated lymph nodes 
To assess the impact of miR-155 deficiency on macrophage phenotype and numbers in early 
pregnancy, we first collected the uterus and PALN from oestrus or DPC 3.5 miR-155+/+ or miR-155-/- 
females. In these experiments, we were able to assess the uterus in addition to the lymph nodes as 
substantial numbers of macrophages and DC can be recovered from the uterus. 
5.3.2.1.1 PALN  
Within the PALN, mating resulted in a significant increase in the proportion of macrophages amongst 
total viable cells in miR-155+/+ (1.4-fold, p<0.05) but not in miR-155-/- females compared to the  
genotype-matched oestrus controls (Figure 5.6A). No change in the proportion of macrophages was 
observed at oestrus or on DPC 3.5 in miR-155-/- mice compared with WT (Figure 5.6A). Mating resulted 
in an increase in the total CD11B+ F4/80+ macrophage number in miR-155+/+ (1.8-fold, p<0.01) but 
this was not evident in miR-155-/- females. Indeed, miR-155 deficiency was associated with a reduction 
in CD11B+ F4/80+ macrophages on DPC 3.5 (38%, p<0.01) (Figure 5.6B). Thus, in the absence of  
miR-155, the population of macrophages is impacted on DPC 3.5 but not at oestrus. These results show 
fewer macrophages were present in the PALN in the absence of miR-155, and this would be expected 
to adversely impact the antigen-presenting role that macrophages perform. 
We then further examined whether miR-155 deficiency impacted the subpopulation of activated 
macrophages (MHCII+ CD11B+ F4/80+ macrophages) in the PALN. Mating resulted in a significant 
elevation in the proportion of activated macrophages in both miR-155+/+ (1.1-fold, p<0.05) and  
miR-155-/- females (1.2-fold, p<0.05), compared to genotype-matched oestrus controls (Figure 5.6C). 
However, this did not translate to changes between genotypes in percent of macrophages that exhibited 
activation markers either at oestrus or on DPC 3.5 (Figure 5.6C). In contrast, the total number of 
activated macrophages was affected by genotype, with an increase observed following mating in  
miR-155+/+ mice (2.0-fold, p<0.01) (Figure 5.6D). This did not occur in miR-155-/- females, where  
miR-155 deficiency was associated with fewer activated macrophages compared with WT on DPC 3.5 
(41%, p<0.05) (Figure 5.6D).  
Expression of the co-stimulatory molecules CD80 and CD86 within the macrophage population was 
then examined to evaluate capacity for co-stimulation, which is necessary for T cell activation and 
survival. No change in the proportion of CD80 positive macrophages was observed following mating in 
either  
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miR-155+/+ or miR-155-/- females, with 17-27% of the macrophage population expressing CD80. 
Furthermore, miR-155 deficiency did not impact the CD80+ macrophage population on DPC 3.5 but did 
result in an increase in the proportion of CD80+ macrophages at oestrus (1.6-fold, p<0.05) (Figure 5.6E). 
In contrast, while the total number of CD80+ macrophages was increased following mating in  
miR-155+/+ females (1.8-fold, p<0.01), no change was observed in miR-155-/- females (Figure 5.6F). 
As a consequence, miR-155 deficiency caused a significant reduction in the total number of CD80+ 
macrophages compared with WT females on DPC 3.5 (31%, p<0.05) but not at oestrus (Figure 5.6F).  
Within the macrophage population, no change in the proportion of CD86+ macrophages was observed 
following mating or between genotypes (Figure 5.6G) with CD86+ macrophages making up >80% of the 
total macrophage population. However, changes were observed in the total number of CD86+ 
macrophages, with a significant increase observed following mating in miR-155+/+ females (1.8-fold,  
p<0.01) but this did not occur in miR-155-/- females (Figure 5.6H). As a consequence, miR-155 
deficiency resulted in a significant decrease in the number of CD86+ macrophages compared to WT 
females on DPC 3.5 (43%, p<0.05), but not at oestrus (Figure 5.6H).  
These data indicate that as well as reduced numbers, the activation status and antigen presentation 
capabilities of macrophages are compromised on DPC 3.5 in miR-155-/- mice.  
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Figure 5.6 The effect of miR-155 deficiency on population of macrophages and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in PALN. miR-155+/+ and miR-155-/- B6 mice were mated with 
Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the PALN were analysed by flow cytometry to quantify 
proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as  
non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ macrophages within 
viable cells (A), the total number of macrophages x 106 (B), the percentage of activated macrophages (MHCII+ 
macrophages) (C), the total number of activated macrophages x 106 (D), the percentage of CD80+ macrophages 
(E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ macrophages (G) and the total 
number of CD86+ macrophages x 106 (H). Differences between groups were evaluated using Kruskal-Wallis test 
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5.3.2.1.2 Uterus 
In addition to the PALN, we also assessed the macrophage population in the uterus. Unlike the PALN, 
there was no change in the proportion or the total number of macrophages, activated macrophages, 
CD80+ macrophages or CD86+ macrophages between oestrus and mated females, or between 
genotypes, in miR-155+/+ or miR-155-/- mice. (Figure 5.7, A-H). It is notable that the variance within 
data sets is higher for the uterus compared with PALN, and this makes it more difficult to detect 
significant effects of miR-155 deficiency. 
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Figure 5.7 The effect of miR-155 deficiency on the population of macrophages and expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in uterine tissues. miR-155+/+ and miR-155-/- B6 mice were mated 
with Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the uterine tissue were analysed by flow 
cytometry to quantify proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus 
mice were used as non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ 
macrophages within viable cells (A), the total number of macrophages x 106 (B), the percentage of activated 
macrophages (MHCII+ macrophages) (C), the total number of activated macrophages x 106 (D), the percentage 
of CD80+ macrophages (E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ 
macrophages (G) and the total number of CD86+ macrophages x 106 (H). Differences between groups were 














ZHANG                                                        Chapter 5                                                           96 
5.3.2.2 Dendritic cell profile in female reproductive tract tissues and associated lymph nodes 
To assess the impact of miR-155 deficiency on dendritic cell numbers and phenotype in early pregnancy, 
uterus and PALN were collected from oestrus or DPC 3.5 miR-155+/+ or miR-155-/- females.  
5.3.2.2.1 PALN 
Within the population of viable cells, there was no change in the proportion of F4/80-CD11C+ DCs in  
miR-155+/+ or miR-155-/- mice following mating or between genotypes (Figure 5.8A). However, a  
2.8-fold (p<0.05) increase in the total number of F4/80- CD11C+ DCs following mating in miR-155+/+ 
females was observed but this was not evident in miR-155-/- females (Figure 5.8B). miR-155 deficiency 
resulted in a significant reduction in the total number of F4/80- CD11C+ DCs on DPC 3.5 (71%, p<0.01) 
but there was no difference between genotypes at oestrus (Figure 5.7B).  
The DC population was then further examined to explore the impact of miR-155 deficiency on MHCII+ 
mature DC in the PALN. The proportion of MHCII+ DCs was increased following mating in miR-155+/+ 
(1.8-fold, p<0.05) but not in miR-155-/- mice, and no change was observed between genotypes at 
oestrus or on DPC 3.5 (Figure 5.8C). Similar to macrophages, a reduced DC population in the PALN of  
miR-155-/- mice on DPC 3.5 may indicate less capability for antigen presentation to activate T cells after 
mating. 
Examination of MHCII+ DC numbers showed that the increase in MHCII+ DCs observed following 
mating in miR-155+/+ females (3.2-fold, p<0.05), did not occur in miR-155-/- females. As a 
consequence, miR-155 deficiency resulted in a significant reduction in MHCII+ DCs on DPC 3.5 (69%, 
p<0.01) but there was no difference at oestrus (Figure 5.8D).  
Expression of the co-stimulatory factors CD80 and CD86 were then examined within the DC population 
in the PALN. No change was observed in the percentage of CD80+ DCs within the DC population 
following mating or between genotypes (Figure 5.8E). Mating resulted in a significant elevation in the 
CD80+ DC number in miR-155+/+ (2.4-fold, p<0.05) and in miR-155-/- females (1.9-fold, p<0.05). 
Similar results were observed for CD86+ DCs with no change in proportions following mating or 
between genotypes (Figure 5.8G). Mating resulted in a significant elevation in the CD80+ DC number in 
miR-155+/+ mice (2.9-fold, p<0.01). As a consequence, miR-155 deficiency resulted in a significantly 
lower number of CD86+ DCs on DPC 3.5 (69.1%, p<0.05) but not at oestrus (Figure 5.7H). The less 
activated DCs and reduced costimulatory factor expression on DPC 3.5 may indicate that DCs in  
miR-155-/- mice are less capable of activating T cell responses. 
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Figure 5.8 The effect of miR-155 deficiency on the population of DCs and expression of MHCII, CD80, and 
CD86 by CD11C+ DCs in PALN. miR-155+/+ and miR-155-/- B6 mice were mated with Balb/c males, and on  
DPC 3.5, CD11C+ F4/80- cells from the PALN were analysed by flow cytometry to quantify proportion of DCs and 
the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total number of 
DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated DCs x 106 (D), 
the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ DCs (G) 
and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using Kruskal-Wallis 
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5.3.2.2.2 Uterus 
Within the uterus, the proportion of CD11C+ F4/80- DCs amongst the total viable cells was increased 
following mating in both miR-155+/+ (1.8-fold, p<0.01) and miR-155-/- (1.7-fold, p<0.05) mice (Figure 
5.9A). miR-155 deficiency did not alter in the proportion of CD11C+ F4/80- DCs at oestrus or on  
DPC 3.5 (Figure 5.9A). The absolute number of CD11C+ F4/80- DCs increased with mating in  
miR-155+/+ females (3.3-fold, p<0.0001). Mating in miR-155-/- females resulted in a similar shift in 
mean number of DCs, but this did not reach statistical significance. miR-155 deficiency did not impact 
the number of CD11C+ F4/80- DCs at oestrus or on DPC 3.5 compared to WT mice (Figure 5.9B).  
The DC population was then further examined to explore the impact of miR-155 deficiency on 
expression of MHCII amongst DC in the uterus. The proportion of MHCII+ DCs was high at 50-90% and 
was not altered following mating or between genotypes in miR-155+/+ or miR-155-/- mice (Figure 5.9C). 
However, MHCII+ DC number was increased following mating in miR-155+/+ females (3.0-fold, p<0.001) 
with only a trend towards significance in miR-155-/- females. miR-155 deficiency did not impact MHCII+ 
DC numbers at oestrus or on DPC 3.5 (Figure 5.9D). 
Expression of the co-stimulatory factors CD80 and CD86 were then explored within the DC population in 
the uterus. No change in the proportion of CD80+ DCs was observed following mating in either  
miR-155+/+ or miR-155-/- females, and these was no difference between genotypes (Figure 5.9E). 
However, CD80+ DC numbers were increased following mating in miR-155+/+ females (3.4-fold, 
p<0.001) but not in miR-155-/- females (Figure 5.9F). No changes were seen in the total number of 
CD80+ DCs in the absence of miR-155 at oestrus or on DPC 3.5. Similar results were observed in the 
CD86+ DC population with no changes in the proportion of DCs following mating or between genotypes 
in both miR-155+/+ or miR-155-/- females, and an increase in the number of CD86+ DCs following 
mating in miR-155+/+ (3.7-fold, p<0.0001) but not miR-155-/- females (Figure 5.8H).  
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Figure 5.9 The effect of miR-155 deficiency on the population of DCs and expression of MHCII, CD80, and 
CD86 by CD11C+ DCs in uterine tissues. miR-155+/+ and miR-155-/- B6 mice were mated with Balb/c males, 
and on DPC 3.5, CD11C+ F4/80- cells from the uterine tissue were analysed by flow cytometry to quantify 
proportion of DCs and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated 
controls. Data are presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the 
total number of DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated 
DCs x 106 (D), the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of 
CD86+ DCs (G) and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using 
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5.3.3 Systemic impact of miR-155 deficiency on DPC 3.5 
To evaluate the extent to which the impact of miR-155 deficiency was associated with local as opposed 
to systemic changes to the immune system, the spleen, peripheral blood and mLN were also evaluated 
at oestrus and on DPC 3.5.  At oestrus, a reduced number of CD4+ T cells was observed in the mLN 
and spleen, compared to the WT oestrous control. Consistent with literature (Lu et al., 2009a), miR-155 
deficiency resulted in a reduction in CD4+ Treg cells, measured as proportion of CD4+ T cells, or total 
numbers.  As well, Foxp3 MFI was reduced in the mLN and spleen (Figure 8.4 to 8.6, appendix section 
8.2.1), compared to the WT controls.  
miR-155 deficiency was not associated with any change in CD4+ T cell proportion or numbers in the 
spleen, mLN or in peripheral blood on DPC 3.5. As in oestrus mice, the proportion and number of Treg 
cells was reduced in all three tissues. However, the extent of reduction in the Treg cells population was 
not as great as that observed in the PALN, indicating that miR-155 deficiency had a greater local impact 
on the Treg cell expansion in this site. 
On DPC 3.5, miR-155 deficiency did not alter macrophage population and phenotype in the spleen, 
mLN or peripheral blood, but a systemically reduced proportion and number of DC was observed in the 
mLN and spleen. In addition, the number of MHCII+ DC was decreased in the mLN, and a diminished 
number of CD86+ DC was observed in both mLN and spleen in the absence of miR-155 on DPC 3.5. 
These data suggest that the antigen-presenting capability of macrophages and DCs is systemically 
altered in the absence of miR-155, and therefore can impact on T cell activation. 
Taken together, the studies in other tissue sites indicate that miR-155 deficiency causes a systemic 
reduction in Treg cell populations and alters DC phenotypes, however the impact on Treg cells in the 
reproductive tissues on DPC 3.5 is greater in magnitude than that seen in other sites. 
5.3.4 Maternal miR-155 deficiency elevates LPS-induced fetal loss 
As detailed above, miR-155 deficiency results in an altered maternal immune environment in early 
pregnancy. This altered environment appeared not to overtly affect fertility in our breeding colony, where 
miR-155-/- females were mated with syngeneic miR-155-/- males to yield normal litter sizes at regular 
intervals, indicating steady state pregnancy progresses relatively unperturbed (Zhang, data not shown). 
As detailed in chapter 3, the functional requirements for immune mediators can become apparent 
following inflammatory challenge. Therefore, to formally investigate the impact that miR-155 deficiency 
may have on the generation and maintenance of a tolerogenic immune environment, miR-155-/- and  
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miR-155+/+ female mice were mated to allogeneic Balb/c males to produce pregnancies with maternal, 
but not fetal, miR-155 deficiency. On DPC 9.5, pregnant females were administrated a low-dose 
inflammatory challenge of 1.0 µg LPS, or PBS control. This dose of LPS was chosen as it was 
determined to be just below the threshold for impact on pregnancy loss in miR-155+/+ mice  
There was no detectable impact of miR-155 deficiency on fertility or fecundity evident in mice 
administered PBS and examined just before term on DPC 17.5. The incidence of progression from 
mating to pregnancy, total and viable implantation sites, and fetal and placental weights were not 
different between genotypes (Figure 5.10A-E).  
A major impact of miR-155 deficiency was revealed in the response to LPS challenge. miR-155-/- 
females were more severely affected than miR-155+/+ mice, with a lower proportion of miR-155-/- mice 
carrying viable fetuses (p<0.05, Figure 5.10A) and a lower number of viable fetuses per mated female 
(p<0.0001, Figure 5.10B) on DPC 17.5. The change in viable fetuses was associated with a 
substantially higher rate of fetal resorption in miR-155-/- dams following LPS treatment (19.2-fold, 
p<0.0001, Figure 5.10C). Additionally, LPS treatment impacted fetal outcomes in miR-155-/- females 
with an 8.3% reduction in fetal weights (p<0.05, Figure 5.10D) and a 14% reduction in the fetal: 
placental weight ratio (p<0.0001, Figure 5.10F). No effect of LPS treatment on placental weight was 
observed in either genotype (Figure 5.10E). Thus, maternal miR-155 deficiency appears to impact the 
maternal immune environment in pregnancy, such that miR-155 deficient mice exhibited greater 
susceptibility to fetal loss after inflammatory challenge in mid-gestation. 
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Figure 5.10 The effect of miR-155 deficiency on pregnancy parameters after low-dose LPS challenge.  
miR-155+/+ and miR-155-/- mice were mated with Balb/c males and injected i.p. with LPS (1µg) or control (PBS) 
on DPC 9.5, then autopsied on DPC 17.5. Data are the percentage of mated females pregnant with viable fetus 
(A), the number (mean ± SEM) of viable implantation sites per mated mouse (individual data points with mean 
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value shown; B), the percentage of total implantation sites per pregnant female undergoing resorption (individual 
data points with mean ± SEM; C), the fetal weight (estimated marginal mean ± SEM; D), the placental weight 
(marginal mean ± SEM; E), and the fetal: placental weight ratio (estimated marginal mean ± SEM; F). Numbers 
of mated mice are shown in parentheses. The effect of genotype was evaluated in A by Chi-square analysis and 
in B by ANOVA and Sidak t-test. The effect of genotype was evaluated in D-F by mixed model analysis, using 
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5.4 Discussion  
A sufficient number and functional competence in Treg cells is critical for maternal immune tolerance in 
pregnancy. As detailed in chapter 1, Treg cells suppress inflammation and promote immune adaptation 
at the maternal-fetal interface (Aluvihare et al., 2004, Guerin et al., 2009). Understanding the function of 
Treg cells is crucial for developing treatment for human gestational complications, such as preeclampsia 
and recurrent miscarriage (Guerin et al., 2009), where altered Treg cells are implicated. In order to 
develop this knowledge, it is important to understand how Treg cells are normally regulated during 
pregnancy. miR-155 is one of the most well studied microRNAs in the immune system. It is involved in 
the regulation of multiple cell types including antigen presenting cells and also Treg cells, therefore it 
may impact on the immune response required for pregnancy success. miR-155 is induced after 
inflammatory challenge in DCs (Dunand-Sauthier et al., 2014), and has been reported to regulate the 
antigen presentation capacity of DCs (Rodriguez et al., 2007). miR-155 appeared to have conserved 
function in both human and mice and is associated with phenotype regulation in macrophages (Zhang 
et al., 2013, Graff et al., 2012). miR-155 deficiency resulted a systemic reduction in Treg cells in mice 
(Cobb et al., 2006, Lu et al., 2009a) and it’s expression is regulated by Foxp3 (Lu et al., 2009a, Marson 
et al., 2007). However, no study has previously investigated the role of miR-155 in antigen presenting 
cells and Treg cells in early pregnancy.  
Altered miR-155 expression patterns are found in pregnancy complications. In recurrent pregnancy loss 
patients, miR-155 expression is higher in the peripheral blood as well as in placenta (Tang et al., 2016, 
Winger et al., 2015). Altered immune regulatory microRNA expression in the peripheral blood 
mononuclear cells including miR-155 is associated with preeclampsia (Winger et al., 2015). To 
understand how aberrant miR-155 expression patterns may contribute to pregnancy complications, the 
role of miR-155 in normal pregnancy needs to be addressed.  
In the studies described in this chapter, miR-155 deficiency in mice was found to result in an overall 
diminished total cell number in PALN. This was evident at oestrus and on DPC 3.5, and is associated 
with the total CD4+ T cell number being diminished in the PALN at oestrus and also on DPC 3.5, when 
the cell proliferation induced with the immune response to conception is clearly evident in WT mice 
(Johansson et al., 2004). In the PALN, the smaller CD4+ T cell population is associated with a reduction 
in Treg cells. This manifests as a reduction in the proportion of Treg cells amongst CD4+ T cells as well 
as reduced Foxp3+ CD4+ T cell number. It is notable that the proportion of CD4+ T cells are elevated in 
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the PALN in miR-155-/- females at oestrus but not on DPC 3.5, indicating that miR-155 deficiency 
impacts on the CD4+ T cell expansion, and affects the Foxp3+ Treg cells to an even greater extent than 
CD4+ effector cells.   
In the current study, miR-155 deficiency did not impact on the total CD4+ T cells on DPC 3.5 in the 
spleen, blood and also mLN which is consistent with a previous study demonstrating that under  
steady-state circumstances (e.g. without antigen challenge) the number of CD4+ T cells in thymus and 
spleen are not reduced in the absence of miR-155 (Lu et al., 2009a). However, in the reproductive 
setting, paternal MHC alloantigens are present in seminal fluid at conception and are released by the 
placenta and can be found in the maternal circulation from mid-gestation (Herberth et al., 2014, 
Walknowska et al., 1969) and the maternal immune system can interact with fetal MHC (Hunt et al., 
2003, Van Rood et al., 1958, Tilburgs et al., 2009). In mated miR-155 deficient mice, the paternal 
alloantigen challenge can be seen to induce expansion in the PALN CD4+, CD8+ and Treg cell pool by 
DPC 3.5. However absence of miR-155 is associated with a less robust T cell response, resulting in a 
diminished CD4+ T cell population on DPC 3.5.  There is a selective adverse impact on the Treg cells, 
such that the absence of miR-155 appears likely to have a substantial impact on establishment of 
maternal immune tolerance.  
The absence of miR-155 appears to cause Treg cells to be diminished in the PALN partly because of a 
smaller resident population at oestrus before mating, and mainly because of failure of T cell proliferation 
to be activated after mating. With reduced total lymph node cell numbers at oestrus on DPC 3.5, and a 
particularly diminished Treg cell proportion (Figure 5.11). This reduction in the number of Treg cells in 
the absence of miR-155 was largely specific to the PALN, with a much smaller systemic reduction 
observed at oestrus and on DPC 3.5. This is consistent with previous studies which have demonstrated 
that the Treg cell population was diminished systemically (Cobb et al., 2006, Lu et al., 2009a). This 
study is the first one which addressed that miR-155 deficiency resulted in Treg cell reduction in the early 
pregnancy, indicating that the miR-155 impact on the capability of Treg cell expansion and proliferation.  
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Figure 5.11 Proportion of CD4+, CD8+ and CD4+ CD25+ Foxp3+ Treg cells in the PALN in miR-155+/+ and 
miR-155-/- mice at oestrus and on DPC 3.5. Fewer Treg cells are present in PALN of the miR-155-/- mice at 
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In addition, the MFI of Foxp3 is reduced in PALN on DPC 3.5.  As Foxp3 is the ‘master switch’ which is 
critical in Treg cell development and suppressive function (Fontenot et al., 2005, Fontenot et al., 2003), 
reduced MFI of Foxp3 indicates that Treg cells in miR-155-/- mice may have poorer commitment to the 
Treg cell lineage and potentially reduced functional competence. Notably, the reduced Foxp3 MFI was 
only observed on DPC 3.5 but not at oestrus in PALN, indicating that in the absence of miR-155, Treg 
cells in PALN may maintain normal suppressive activity. However, after mating the Treg cells in  
miR-155-/- may not be as suppressive as those from miR-155+/+ female mice. Although previous 
studies reported that miR-155 deficiency does not impact the suppressive capabilities in natural Treg 
cells (Stahl et al., 2009, Lu et al., 2009a), Chauhan et al have demonstrated that reduced expression of 
Foxp3 indicates the suppressive function of Treg cells is compromised (Chauhan et al., 2009).  
The diminished Treg cell pool in early gestational period in miR-155-/- mice is accompanied by, and 
may be the consequence of altered phenotype of DCs. The DCs are differentially regulated in the 
absence of miR-155, and in particular, a more than 4-fold reduction in the number of DCs was found in 
the PALN. These DCs are less activated, with decreased expression of MHCII, CD80 and CD86. These 
observations are consistent with previous studies showing that miR-155 is upregulated in mature or 
activated DCs (Stumpfova et al., 2014, Ceppi et al., 2009). Less MHCII expression may suggest that DC 
presentation capability is impaired. The antigen presenting capability was not addressed in this study, 
however Rodriguez et al (Rodriguez et al., 2007) have demonstrated that antigen presentation capacity 
is impacted by miR-155 deficiency, such that miR-155 deficient DCs fail to activate T cells effectively. It 
has also been demonstrated that DCs isolated from miR-155-/- mice are incompetent to activate T cells 
in vitro due to repression of Arginase-2, which suggests that miR-155 activity is crucial for DCs to 
activate T cells (Dunand-Sauthier et al., 2014). In the current study, the reduced Treg cell population 
and diminished expression of MHCII, CD80 and CD86 are consistent with the literature. Therefore, the 
reduced Treg cell population in early pregnancy may be due to diminished capacity for DCs to prime 
and activate Treg cell proliferation.  
In the mouse uterus, both mature macrophages and DCs are thought to be differentiated from 
undifferentiated macrophage precursors (Keenihan and Robertson, 2004), indicating that the 
possibilities of impaired reservoir of macrophages in miR-155 deficient mice for DC differentiation and 
could therefore impact on the DC population as well as the T cell population.  
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Macrophages are amongst the antigen presenting cell influx found in the cervix 12h post coitus in 
human (Sharkey et al., 2012b) and the day after mating in mice (Robertson et al., 1996, Robertson et al., 
1998, Robertson et al., 1992). An altered phenotype of PALN macrophages with antigen presenting cell 
activity might also contribute to the reduced Treg cell population. In the current study, the expected 
increase in macrophages seen in WT mice on DPC 3.5 did not occur in miR-155 deficient mice. 
Similarly, fewer MHCII+ activated macrophages, and CD80+ and CD86+ macrophages, were found on 
DPC 3.5 in PALN. DPC 3.5 may not be the optimal time points to quantify DC and macrophage 
population and phenotype. It would be relevant to further investigate the impact of miR-155 deficiency 
on the inflammation-like response to seminal fluid induction in the 12-24 hours after coitus, where even 
greater differences might be expected to be seen. 
miR-155 deficiency did not impact on the number or phenotype of macrophages in the mLN of the 
spleen, consistent with a specific effect in the context of the inflammatory response accompanying 
insemination. Also, there was no change in the uterus, but the greater variation between individual mice 
was likely a factor in this result.  
Additionally miR-155 deficiency results in attenuated IL-2 signalling in lymphocytes in mice, and IL-2 is 
well known for its pivotal role in Treg cell homeostasis (Bayer et al., 2007). Therefore, it is also possible 
that limited IL-2 signalling contributes to reduced Treg cell proliferative activity during early pregnancy. 
Altered T cell immunity in miR-155 deficient mice does not affect tolerance of fetal alloantigen, as  
miR-155 deficient female mice mated to Balb/c males are capable of maintaining pregnancy with 
generally comparable outcomes to WT control mice. However, the importance of miR-155 becomes 
apparent when pregnant miR-155-/- female mice were administered low dose LPS to induce a systemic 
inflammatory response in mid-gestation. When miR-155-/- female mice were challenged with 
inflammatory stimuli, they had a reduced capacity to sustain pregnancy with a 51.4% resorption rate, 
compared to WT mice in which pregnancy was not impacted by the same LPS dose. miR-155 is known 
to down-regulate inflammatory cytokine production in response to bacterial stimuli (Ceppi et al., 2009). 
In the current study, inflammatory cytokines may not be regulated appropriately in miR-155 deficient 
mice after administration of LPS in mid-gestation. In part, this may be attributed to the insufficient Treg 
cell response, as Treg cells are important for suppressing and controlling inflammatory cytokine 
responses (Collison et al., 2009, Collison et al., 2007, Sakaguchi et al., 2009a, Liang et al., 2008). In 
miR-155 deficient mice challenged with LPS, the limited population of Treg cells may not be able to 
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control the excess inflammatory responses after inflammatory insults. Taken together, these data 
suggest that miR-155 is essential in protecting the fetus from excessive inflammation via regulating Treg 
cell development and antigen presenting cell function.  
The current study does not quantify the Treg cell and antigen presenting cell population during mid and 
late gestation. Moreover, the dynamics of Treg cell population and antigen presenting cells were not 
mapped with LPS-induced systemic inflammation. Further studies are required to address the 
mechanisms of altered suppressive activity of Treg cells in the absence of miR-155 during gestation. In 
addition, this antigen presentation capability and phenotypes in antigen presenting cells and polarisation 
of macrophages in miR-155-/- mice has not been addressed. Further studies are required to address 
these questions in order to better understand how Treg cell responses are impacted in the absence of 
miR-155 over the course of gestation. Furthermore, adoptive transfer of Treg cells from pregnant WT 
mice into miR-155 deficient females prior to inflammatory challenge could be performed to investigate 
the protective role of Treg cells in the inflammation-induced fetal loss, and to confirm that the elevated 
fetal loss can indeed be attributed to these cells.  
In summary, the current study reinforces a pivotal role for miR-155 in both innate and adaptive immunity 
and expands current knowledge to show a key role for miR-155 in pregnancy. Both Treg cell and 
antigen presenting cell populations are dysregulated and likely to be functionally impaired in the 
absence of miR-155. In particular, the expansion in Treg cells associated with seminal fluid contact at 
conception is impaired, presumably as a consequence of the compromised activation and antigen 
presentation capability of DCs. This leads to a diminished Treg cell population in the PALN at the time of 
implantation on DPC 3.5. Treg cells generated in the absence of miR-155 are competent to sustain the 
allogeneic fetus under steady-state conditions. However, when pregnant mice with miR-155 deficiency 
are challenged with a mid-gestation inflammatory insult, the diminished Treg cell population is unable to 
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6.1 Abstract 
Immune tolerance of the semi-allogeneic fetus requires CD4+Foxp3+ T-regulatory (Treg) cells, which 
suppress inflammation and anti-fetal immunity. In mice, Treg expand at the outset of pregnancy in 
response to signals in seminal fluid. Recent studies have demonstrated that microRNAs (miRNA) play a 
role in the regulation of immune responses. In particular, miR-223 is known to be a pivotal modulator of 
macrophage and neutrophil differentiation, and a negative regulator of the inflammatory response. In 
addition, miR-223 is expressed by T cells and is highly enriched in the CD4+ T cell to Treg cell transition.  
miR-223 expression is induced in endometrial tissue by seminal fluid in the mouse uterus after mating, 
however, the contribution of miR-223 to the maternal immune environment in early pregnancy is yet to 
be assessed. To investigate the contribution of miR-223 to Treg cell activation and proliferation in early 
pregnancy, miR-223-/- or miR-223+/+ C57Bl/6 females (n=10-15) were mated to Balb/c males. T cell 
and antigen presenting cells from the uterus and the uterus draining lymph nodes (PALN) were 
assessed using flow cytometry on day 3.5 postcoitum (DPC).  Virgin oestrous miR-223-/- and  
miR-223+/+ females were used as non-mated controls. To investigate the impact of miR-223 deficiency 
on susceptibility to a pro-inflammatory challenge, a separate cohort of pregnant females on DPC 9.5 
were administered lipopolysaccharide (LPS) (1.0 µg) or phosphate saline buffer (PBS) control, and 
pregnancy outcomes were determined on DPC 17.5.  
miR-223 deficiency resulted in a significant alteration in the Treg cell profile in early pregnancy with the 
most striking changes being observed in the PALN following mating where reductions were observed in 
the proportion of Treg cells amongst the CD4+ T cell pool (22%), Treg number (28%) and Foxp3 mean 
fluorescent intensity (MFI) (1.3-fold) compared to mated miR-223+/+ females. In the absence of  
miR-223, a reduction in macrophages as a proportion of total cells (58%) and in the number of activated 
macrophages (15%) was observed in the PALN on DPC 3.5 compared to mated miR-223+/+ mice. 
Finally, the absence of miR-223 led to altered outcomes in pregnancy following LPS inflammatory 
challenge, with a 10% reduction in fetal weight and a 19% reduction in the fetal: placental weight ratio in 
late gestation. LPS administration also significantly increased the resorption rate (8.78-fold) in  
miR-223-/- females compared to miR-223+/+ females.  
Collectively, these data show that the absence of miR-223 alters the maternal immune profile in early 
pregnancy and this may cause increased susceptibility to inflammation-induced fetal loss later in 
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gestation. These findings suggest that miR-223 has a pivotal role establishing the appropriate maternal 
immune environment during the peri-conception period that activates immune tolerance to facilitate 
appropriate protection against inflammatory challenge in later gestation. These findings may be relevant 
to understanding how Treg-associated pregnancy pathologies such as preeclampsia arise in women 
where reduced miR-223 has been noted.  
6.2 Introduction  
Maternal immune tolerance is required to prevent rejection and accommodate the semi-allogeneic fetus. 
Immune adaptions towards the conceptus are required to establish a tolerogenic immune milieu and 
suppress excessive inflammatory responses which can contribute to gestational disorders. The 
immunological process to establish maternal immune tolerance requires Treg cells (Aluvihare et al., 
2004) which are potent suppressors of the generation and function of Th1- and Th17-mediated immune 
responses.  
Seminal fluid plays an important role in the expansion of Treg cell numbers at the outset of pregnancy 
(Robertson et al., 2009a). Initially, seminal fluid deposition in the female reproductive tract results in a 
transient inflammatory response that initiates immune changes. An influence of seminal fluid on the 
female tract immune response has been reported in humans (Pandiyan et al., 2007, Sharkey et al., 
2007), mice (Johansson et al., 2004) and all other mammalian species studied thus far (Schjenken and 
Robertson, 2014). Interactions between seminal fluid and epithelial cells in the reproductive tract induce 
elevated synthesis of cytokines and chemokines (Sharkey et al., 2012a, Sharkey et al., 2012b, Sharkey 
et al., 2007, Schjenken et al., 2015) which results in an influx of antigen presenting cells, as described in 
both humans (Sharkey et al., 2012b) and mice (De et al., 1991, McMaster et al., 1992, Robertson et al., 
1998, Robertson et al., 1996, Robertson et al., 1992). These changes help to prepare the female 
reproductive tract for pregnancy by promoting the development of the pre-implantation embryo 
(Bromfield et al., 2014, Chin et al., 2009, Robertson et al., 2001) preparing for embryo implantation 
(Plaks et al., 2008, Jasper et al., 2011) and clearing the uterine cavity of microorganisms introduced at 
mating (Robertson et al., 1999).  
There is evidence that both the cellular and acellular components of the ejaculate contribute to the 
expansion of Treg cells. Uterine DCs cross-present male alloantigens to activate maternal T cells 
(Moldenhauer et al., 2009), and initiate activation and proliferation of the Treg cell subset. Examination 
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of the Treg cell population in the uterus and PALN of mice highlights the role of seminal plasma, as a 
Treg cell expansion is only observed following exposure to complete seminal fluid and seminal plasma, 
but not sperm or the mechanical stimulation to mimic copulation (Guerin et al., 2011, Schumacher et al., 
2007). Interestingly, the induction of Foxp3 expression observed following mating requires the complete 
ejaculate as exposure to seminal plasma or sperm alone failed to induce a comparable Treg cell 
response (Guerin et al., 2011). Perturbations to Treg cells and their function are associated with human 
gestation disorders, such as pregnancy loss (Winger and Reed, 2011), preeclampsia (Quinn et al., 2011,  
Santner-Nanan et al., 2009, Sasaki et al., 2007, Prins et al., 2009, Tian et al., 2016). Therefore, to 
address how Treg cells are regulated, it is essential to understand the contribution of both DCs and 
Treg cell responses.  
In addition to Treg cells and DCs, macrophages are thought to have roles in antigen presentation, 
immune regulation, as well as tissue remodelling, particularly changes to the uterine vasculature (Ma et 
al., 2001, Aplin, 2002) to support placental development. Macrophages secrete vascular endothelial 
growth factor (VEGF) and other angiogenic factors which are regulated in the oestrous cycle and early 
pregnancy (Ma et al., 2001). Seminal fluid is involved in the regulation of angiogenesis as hamster 
females mated to accessory gland-deficient males exhibited reduced expression of Vegf (Chow et al., 
2003).  
Amongst the factors that contribute to Treg cell number and function, miRNAs are well studied but not in 
the context of pregnancy. miRNAs are involved in nearly all developmental, homeostatic and 
pathological processes (Griffiths-Jones et al., 2008) and are known to regulate immune cells (Mehta and 
Baltimore, 2016) and are involved in establishing pregnancy (Bidarimath et al., 2014).  
We have recently demonstrated that immune-regulatory miRNAs are induced in the endometrium 
following seminal fluid exposure at coitus. One of the most highly regulated miRNAs is miR-223 which is 
induced in the endometrium after mating (Schjenken, unpublished observations). This miRNA has been 
identified as a marker for pregnancy complications such as miscarriage, preeclampsia and recurrent 
pregnancy loss (Winger et al., 2015, Tang et al., 2016) and an elevated expression of miR-223 is 
associated with membrane with chorioamnionitis in advancing gestation (Montenegro et al., 2007).  
miR-223 is involved in the regulation of multiple leukocytes, including neutrophils, macrophages, DCs 
and also Treg cells. miR-223 negatively regulates differentiation and activation in neutrophils, and mice 
with miR-223 null mutation exhibit increased number of circulating neutrophils, and these neutrophils 
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exhibit an unusual hyper-maturation (Johnnidis et al., 2008). M2 macrophages are immuno-suppressive 
and miR-223 is known to contribute to M2 polarisation in macrophages (Zhou et al., 2015, Zhuang et al., 
2012, Zhang et al., 2013). In the intestine, elevated secretion of pro-inflammatory cytokines IL1β and 
tumour necrosis factor, and reduced production of the anti-inflammatory cytokine TGF-β are found in 
macrophages in the miR-223 deficient mice (Zhou et al., 2015). A dysregulated population of DCs are 
also observed, such that intestinal DCs produce more pro-inflammatory cytokines upon activation (Zhou 
et al., 2015).  
The pattern of seminal fluid induction of miR-223 expression in the endometrial lining of the female 
reproductive tract after coitus in mice (Schjenken, unpublished), is consistent with an influence on 
induction of tolerogenic DCs and Treg cells to establish tolerance for pregnancy. Given the role of  
miR-223 in immune tolerance in other tissues, the roles of miR-223 in the regulation of Treg cells and 
antigen presenting cells in early pregnancy are essential to elucidate.  
In the experiments described in this chapter, we utilised miR-223-/- mice to investigate the role of  
miR-223 in the regulation of the peri-conception immune environment and the role of miR-223 in 
regulation of Treg cells, macrophages and DC in early pregnancy. 
6.3 Result  
6.3.1 miR-223 deficiency results in a systemic change to the maternal T cell profile in early 
pregnancy  
To determine the impact of miR-223 deficiency on the T cell profile in early pregnancy, miR-223-/- and 
miR-223+/+ female mice were mated to Balb/c males. The PALN, mesenteric lymph nodes (mLN), 
spleen and blood were collected from females on DPC 3.5 for T cell quantification. Virgin oestrous 
females were used as an unmated control. Treg cells were identified as CD3+ CD4+ CD25+ Foxp3+ T 
cells, and the gating strategies were the same as detailed in chapter 5 (Figure 5.1). Data for PALN are 
described in detail in this chapter, while the results for mLN, spleen and blood are presented in chapter 
8, section 8.3.1 
6.3.1.1 Total cell expansion in the PALN  
Hypertrophy in the PALN draining the uterus within the days after mating is an indication of the female 
immune response required to establish pregnancy. To assess the impact of miR-223 deficiency on 
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lymph node cellularity in early pregnancy, we firstly examined the total cell number in the PALN on DPC 
3.5. While the total number in the PALN increased by 1.3-fold (p<0.05, Figure 6.1) in miR-223+/+ 
females after mating, this elevation was not observed in the absence of miR-223 (Figure 6.1). No 




Figure 6.1 The effect of miR-223 deficiency on populations of total cells in the PALN. miR-223+/+ and  
miR-223-/- mice were mated with Balb/c males, and on DPC 3.5, total cells from the PALN were quantified by a 
haemocytometer. Unmated virgin oestrus mice were used as non-mated controls. Data are presented as mean ± 
SEM and are number of total cells x106 in the PALN. Differences between groups were evaluated using  
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6.3.1.2 T cell profile in the PALN 
To determine whether miR-223 deficiency affects the Treg cell population on DPC 3.5 in the PALN, we 
firstly defined the population of T cells expressing CD4. Within the CD3 population, the proportion of T 
cells expressing CD4 was not changed (Figure 6.2A) after mating or between genotypes. However, 
while mating resulted in an elevation in the number of CD4+ T cells in miR-223+/+ mice (2.3-fold, 
p<0.0001), no change was observed following mating in miR-223-/- females. While miR-223 deficiency 
did not alter the number of CD4+ T cells at oestrus, a significant decrease (22%, p<0.05) was observed 
on DPC 3.5 (Figure 6.2B). Similarly, while mating resulted in an elevation in the MFI of CD4 in  
miR-223+/+ females (1.6-fold, p<0.01), no change was observed in miR-223-/- females (Figure 6.2C). In 
reference to CD4 MFI, miR-223 deficiency resulted in a significant reduction at both oestrus (16%, 
p<0.001) and DPC 3.5 (52%, p<0.001) (Figure 6.2C).  
To understand the impact of miR-223 deficiency on Treg cells, we then assessed the CD4+CD25+ 
Foxp3+ Treg cell profile within the PALNs. miR-223 deficiency resulted in a significantly lower proportion 
of Treg cells amongst CD4+ T cells, both at oestrus (43%, p<0.0001) and on DPC 3.5 (28%, p<0.0001) 
(Figure 6.2D). No change was observed in the proportion of Treg cells following mating in miR-223+/+ 
females, but a significant increase (1.3-fold, p<0.01) was observed in miR-223-/- females (Figure 6.2D). 
Consistent with our previous observations (Guerin et al., 2011) the total number of Treg cells was 
increased following mating in miR-223+/+ females (2.1-fold, p<0.001). A similar increase was observed 
in miR-223-/- females following mating (1.4-fold, p<0.01) but not to the same extent. Further, while  
miR-223 deficiency did not impact Treg cell numbers at oestrus, a significant reduction was observed on 
DPC 3.5 (42%, p<0.01) (Figure 6.2E). Similar results were observed for Foxp3 MFI with a significant 
increase (1.3-fold, p<0.01) in Foxp3 MFI on DPC 3.5 in miR-223+/+ mice, but not in miR-223-/- mice 
(Figure 6.2F). While miR-223 deficiency did not impact Foxp3 MFI at oestrus, a significant reduction 
(24%, p<0.001) was seen on DPC 3.5 (Figure 6.2F). Taken together, miR-223 deficiency acted to 
reduce total CD4+ T cells and CD4+ Treg cells and suppressed the capacity of mating to induce the 
expected increase in the number and Foxp3 MFI of Treg cells. This reduction would be expected to 
potentially impact on the quality of immune tolerance in pregnancy.  
 
 
ZHANG                                                        Chapter 6                                                           119 
 
Figure 6.2 The effect of miR-223 deficiency on T cell populations in the PALN. miR-223+/+ and miR-223-/- 
mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the PALN 
were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. Data 
are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the total 
number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of CD3+ CD4+ CD25+ Foxp3+Treg cells (D), 
the total number of CD3+ CD4+ CD25+ Foxp3+ Treg cells x106 (E), and the MFI of Foxp3 (F). Differences 
between groups were evaluated using Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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6.3.2 Effect of miR-223 deficiency on the macrophage and dendritic cell profile during early 
pregnancy 
Given the importance of antigen presenting cells in the peri-conception immune environment and 
generating the T cell response, we then assessed the impact of miR-223 deficiency on the profile of 
macrophages and DCs in early pregnancy. At oestrus and on DPC 3.5, cells from mLN, spleen, PALN 
and uterus were collected for analysis of the antigen presenting cell profile using flow cytometry.  
Macrophages were assessed by examining the population of total macrophages (CD11B+ F4/80+ cells), 
activated macrophages (MHCII+ CD11B+ F4/80+ cells), and macrophages expressing the co-
stimulatory molecules CD80 (CD80+ CD11B+ F4/80+ cells) and CD86 (CD86+ CD11B+ F4/80+ cells). 
DCs were assessed by examining the total population of dendritic cells (CD11C+ F4/80- cells), activated 
DCs (MHCII+ CD11C+ F4/80- cells), as well as DCs expressing the co-stimulatory molecules CD80 
(CD80+ CD11C+ F4/80- cells) and CD86 (CD86+ CD11C+ F4/80- cells). Macrophages and DCs were 
identified using the flow cytometry gating strategy described in chapter 5 (Figure 5.3 and 5.4). 
Data for uterus and PALN are described in detail in this chapter, while the results of mLN and spleen 
are presented in chapter 8, section 8.3.2 and 8.3.3. 
6.3.2.1 Macrophage profile in uterus and PALN 
To assess the impact of miR-223 deficiency on the macrophage number and phenotype in early 
pregnancy, uterus and PALN were collected from oestrous or DPC 3.5 miR-223+/+ or miR-223-/- 
females. In these experiments, we were able to assess the uterus in addition to the lymph nodes as 
substantial numbers of macrophages and DC can be recovered from the uterus. 
6.3.2.1.1 PALN 
In the PALN, a significant increase in the proportion of macrophages in the viable leukocyte population 
(1.4-fold, p<0.05) was observed on DPC 3.5 in miR-223+/+ females, however this change was not 
evident in miR-223-/- females on DPC 3.5. While there was no difference at oestrus, miR-223 deficiency 
resulted in a significant reduction in the proportion of macrophages on DPC 3.5 (58%, p<0.05) (Figure 
6.3A). A similar pattern was observed in the total number of macrophages in the PALN. A significant 
increase in macrophage numbers following mating (1.8-fold, p<0.01) was found in miR-223+/+ females 
but this did not occur in miR-223-/- females, compared to the genotype matched oestrus controls 
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(Figure 6.3B). Again, while there was no difference at oestrus, miR-223 deficiency resulted in a 
significant reduction (61.9%, p<0.01) in the number of macrophages on DPC 3.5 (Figure 6.3B).  
We then further examined the macrophage population to identify whether miR-223 deficiency impacted 
the population of activated macrophages (MHCII+ CD11B+ F4/80+ macrophages) in the PALN. Mating 
resulted in a significant elevation in the proportion of activated macrophages, compared to genotype 
matched oestrus controls in both miR-223+/+ (1.1-fold, p<0.05) and miR-223-/- (1.2-fold, p<0.05) 
(Figure 6.3C). However, miR-223 deficiency resulted in a smaller proportion of activated macrophages 
at oestrus (21%, p<0.01) and on DPC 3.5 (15%, p<0.01), compared to genotype matched controls 
(Figure 6.3C). The total number of activated macrophages was significantly increased in miR-233+/+ 
females (2.0-fold, p<0.01) but not in miR-223-/- females, compared to oestrus genotype matched 
controls (Figure 6.3D). While there was no difference at oestrus, miR-223 deficiency led to a significant 
reduction (69%, p<0.001) in macrophage number on DPC 3.5 (Figure 6.3D).  
Expression of the co-stimulatory molecules CD80 and CD86 within the macrophage population was 
then examined to evaluate co-stimulatory capacity, which is necessary for T cell activation and survival 
(June et al., 1987, Linsley et al., 1991). The percentage of CD80+ macrophages was not changed after 
seminal fluid exposure in either miR-223+/+ or miR-223-/- mice (Figure 6.3E). Interestingly, miR-223 
deficiency resulted in a significant increase in the proportion of CD80+ macrophages at oestrus (1.6-fold, 
p<0.05), but not on DPC 3.5 (Figure 6.3E). In contrast, CD80+ macrophage numbers were significantly 
increased following mating in miR-223+/+ females (2.0-fold, p<0.05), but not in miR-223-/- females 
(Figure 6.3F). A 49% reduction (p<0.05) in the number of CD80+ macrophage was observed in  
miR-223-/- females on DPC 3.5, compared to WT controls. In regards to CD80+ macrophage numbers, 
there was no impact of miR-223 deficiency at either oestrus or on DPC 3.5 (Figure 6.3F).  
The percentage of macrophages positive for CD86 was not changed after seminal fluid exposure or 
between genotypes (Figure 6.3G). However, CD86+ macrophage numbers were significantly increased 
following mating in miR-223+/+ mice (1.8-fold, p<0.05), but not in miR-223-/- mice (Figure 6.3H). While  
miR-223 deficiency did not affect CD80+ macrophage number at oestrus, a significant reduction (66%, 
p<0.0001) was observed on DPC 3.5 (Figure 6.3H). These data suggest that in the absence of miR-223, 
the population of macrophages is impacted on DPC 3.5 but not at oestrus. 
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Figure 6.3 The effect of miR-223 deficiency on the macrophage population and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in the PALN. miR-223+/+ and miR-223-/- B6 female mice were 
mated with Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the PALN were analysed by flow cytometry 
to quantify the proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus mice 
were used as non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ 
macrophages within viable cells (A), the total number of macrophages x 106 (B), the percentage of activated 
macrophages (MHCII+ macrophages) (C), the total number of activated macrophages x 106 (D), the percentage 
of CD80+ macrophages (E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ 
macrophages (G) and the total number of CD86+ macrophages x 106 (H). Differences between groups were 
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6.3.2.1.2 Uterus 
In the uterus, no change in the proportion of cells comprised by macrophages, or the total number of 
macrophages were observed following mating, or between genotypes at oestrus or on DPC 3.5. (Figure 
6.4A-B). 
We then further examined the macrophage population to identify whether miR-223 deficiency impacted 
the population of activated macrophages (MHCII+ CD11B+ F4/80+ macrophages) in the uterus. In 
contrast to what was observed in the PALN, a significant reduction in the proportion of activated 
macrophages was observed in miR-223-/- mice at oestrus (12%, p<0.0001) and on DPC 3.5 (29%, 
p<0.05), compared to the WT (Figure 6.4C). Irrespective of the changes observed in the proportion of 
activated macrophages, no change was observed in the number of activated macrophages following 
mating or between genotypes at oestrus or on DPC 3.5 (Figure 6.4D). 
Analysis of the CD80+ and CD86+ macrophage population showed no change in the percentage or 
number of these macrophages after mating or between genotypes at oestrus or on DPC 3.5 (Figure 
6.4E and F). These data suggest that miR-223 deficiency causes moderate changes to uterine 
macrophage activation status as measured by MHCII expression at oestrus and on DPC 3.5, but this 
does not substantially impact the number of activated macrophages present.  
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Figure 6.4 The effect of miR-223 deficiency on macrophage populations the uterine tissues. miR-
223+/+ and miR-223-/- B6 female mice were mated with Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells 
from the uterine tissues were analysed by flow cytometry to quantify the proportion of macrophages and the 
expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of F4/80+ macrophages within viable cells (A), the total 
number of macrophages x 106 (B), the percentage of activated macrophages (MHCII+ macrophages) (C), the 
total number of activated macrophages x 106 (D), the percentage of CD80+ macrophages (E), the total number of 
CD80+ macrophages x 106 (F), the percentage of CD86+ macrophages (G) and the total number of CD86+ 
macrophages x 106 (H). Differences between groups were evaluated using Kruskal-Wallis test and Mann-Whitney 
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6.3.2.2 Dendritic cell profile in uterus and PALN 
To assess the impact of miR-223 deficiency on the DC number and phenotype in early pregnancy, 
uterus and PALN were collected from miR-223+/+ and miR-223-/- females at oestrus or DPC 3.5. In 
these experiments, we were able to assess the uterus in addition to the lymph nodes as substantial 
numbers of macrophages and DC can be recovered from the uterus.  
6.3.2.2.1 PALN 
In the PALN, there was no change in the number of F4/80-CD11C+ DCs expressed as a proportion of 
viable cells in miR-223+/+ or miR-223-/- mice following mating or between genotypes (Figure 6.5A). A 
2.8-fold (p<0.01) elevation in the number of DCs was observed on DPC 3.5 in miR-223+/+ females, 
however miR-223 deficiency led to failure to induce this elevation. No change was observed at oestrus 
or on DPC 3.5 between genotypes (Figure 6.5B).  
We then further examined the DC population to identify whether miR-223 deficiency impacted the 
population of activated DCs (MHCII+ CD11C+ F4/80- DCs) in the PALN. Following mating, the 
proportion of activated DCs was significantly increased in both miR-223+/+ (1.8-fold, p<0.05) and  
miR-223-/- mice (1.6-fold, p<0.05) compared to the oestrus genotype matched controls. No change in 
the proportion of activated DCs was observed at oestrus or on DPC 3.5 between genotypes (Figure 
6.5C). Seminal fluid exposure induced an increase in the number of activated DCs in both miR-223+/+ 
(3.2-fold, p<0.001) and miR-223-/- females (3.4-fold, p<0.05), compared to genotype matched oestrous 
controls (Figure 6.5D). The percentage of DCs positive for CD80 was not changed following mating, in 
either miR-223+/+ or miR-223-/- females, and no change in CD80+ DCs was observed between 
genotypes at oestrus or on DPC 3.5 (Figure 6.5E). In contrast, mating resulted in a significant increase 
in the number of CD80+ DCs in both miR-223+/+ (2.4-fold, p<0.05) and miR-223-/- females (2.7-fold, 
p<0.05), compared to genotype matched oestrus controls. No change in the number of CD80+ DCs was 
observed at oestrus or on DPC 3.5 between genotypes (Figure 6.5F).  
The percentage and number of CD86+ DCs was not changed after seminal fluid exposure, in either  
miR-223+/+ or miR-223-/- females (Figure 6.5G). A 2.9-fold increase (p<0.05) in the number of CD86+ 
DCs was observed in miR-223+/+ females on DPC 3.5, however miR-223 deficiency failed to induce 
this elevation. No change was observed between genotypes at oestrus or on DPC 3.5 (Figure 6.5H). 
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Figure 6.5 The effect of miR-223 deficiency on DC population and expression of MHCII, CD80, and CD86 
by CD11C+ DCs in the PALN. miR-223+/+ and miR-223-/- B6 mice were mated with Balb/c males, and on DPC 
3.5, CD11C+ F4/80- cells from the PALN were analysed by flow cytometry to quantify proportion of DCs and the 
expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total number of 
DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated DCs x 106 (D), 
the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ DCs (G) 
and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using Kruskal-Wallis 
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6.3.2.2.2 Uterus 
In the uterus, a significant increase in the proportion of cells comprised by DCs was observed following 
mating in both miR-223+/+ (1.8-fold, p<0.01) and miR-223-/- females (1.6-fold, p<0.01), compared to 
the genotype matched oestrus controls (Figure 6.6A). No changes in the proportion of DCs were 
observed at oestrus or on DPC 3.5 between genotype (Figure 6.6A). DC numbers followed a similar 
pattern after mating, with significant increases in miR-223+/+ (3.3-fold, p<0.0001) and miR-223-/-  
(1.8-fold, p<0.05) observed compared to genotype matched oestrus controls (Figure 6.6B). Further, 
miR-223 deficiency resulted in a significant reduction in DC number (41%, p<0.05) on DPC 3.5, 
compared to WT females, but this was not the case at oestrus (Figure 6.6B).  
We then further examined the DC population to identify whether miR-223 deficiency impacted the 
population of activated DCs (MHCII+ CD11C+ F4/80- DCs) in the uterus. While no change was 
observed in the proportion of activated DCs in miR-223+/+ females following mating, a significant 
increase was observed in miR-223-/- females (1.2-fold, p<0.05) following mating, compared to genotype 
matched oestrus controls. Further, miR-223 deficiency resulted in overall significantly lower proportion 
of activated DCs at oestrus (26%, p<0.05) and on DPC 3.5 (20%, p<0.05), compared to genotype 
matched controls (Figure 6.5C). In contrast, a significant increase in activated DC number was observed 
following mating in miR-223+/+ (3.0-fold, p<0.0001), but not in miR-223-/- (Figure 6.6D). While there 
was no change at oestrus, miR-223 deficiency did result in a significant reduction (53%, p<0.001) in the 
number of activated DCs on DPC 3.5, compared to genotype matched controls (Figure 6.6D). 
Analysis of the CD80+ and CD86+ DC population showed no change in the proportion of CD80+ DCs 
following mating in both miR-223+/+ or miR-223-/- females or at oestrus or on DPC 3.5 between 
genotypes (Figure 6.6E). However, a significant increase in CD80+ DC number was seen following 
mating in miR-223+/+ (3.4-fold, p<0.05) but not in miR-223-/- females compared to genotype matched 
oestrus controls (Figure 6.6F). At oestrus or on DPC 3.5, no change in the total number of CD80+ DCs 
was observed between genotypes (Figure 6.6F).  
While no change in the proportion of CD86+ DCs was observed following mating in miR-223+/+ females, 
a significant increase was observed in miR-223-/- females (1.3-fold, p<0.05), compared to oestrous  
miR-223-/-females. No change in the proportion of CD86+ DCs was observed at oestrus or on DPC 3.5 
between genotypes (Figure 6.6G). An increase in CD86+ DCs was observed in both miR-223+/+  
(3.7-fold, p<0.0001) and miR-223-/- females (2.2-fold, p<0.05) following mating, compared to  
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genotype-matched oestrus controls (Figure 6.6H). However, no change was observed at oestrus or on 
DPC 3.5 between genotypes (Figure 6.6H). In summary, these data show that the number of DCs and 
activation status of DCs are reduced at oestrus and on DPC 3.5.  
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Figure 6.6 The effect of miR-223 deficiency on population of DCs and expression of MHCII, CD80, and 
CD86 by CD11C+ DCs in uterine tissues. miR-223+/+ and miR-223-/- B6 mice were mated with Balb/c males, 
and on DPC 3.5, CD11C+ F4/80- cells from the uterine tissues were analysed by flow cytometry to quantify 
proportion of DCs and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated 
controls. Data are presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the 
total number of DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated 
DCs x 106 (D), the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of 
CD86+ DCs (G) and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using 
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6.3.3 Maternal miR-223 deficiency elevates LPS-induced fetal loss 
(The results in this section were generated and kindly provided by Dr. John Schjenken and are included 
here to allow a full discussion of the implication of immune cell changes in miR-223-/- mice). 
As detailed above, miR-223 deficiency results in an altered maternal immune environment in early 
pregnancy. However, this altered environment appeared not to affect fertility, because in the breeding 
colony, where miR-223-/- females were mated with syngeneic miR-223-/- males, steady state 
pregnancy rates were comparable to controls (Schjenken, data not shown). As detailed in chapter 3, the 
functional requirements for immune mediators can become apparent following inflammatory challenge. 
Therefore, to investigate the impact of miR-223 deficiency on immune tolerance in pregnancy,  
miR-223-/- and miR-223+/+ female mice were mated to allogeneic Balb/c males to generate 
pregnancies with maternal, but not fetal, miR-223 deficiency. On DPC 9.5, pregnant females were 
administrated a low-dose inflammatory challenge of 1.0 µg LPS, or PBS control. This dose of LPS was 
chosen as it was determined in preliminary experiments to be just below the threshold for impact on 
pregnancy loss in miR-155+/+ mice. 
In mice examined just before term on DPC 17.5, miR-223-/- females were more severely affected by 
LPS challenge than miR-223+/+ mice, with a lower proportion of miR-223-/- mice carrying viable fetuses 
(39% reduction, p<0.05, Figure 6.6A) and a lower number of viable fetuses per mated female (50% 
reduction, p<0.001, Figure 6.7B) on DPC 17.5. The change in viable fetuses was associated with a 
significantly higher rate of fetal resorption in miR-223-/- mothers (8.8-fold, p<0.0001) following LPS 
treatment (Figure 6.7C). The LPS treatment impacted fetal weights in both miR-223+/+ (11% reduction, 
p<0.05) and miR-223-/- (10% reduction, p<0.05) (Figure 6.7D). Strikingly, miR-223 deficiency impacted 
fetal weights even in the PBS treatment group with a significant reduction observed (9.3% reduction, 
p<0.05) (Figure 6.7D). No effects of genotype or LPS treatment on placental weight was observed 
(Figure 6.7E). However, the changes in fetal weights led to a significant reduction in the fetal: placental 
weight ratio in miR-223-/- following LPS (19% reduction, p<0.0001, Figure 6.7F), but not PBS treatment 
compared to miR-223+/+ females. Thus, maternal miR-223 deficiency appears to impact the 
establishment and maintenance of the appropriate maternal immune environment in pregnancy, such 








Figure 6.7 The effect of miR-223 deficiency on pregnancy parameters after low-dose LPS challenge.  
miR-223+/+ and miR-223-/- mice were mated with Balb/c males and injected i.p. with LPS (1µg) or control (PBS) 
on DPC 9.5, then autopsied on DPC 17.5. Data are the percentage of mated females pregnant with viable fetuses 
(A), the number (mean ± SEM) of viable implantation sites per mated mouse (individual data points with mean 
value shown; B), the percentage of total implantation sites per pregnant female undergoing resorption (individual 
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data points with mean ± SEM; C), the fetal weight (estimated marginal mean ± SEM; D), the placental weight 
(estimated marginal mean ± SEM; E), and the fetal: placental weight ratio (estimated marginal mean ± SEM; F). 
Numbers of mated mice are shown in parentheses. The effect of genotype was evaluated in A by chi-square 
analysis and in B by ANOVA and Sidak t-test. The effect of genotype was evaluated in D-F by mixed model 
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6.3.4 Systemic impact of miR-223 deficiency on DPC 3.5 
miR-223 deficiency resulted in a reduction in the proportion but not the absolute number of CD4+ T cells 
in the mLN, but no impact was observed in the proportion and number of CD4+ T cells in spleen or 
peripheral blood, indicating that miR-223 deficiency had minimal influence on the CD4+ T cell 
population at oestrus or on DPC 3.5 in these sites. A reduced proportion in Treg cells amongst CD4+ T 
cells was observed in the mLN and the spleen at oestrus and on DPC 3.5, but this did not occur in the 
peripheral blood. Together, these data indicate that miR-223 deficiency did not exert substantial 
systemic changes in the maternal immune response in oestrus or early pregnancy.    
On DPC 3.5, miR-223 deficiency did not alter macrophage populations or phenotype systemically, with 
a small reduction in the proportion of macrophages observed at oestrus and on DPC 3.5 and a 
reduction in the proportion of CD80+ macrophages at oestrus in the mLN. In addition, miR-223 
deficiency was associated with a small reduction in the proportion of activated macrophages in the 
spleen at oestrus. Furthermore, miR-223 deficiency failed to induce the same extent of activated DCs 
and CD80+ DCs expansion in the mLN on DPC 3.5. These data suggest that the miR-223 deficiency 
had minimal impact on the number and phenotype of Treg cells and antigen presenting cells in other 
distal lymphoid organs or in peripheral blood. Taken together, these data show less profound change 
due to miR-223 deficiency on the number and phenotype of Treg cell and antigen presenting cells in 
systemic tissues compared with the more substantial changes in the PALN.  
6.4 Discussion  
A sufficient number of functional Treg cells are essential for maternal immune tolerance in pregnancy. 
Treg cells suppress inflammation and promote immune adaptation at the maternal-fetal interface 
(Aluvihare et al., 2004, Guerin et al., 2009). Understanding the regulation and function of Treg cells is 
crucial for developing treatment for human gestational complications, such as preeclampsia and 
recurrent miscarriage where altered Treg cells are implicated (LaMarca et al., 2013, Santner-Nanan et 
al., 2009, Prins et al., 2009, Wallace et al., 2011). In order to develop this knowledge, it is crucial to 
understand how Treg cells are normally regulated during pregnancy.  
There are growing studies focusing on the miRNAs in immune cells and in non-immune cells that 
influence immune response. Depletion of miRNA by Dicer null mutation results in a systemic 
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compromise in T cells (Taganov et al., 2007). The miRNA expression profile in conventional CD4+ T 
cells and Treg cells has been investigated in mouse.  
Treg cells have a distinct miRNA expression profile, compared with CD4+ T cells, and miR-223 is highly 
enriched in the CD4+ T cell to Treg cell transition (Cobb et al., 2006). Treg cells have a distinctive 
miRNA expression profile with miR-146a, miR-155 and miR-223 and another 32 miRNAs preferentially 
expressed in Treg cells compared to conventional CD4+ T cells (Cobb et al., 2006). However, few 
studies have addressed the role of miR-223 in Treg cell development and function and little is known 
about the role of miR-223 in regulation of the Treg cell response.  
A correlation between higher miR-223 and a lower Treg cell population has been observed in maternal 
blood (Herberth et al., 2014). High miR-223 level in the maternal blood is correlated with lower maternal 
Treg cell numbers in women who smoke (Herberth et al., 2014). Clinical studies have revealed that 
altered miR-223 expression patterns are found in pregnancy complications. In recurrent pregnancy loss 
patients, miR-223 expression is higher in the peripheral blood as well as placentas (Tang et al., 2016, 
Winger et al., 2015). In addition, seven miRNAs, including miR-223 in peripheral blood are identified as 
potential markers to screen pregnancy complications during first trimester or prior to conception, 
including miscarriage and preeclampsia (Winger et al., 2015). In recurrent pregnancy loss patients,  
miR-223 expression is higher in placental samples or peripheral blood (Tang et al., 2016). 
To understand how aberrant miR-223 expression patterns may contribute to pregnancy complications, 
the role of miR-223 in normal pregnancy needs to be elucidated. The current study has demonstrated 
that miR-223 deficiency results in a local change to the response to male alloantigens in the PALN. 
Although the proportion of CD4+ T cells is not reduced in the absence of miR-223 in the PALN, the total 
number of CD4+ T cells are reduced on DPC 3.5, with a decreased CD4+ MFI at oestrus and on DPC 
3.5. At oestrus (steady-state), the number of CD4+ T cells are not influenced by the absence of miR-233 
in PALN, but a distinct reduction is seen on DPC 3.5 when male alloantigen challenge has occurred. 
This reduction seems to be due to limited total cell expansion in the PALN in the miR-223 deficient mice 
on DPC 3.5 (Figure 6.8).  
Previous studies have focused on investigating how miR-223 regulates maturation, proliferation and 
differentiation of myeloid cells (Chen et al., 2004, Johnnidis et al., 2008). The current study has revealed 
that miR-223 may be also involved in CD4+ T cell activation and proliferation. In addition, the reduction 
pattern in the CD4+ T cell numbers are not observed in the mLN, spleen and peripheral blood at oestrus 
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or on DPC 3.5 in the absence of miR-223, indicating that miR-223 deficiency has a local impact in the 
reproductive setting, that becomes evident after the antigenic challenge of mating and early pregnancy.  
In the present study, we firstly demonstrated that in the absence of miR-223, Treg cells are diminished 
in the PALN which drain the uterus. With limited total cell expansion, as well as reduced Treg cell 
proportion amongst the CD4+ T cells, the most striking reduction in the number of Treg cells is evident 
in the PALN, and a smaller reduction in the Treg cell proportion is also observed in mLN and spleen at 
oestrus and on DPC 3.5 in miR-223 deficient mice (see chapter 8, section 8.3.1). Currently only two 
studies have focused on miR-223 and Treg cells, one study linked reduced Treg cell numbers are 
associated with dysregulated macrophages and DCs in the intestine of miR-223 deficient mice (Zhou et 
al., 2015), and the other study reports that an elevation of miR-223 is correlated with lower Treg cell 
numbers in maternal blood in women who smoke (Herberth et al., 2014). This study has firstly 
addressed that of miR-223 is required in the Treg cell expansion in the early gestation period, which is 
consistent with the literature that miR-223 is highly expressed in Treg cells (Cobb et al., 2006).  
The MFI of Foxp3 is reduced in PALN and other tissues on DPC 3.5 but not at oestrus.  As Foxp3 is the 
‘master switch’ which is critical in the Treg cell development and suppressive function (Fontenot et al., 
2005, Fontenot et al., 2003), reduced MFI of Foxp3 indicates that Treg cells in miR-223-/- mice may be 
associated with reduced stability or impaired commitment to the Treg cell lineage. Notably, the reduced 
Foxp3 MFI was only observed on DPC 3.5 not at oestrus in the PALN. Since Foxp3 MFI is has been 
linked with suppressive competence (Wan and Flavell, 2007), this may indicate that in the absence of 
miR-223, Treg cells in PALN are impaired in achieving their optimal suppressive activity after priming to 
male alloantigens. Currently, no study has addressed the relationships between miR-223 and Treg cell 
suppressive activity.  
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Figure 6.8 Proportion of CD4+, CD8+ and Treg cells in the uterus and PALN in the miR-223+/+ and  
miR-223-/- mice at oestrus and on DPC 3.5. Comparable amount of celles were discovered in the miR-223-/- 
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After seminal fluid exposure, an influx of antigen presenting cells including macrophages and DCs are 
recruited to the uterus. These cells are important for priming T cells and inducing Treg cell population 
expansion (De et al., 1991, McMaster et al., 1992, Robertson et al., 1998, Robertson et al., 1996, 
Robertson et al., 1992). In addition, macrophages are involved in tissue remodelling and assist in 
preparing the uterus for fetal implantation, for example through effects on epithelial cell expression of 
embryo attachment ligands (Das et al., 1997, Feng et al., 1998, Jasper et al., 2011). Notably, in the 
absence of miR-223, a reduced proportion and number of macrophages and activated macrophages 
are observed in the uterus and PALN at oestrus and on DPC 3.5. This suggests that miR-223-/- females 
are less competent to respond to male alloantigens and the capacity to prepare for fetal implantation 
may be compromised. Previous studies show that absence of miR-223 reduces the number and 
proportion of macrophages and miR-223 is found to regulate the differentiation of macrophages and 
maintain their M2-like phenotype (Zhou et al., 2015, Zhuang et al., 2012). The current study also found 
a reduced proportion of macrophages in the mLN at oestrus and on DPC 3.5, and a reduced proportion 
of activated macrophages in the spleen on DPC 3.5, but the reduction is not to the same extent as in 
the uterus and PALN. Taken together, miR-223 deficiency has a greater impact on the macrophage 
population in reproductive tract, compared with systemic lymph nodes. This likely reflects a failure to 
respond to the activating signals that are present in the uterus following seminal fluid contact. 
The diminished Treg cell pool in early gestational period in miR-223-/- mice is accompanied by, and 
may be the consequence of altered phenotype of DCs. A 1.68-fold reduction in numbers of DCs were 
found in PALN on DPC 3.5 in miR-223-/- females, suggesting that miR-223 is important in DC 
recruitment and/or proliferation. This contrasts with a previous study which demonstrated that CD11C+ 
DCs are not changed in the small intestine in the absence of miR-223 (Zhou et al., 2015). This may be 
due to the difference of tissues examined. In addition, miR-223 deficient mice did exhibit a decrease in 
myeloid DCs in the central nerve system in experimental autoimmune encephalomyelitis model (Ifergan 
et al., 2016), which is consistent with the current study.  
As well as being fewer in number, these DCs appear less activated, with decreased expression of  
MHCII on DPC 3.5. Less MHCII expression suggests that antigen presenting cell presentation capability 
may be impaired which would contribute to explaining the reduced Treg cell population. Dysregulated 
macrophages and DCs have been linked with a reduced Treg cell population in the small intestine of  
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miR-223-/- mice (Zhou et al., 2015). This implies a similar mechanism exists in the PALN where less 
activated DCs in miR-223-/- mice are unable to induce Treg cell responses.  
Antigen presenting cell influx is most obvious in the acute early phase of the inflammation-like response 
to seminal fluid, in the cervix 12 h post coitus in human (Sharkey et al., 2012b) and 8-12 hours after 
mating in mice (Robertson et al., 1998, Robertson et al., 1996, Robertson et al., 1992). In the current 
study, the antigen presenting cell population and phenotype were examined on DPC 3.5, which may not 
be the optimal time points to quantify differences in antigen presenting cell population and phenotype. In 
addition, the M1 vs M2 polarisation of macrophages was not determined in the current study. It would 
be relevant to further investigate the impact of miR-223 deficiency on the inflammation-like response to 
seminal fluid induction at 12-24 hours after coitus, and also to examine markers of M1 and M2 
polarisation.   
Despite all of the changes in the immune cells around peri-conception period, altered T cell immunity in 
miR-223 deficient mice does not overly affect tolerance of fetal alloantigen, as miR-223 deficient female 
mice mated to Balb/c males are capable of maintaining pregnancy with generally comparable outcomes 
to WT control mice. However, the importance of miR-223 becomes apparent when pregnant miR-223-/- 
female mice are administrated low dose LPS to induce a systemic inflammatory response on DPC 9.5 in 
mid-gestation. When miR-223-/- female mice are challenged with inflammatory stimuli, they have a 
reduced capacity to sustain pregnancy with a 51.3% in resorption rate, compared to WT mice in which 
pregnancy was not impacted by the same LPS dose.  
miR-223 is known to promote M2 polarisation of macrophages which is anti-inflammatory (Zhou et al., 
2015, Zhuang et al., 2012, Zhang et al., 2013), and macrophages and DCs in miR-223 deficient mice 
are highly pro-inflammatory (Zhou et al., 2015). Although we did not evaluate the macrophage response 
to LPS in this study, it can be assumed that LPS administration caused a similar pro-inflammatory 
activation. In part, this may be attributed to the insufficient Treg cell response, as Treg cells are 
important for suppressing and controlling inflammatory cytokine responses (Collison et al., 2009, 
Collison et al., 2007, Sakaguchi et al., 2009a, Liang et al., 2008). In miR-223 deficient mice challenged 
with LPS, the limited population of Treg cells may be insufficient to control the excessive inflammatory 
response induced by the LPS inflammatory insult.  
The placenta hypertrophy in miR-223 deficient mice challenged with LPS may be a consequence of 
fewer macrophages observed in the uterus and PALN. Macrophages are known to be an important 
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source of VEGF and other angiogenic factors (Yoshida et al., 1997) in a pattern that tightly regulated by 
oestrous cycle stage and early pregnancy (Ma et al., 2001). When an inflammatory insult occurs in  
mid-gestation, these dysregulated macrophages may have compromised capability to support the last 
phases of placental development. Taken together, these data suggest that miR-223 is essential in the 
protecting foetus from excessive inflammation via regulating Treg cell development and antigen 
presenting cell phenotype and function.     
Further functional studies are required to address the suppressive activity of Treg cells in the absence 
of miR-223 during gestation. In addition, the antigen presentation capability and phenotypes in antigen 
presenting cells and polarisation of macrophages in miR-223-/- mice has not yet been addressed. 
Assessment of the response to antigen or non-specific stimulation, and assay of suppressive function in 
Treg cells are required to address these questions, in order to better understand how Treg cell 
responses are impacted in the absence of miR-223. Furthermore, adoptive transfer of Treg cells from 
pregnant WT mice into miR-223 deficient females prior to inflammatory challenge could be performed to 
specifically investigate the protective role of Treg cells in the inflammation-induced fetal loss. It could be 
predicted that transfer of wild-type Treg cells from pregnant B6 donors would mitigate the elevated 
susceptibility to inflammatory challenge seen in miR223 null mutant mice. 
In summary, the current study reinforces the pivotal role of miR-223 in both innate and adaptive 
immunity. Both Treg cell and antigen presenting cell populations are impaired in the absence of  
miR-223, in particular diminished Treg cell population are found in PALN. While Treg cells generated in 
the absence of miR-223 are competent to sustain the semi-allogeneic fetus under steady-state 
conditions, the absence of miR-223 and its impact on the maternal immune environment may contribute 
to fetal loss under inflammatory conditions. This may be relevant to understanding the significance of 
microRNAs in influencing Treg cell generation and suppressive competence in women, and their role in 
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7.1 Introduction 
The peri-conception period, when the fertilised oocyte develops to the blastocyst stage and implantation 
commences, is a crucial phase in pregnancy. Disturbance in embryo development and/or uterine 
receptivity can cause infertility and impact fetal growth and placentation leading to pregnancy 
complications (Fowden et al., 2008), and is implicated as a key determinant in fetal programming of 
metabolic, immune and neurological issues in offspring (Hoet et al., 2000, Kwong et al., 2000, Sjoblom 
et al., 2005). Therefore, it is essential to determine factors that contribute to the regulation of the  
peri-conception environment, to address the causes of pregnancy complications. 
There are many environmental factors and exposures which influence conception to impact on 
implantation and placental formation, fetal growth and infant health. Factors that contribute include but 
are not limited to nutrition intake and obesity of the mother and father prior to conception (Fleming et al., 
2011), oocyte integrity and structure (Lane et al, Science 2015), epigenetic remodelling from fertilisation 
to implantation (Reik, 2007), changes to the sperm epigenome (Gannon et al., 2014, Yadav and Kotaja, 
2014) and other paternal factors present in seminal plasma, the non-sperm fraction of seminal fluid 
(Bromfield et al., 2014).  
Amongst the key local regulators of the maternal peri-conception environment are reproductive tract 
cytokines and immune cells. Appropriate regulation and adaption of the maternal immune environment 
is crucial to accommodate the semi-allogeneic fetus. The female tract microenvironment, local cytokine 
production and immune cells cooperate together and are tightly regulated to promote embryo 
implantation and developmental competence, to suppress inflammation and development of effector 
immunity to paternally-derived fetal antigens, as well to regulate the decidual response and vascular 
changes that support placentation (Schjenken and Robertson, 2014). Altered immune responses in the 
early pregnancy phase can impair placental development and change the trajectory of fetal growth, 
which explains why this early time is associated with pregnancy complications, such as preeclampsia, 
miscarriage and infertility (Guerin et al., 2009, Moldenhauer et al., 2017) 
In addition to maternal contributions, the male partner also contributes to the adaptation of the female 
tract environment during the peri-conception period through effects mediated by seminal fluid. Seminal 
fluid contains cytokines, chemokines and antigens specific to individual males, including minor 
antigens and major histocompatibility complex (MHC) in human (Hutter and Dohr, 1998). These 
signalling factors interact with epithelial cells lining the cervix and trigger an influx of leukocytes, 
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including macrophages and dendritic cells (DCs) to initiate a transient inflammatory response. In broad 
terms, similar responses to seminal fluid are seen in humans (Sharkey et al., 2012b), mice (Robertson 
et al., 1998, Robertson et al., 1996), and all mammalian species examined to date (Schjenken and 
Robertson, 2014).  
Antigens present within seminal fluid activate T cells response after being taken up, processed and 
presented by antigen presenting cells which are recruited to the endometrium following seminal fluid 
exposure (Robertson et al., 1996, McMaster et al., 1992). These antigen presenting cells mediate 
tolerogenic immune responses in the presence of prostaglandin E (PGE) and TGF-β, and capture 
paternal antigens before either emigrating from the uterus via the afferent lymphatics to activate T 
cells in the para-aortic lymph nodes (PALN) which drain the uterus, or interacting with resident T cells 
within tertiary lymphoid structures within the deep endometrium of the uterus (Robertson et al., 
2009b). The net result of seminal fluid exposure is to drive a paternal antigen-specific T cell response 
(Moldenhauer et al., 2009). Amongst the activated T cells, expansion of the Treg cell subset is 
observed in the PALN and also in the uterus in the peri-conception period in mice (Robertson et al., 
2009a, Guerin et al., 2011). In addition to mediating the transient inflammatory response required for 
T cell activation, these immune cells are also thought to be involved in tissue restructuring to promote 
the decidual response, facilitate uterine receptivity and prepare for implantation to support robust 
placental development (Plaks et al., 2008, Robertson, 2005).  
A key consequence of seminal fluid exposure is the expansion of Treg cells which are crucial in 
establishing and maintaining the appropriate immune environment. Maternal inflammation needs to be 
controlled appropriately to achieve optimal fetal outcomes. Treg cells are pivotal in the regulation of 
suppressing inflammation and mediating maternal immune tolerance at the maternal-fetal interface in 
pregnant females (Aluvihare et al., 2004). These cells become activated to proliferate and are increased 
significantly during the peri-conception period in the PALN and uterus (Aluvihare et al., 2004, Zhao et al., 
2007, Guerin et al., 2011). 
In addition, the timing and presence of Treg cells are both crucial in mediating pregnancy success. The 
Treg cell population plays a particularly important role in MHC disparate allogeneic pregnancies. In 
syngeneic pregnancies, 50% of T cell deficient mice remain pregnant after receiving Treg cell-depleted 
T cells on day 4 postcoitum (DPC) (Aluvihare et al., 2004), indicating a lesser requirement for Treg cells 
in maintaining syngeneic pregnancies where there is no MHC disparity between the fetuses and the 
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mother. However, adoptive transfer of Treg cell-depleted T cell population into T cell deficient mice 
carrying allogeneic fetuses fails to rescue pregnancy (Aluvihare et al., 2004) and causes almost 
complete infertility, indicating that Treg cell are essential to maintain the allogeneic pregnancy.  
The presence of a local Treg cell population in early pregnancy is crucial, as the transfer of Treg cells to 
abortion prone mice prior to, but not after implantation rescues pregnancy loss (Zenclussen et al., 2005). 
Adoptive transfer of T cells from normal pregnant mice into 0- to 2-day pregnant abortion-prone mice 
successfully rescues pregnancy, but Treg cell transfer on day 4 or 5 of pregnancy fails to prevent 
abortion, indicating that the presence of Treg cells in the peri-conception period is necessary for 
mediating the establishment of maternal immune tolerance for the genetically disparate fetuses.  
Given the important role that Treg cells play in pregnancy, it is important to investigate how Treg cells 
are normally regulated. While Treg cell number is the top limiting factor in achieving a robust and 
appropriate Treg cell response, other factors including their stability and suppressive function contribute 
to their capacity to regulate the maternal immune environment. Currently, factors that regulate the 
generation, stability and suppressive activity of Treg cells are not fully understood, limiting our capacity 
to understand the biological basis of pregnancy disorders, including preeclampsia and recurrent 
miscarriage, and to develop effective treatments for these conditions.  
In the present study, several factors postulated to play an important role in determining Treg cell 
expansion, stability and function were assessed in mice to better understand the regulation and role of 
Treg cells in the peri-conception period. In these studies, we demonstrated that IL10, miR-155 and  
miR-223 are all required to drive normal Treg cell expansion and stability. In each case, deficiency in 
these regulatory factors did not prevent pregnancy under steady state conditions, but caused elevated 
susceptibility to fetal loss following a mid-gestation inflammatory challenge. Furthermore, we 
demonstrate that while repeated exposure to MHC dissimilar alloantigens in male seminal fluid acts to 
further expand and strengthen the Treg cell response in early pregnancy, we were unable to 
demonstrate a major impact on susceptibility to inflammatory challenge in the model system evaluated 
herein.  
7.2 Treg cell expansion 
The requirement and importance of Treg cells during early pregnancy to maintain the semi-allogeneic 
fetus has been investigated in several studies (Aluvihare et al., 2004, Zenclussen et al., 2005). An 
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appropriate number of Treg cells are thought to be crucial to maintain pregnancy, as Treg cells are 
elevated in first and second trimester decidua and peripheral blood in humans (Heikkinen et al., 2004, 
Tilburgs et al., 2006, Xiong et al., 2013), and in the mouse uterus and PALN prior to embryo 
implantation on DPC 3.5 (Guerin et al., 2011, Robertson et al., 2009a). Experimental strategies that 
cause substantial reduction in the number of these Treg cells are inconsistent with normal implantation 
and progression of viable pregnancy (Aluvihare et al., 2004, Zenclussen et al., 2005, Shima et al., 2010). 
Consistent with numbers of Treg cells being a limiting factor in fertility, a diminished number of Treg 
cells is evident in women experiencing pregnancy complications such as preeclampsia and 
spontaneous miscarriage (Winger and Reed, 2011).  
Despite the fact that most studies on the role of seminal fluid in pregnancy are conducted in mice, a 
number of clinical observations highlight the contribution of seminal fluid exposure in human pregnancy. 
Interestingly, in these studies, pregnancy complications such as preeclampsia are associated with a 
shorter period of sexual cohabitation with the conceiving partner, a change in sexual partners or the use 
of barrier contraceptive methods while longer term exposure to a partner’s seminal fluid is linked with a 
reduction in the incidence of preeclampsia (Dekker et al., 1998, Einarsson et al., 2003, Kho et al., 2009, 
Klonoff-Cohen et al., 1989). In addition, a reduced Treg cell population in the peripheral blood (Prins et 
al., 2009, Santner-Nanan et al., 2009, Steinborn et al., 2008) is evident in clinical studies of 
preeclampsia. As detailed above, we and others have reported previously that seminal fluid contributes 
to the expansion of Treg cells in early pregnancy after a single mating (Robertson et al., 2009a, Guerin 
et al., 2011) and MHC dissimilar males more robustly expand the Treg cell pool (Tilburgs et al., 2009). 
In the current study, we used mouse models to examine the importance of regulatory factor operating at 
conception that alter Treg cell numbers and functional competence at implantation, including extent and 
nature of prior seminal fluid exposure, IL10, miR-155 and miR-223. 
Given that seminal fluid expands Treg cells in early pregnancy (Guerin et al., 2011, Robertson et al., 
2009a) and the association of Treg cells between preeclampsia, we postulated that repeated seminal 
fluid exposure leads to a stronger and more functionally competent Treg cell population in mice. To 
address this, we developed a mouse model to assess the impact on the Treg cell pool of repeated 
mating with allogeneic (MHC disparity) and syngeneic (identical MHC) males, or following partner 
switching at the most recent mating prior to conception. As expected based on previous studies, our 
results demonstrate that a single seminal fluid exposure commences a process of Treg cell expansion 
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evident in the PALN on DPC 3.5 (Figure 7.1). However, substantially greater expansion of the Treg 
cell population is seen if prior repeating mating to allogeneic males (Figure 7.1C). Notably, multiple 
matings with males of the same MHC haplotype resulted in a more robust Treg cell response (Figure 
7.1), as Treg cell numbers from females mated four times to allogeneic males were significantly higher 
than Treg cells from females mated four times to syngeneic males has occurred. Similarly females in 
partner-switching groups also did not exhibit the same extent of Treg cell expansion, even though there 
was a significant expansion in both this group and the group mated with syngeneic males, compared 
with oestrus controls. Given the importance of MHC disparate matings in expanding the Treg cell 
population, we postulate that the number of Treg cells expanded in syngeneic and partner switching 
models may be less capable of facilitating robust placental formation than in females with repeated 
exposure to the same MHC disparate males. These results highlight the crucial role of MHC disparity in 
the expansion of the Treg cell pool and start to provide an explanation of why women who have had 
shorter sexual cohabitation or a new conceiving partner have increased incidence of preeclampsia 
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Figure 7.1 Repeated seminal fluid exposure drives Treg cell expansion and stability in the PALN on  
DPC 3.5. At oestrus, a baseline level of Treg cells located in the PALN (A), after single seminal fluid exposure, a 
moderate expansion of Treg cells is observed (B). Treg cell numbers are further augmented following repeated 
exposure to male alloantigens (C), compared to mice exposed to male minor antigens or in the male switching 
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While paternal factors associated with seminal fluid exposure and signalling capacity therefore are 
important in contributing to the expansion of the Treg cell population in early pregnancy, there is also 
evidence that intrinsic female factors affect Treg cell expansion and immune suppressive function. In 
particular, a large number of recent studies have focused on small non-coding microRNAs (miRNAs) 
and their contribution to the regulation of immune cell development and function (Baltimore et al., 2008). 
miRNAs are involved in the regulation of multiple immune cells, including macrophages, granulocytes, 
natural killer (NK) cells as well as B cell and T cell development and function (Mehta and Baltimore, 
2016). The crucial role of miRNAs in immune function is highlighted by studies of mice with Dicer 
conditional mutation, where the T cell population is diminished in the thymus and periphery (Cobb et al., 
2006, Muljo et al., 2005) and compromised antibody-producing capacity in B cells is also observed 
(Koralov et al., 2008). The critical role of miRNAs in Treg cells is demonstrated in mice with a Dicer null 
mutation in CD4+ T cells, which exhibit failure in Treg cell differentiation and reduced Foxp3 expression 
(Cobb et al., 2006, Cobb et al., 2005). In addition, miRNAs are also specifically implicated in the 
regulation of immune tolerance and immune response to conception (Bidarimath et al., 2014, Mehta and 
Baltimore, 2016).  
There are numerous miRNAs associated with Treg cell function but one of the most well characterised 
miRNAs in Treg cells is miR-155, which is involved in development and function of DCs, macrophages, 
T cells and other immune cells. Within the Treg population, miR-155 deficiency results in a systemic 
decrease in Treg cell number but showed no impact on suppressive function (Lu et al., 2009a). As well 
as influencing antigen presenting capability in DCs (Rodriguez et al., 2007), miR-155 is also upregulated 
in M1 macrophages (pro-inflammatory) and promotes M1-polarisation in macrophages via suppressing 
suppressor of cytokine signalling 1 (Wang et al., 2010a). In addition, miR-155 over-expression is 
thought to contribute to preeclampsia via angiogenic regulating factor CYR61 (Zhang et al., 2010). 
Given these findings, we postulated that miR-155 may be a key miRNA involved in the regulation of the 
immune environment in early pregnancy.  
Our data clearly demonstrate an impact of miR-155 on the Treg cell population with a systemic 
reduction in Treg cell numbers observed in miR-155-/- mice both at oestrus and on DPC 3.5. This study 
is consistent with previous studies showing that miR-155 contributes to Treg cell proliferation and 
competitive fitness (Lu et al., 2009a), and miR-155 deficient mice have a systemic impairment in their 
Treg cell population (Cobb et al., 2006). Interestingly, the greatest reduction was observed on DPC 3.5 
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which is the peri-conception period. The current study has also addressed the functional consequence 
of Treg cell deficiency in the absence of miR-155, and showed that the limited Treg cell population in 
these mice as unable to sustain pregnancy when inflammatory challenge occurs in mid-gestation 
(discussed in section 7.4).  
Previous studies have demonstrated that miR-155 deficient mice exhibit reduced antigen presenting 
capability in DCs (Rodriguez et al., 2007, Dunand-Sauthier et al., 2014) and promotes the development 
of M1-like macrophages (Wang et al., 2010a). Given the link between Treg cell expansion and antigen 
presentation by antigen presenting cells, we assessed the impact of miR-155 deficiency on the antigen 
presenting cell population. In the current study, we demonstrate that in the absence of miR-155, a 
reduction in the number of DCs, activated DCs and also CD86+ DCs in the PALN on DPC 3.5 is 
observed. Previously, miR-155 has been identified to regulate the antigen presentation capability in DCs 
and  
miR-155 deficient DCs are less capable to activate T cells effectively (Rodriguez et al., 2007). There we 
conclude that miR-155 can indirectly regulate Treg cell responses in early pregnancy, through effects on 
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Figure 7.2 The impact of miR-155 deficiency on the female immune environment in the PALN during the 
peri-conception period. In wild-type miR-155+/+ mice, mating resulted in an elevation in the number of 
macrophages/DCs, activated macrophages/DCs as well as CD80/CD86+ macrophages/DCs in the PALN. An 
elevation of CD4+ T cells and Treg cells are also observed after mating in the PALN (A). In the absence of  
miR-155, a reduced CD4+ T cell and Treg cell population is evident in the PALN. Macrophages and DCs were 
reduced in number and developed a phenotype characterised by diminished expression of MHC II and  
co-stimulatory molecules (CD80/CD86) after mating. The reduced CD4+ and Treg cell population after mating 
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Similar to miR-155, miR-223 also contributes to regulation of immune responses. By targeting Pknox1, 
miR-223 is believed to contribute to M2 (anti-inflammatory) polarisation in macrophages (Zhuang et al., 
2012), and mice with a miR-223 null mutation exhibit M1-like macrophage phenotypes, including 
elevated pro-inflammatory cytokine IL-1β, IL-6 and tumour necrosis factor-α (Zhuang et al., 2012). 
Within the DC population, miR-223 deficiency results in an elevated population of DCs that have 
increased capacity to produce pro-inflammatory cytokines following stimulation by regulating C/EBPβ 
(Zhou et al., 2015). Little is known of miR-223 in the regulation of DC responses. In the current study, 
we explore the role of miR-223 in DC and macrophages and the impact on Treg cells in the  
peri-conception period.  
In these studies, miR-223 deficiency resulted in a reduced proportion of activated macrophages at 
oestrus and on DPC 3.5 in the uterus, and reduced number of macrophages, activated macrophages, 
and CD80+/CD86+ macrophages on DPC 3.5 in the PALN as well as reduced number of DC and 
activated DCs in the PALN on DPC 3.5, indicating that miR-223 deficiency leads to an aberrant antigen 
presenting cell response when antigens are present in the inflammation-like response to seminal fluid. 
In addition, these reductions are not seen in other distal lymph organs at oestrus or on DPC 3.5, 
indicating that miR-223 deficiency impacts the local response to seminal fluid which is specific to the 
reproductive tract setting.  
These data suggest that the reduced Treg cell population may be the consequence of an alteration in 
the capacity of DCs to respond to paternal antigens. Changes in the macrophage population may 
impact tissue remodelling and preparation of the uterus for fetal implantation, but any changes have 
minimal impact as normal implantation was observed (Das et al., 1997, Feng et al., 1998). Notably, in 
the absence of miR-223, the reduced proportion and number of macrophages and activated 
macrophages in the uterus and PALN was associated with reduced competence in miR-223-/- females 
to respond to male alloantigens (Figure 7.2). Intestinal macrophages and DCs appear to exhibit more 
pro-inflammatory phenotypes in the miR-223 deficient mice (Zhou et al., 2015), therefore it is consistent 
that macrophages and DCs presented in the uterus and PALN also exhibit a pro-inflammatory 
phenotype. However, tolerogenic phenotypes in DC and M2-like macrophages are more desirable in 
early pregnancy, as seminal fluid enhances DC differentiation into a tolerogenic phenotype in the uterus 
and PALN (Remes Lenicov et al., 2012), and M2-like macrophages are known to be anti-inflammatory.  
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Interestingly, miR-223 is highly enriched in the CD4+ T cell to Treg cell transition but there are few 
studies which have examined the function of this miRNA in Treg cells. Interestingly, one study has 
demonstrated that increased miR-223 correlates with reduced Treg cells in maternal blood in smoking 
women (Herberth et al., 2014) and another study has suggested that the altered macrophage population 
observed in miR-223 -/- mice can impact the Treg cell population (Zhou et al., 2015). miR-223 has been 
identified as a biomarker that can be utilised to predict adverse pregnancy outcomes including 
preeclampsia and miscarriage (Winger et al., 2015). Therefore, we postulated that miR-223 may impact 
the Treg cell population in pregnancy. 
This study is the first to address whether miR-223 is required in the Treg cell expansion in the early 
gestation period. In the current study, we demonstrated that miR-223 can profoundly impact the Treg 
cell population in the PALN on DPC 3.5, and the data indicated that a greater local impact was induced 
compared with other peripheral lymph nodes. This result is consistent with the literature that miR-223 is 
highly expressed in Treg cells (Cobb et al., 2006). Insufficient numbers of Treg cells are associated with 
preeclampsia, recurrent miscarriage and other immune-based pregnancy complications (Nakabayashi 
et al., 2016, Prins et al., 2009), therefore miR-223 deficient may be a contributing factor in impaired 
pregnancy outcomes. It is notable that the Treg cell numbers are not changed at oestrus, indicating that 
miR-223 deficiency does not impact on the baseline Treg cell population. However, when Treg cells 
should be stimulated by the presentation of male alloantigens after mating, the proliferation of Treg cells 




ZHANG                                                        Chapter 7                                                           156 
 
 
Figure 7.3 The impact of miR-223 deficiency on the female immune environment in the PALN during the 
peri-conception period. In wild-type miR-223+/+ mice, mating resulted in an elevation in the number of 
macrophages/DCs, activated macrophages/DCs as well as CD80/CD86+ macrophages/DCs in the PALN. An 
elevation of CD4+ T cells and Treg cells are also observed after mating in the PALN (A). In the absence of  
miR-223, a reduced Treg cell population is evident in the PALN. Macrophages are reduced in number and 
developed a phenotype characterised by diminished expression of MHC II and co-stimulatory molecules 
(CD80/CD86) after mating. The reduced Treg cell population after mating may be the consequence of altered 
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7.3 Treg cell stability 
In addition to Treg cell number, the functional phenotype of Treg cells is also critical for maintaining 
immune tolerance, however there are few studies that have addressed the stability of Treg cells in 
pregnancy. In recent years, several studies have emerged to highlight that T-cell subsets are not as 
stable as previously assumed and under certain conditions, Treg cells can exhibit plasticity and convert 
into effector T-cell subtypes (Gao et al., 2012, Zhou et al., 2009). In particular, a pro-inflammatory 
environment can cause Treg cells to lose Foxp3 expression and convert to IL-17 producing or Th17 
cells (Osorio et al., 2008, Yang et al., 2008). Treg cells can also switch to a Th17 phenotype following 
co-culture with DCs activated by the fungal recognition receptor, dectin-1 (Osorio et al., 2008). In 
addition, TGF-β producing thymic derived Treg cells can induce CD4+CD24- T cells to differentiate into 
Th17 cells in the presence of IL-6 in vitro (Xu et al., 2007).  
Clinically, evidence of possible Treg cell instability has been linked with pregnancy complications. In 
women with preeclampsia, the Treg cell population in peripheral blood is reported to be even lower than 
non-pregnant women, and these cells have a shift towards IL-17 expressing phenotypes  
(Santner-Nanan et al., 2009, Tian et al., 2016). Given the plasticity between Treg cells and Th17 cells, 
studies are required to explore factors controlling Treg cell stability and their importance in supporting 
pregnancy success.  
To understand factors influencing the stability of Treg cells in pregnancy, we initially examined the 
impact of seminal fluid exposure following mating in the multiple mating mouse model. While Treg 
stability was not changed after repeated exposure to allogeneic males, multiple mating with syngeneic 
males led to a decrease in the stability of Treg cells as evidenced by increased IL17 production within 
the Treg cell population following polyclonal activation. These results are consistent with evidence that 
MHC disparity between partners leads to better pregnancy outcomes and raise the question of whether 
poor pregnancy outcomes in MHC similar partners (Ober et al., 1998) is in part due to Treg cell 
instability as well as a reduced Treg cell population. 
Intrinsic female factors are also linked with Treg cell stability. One such factor, IL10 is known to 
stimulate and reinforce modifications to the innate and adaptive immune system, including induction of 
regulatory phenotypes in the dendritic cell (DC), macrophage and T lymphocyte compartments 
(Fiorentino et al., 1991a, Fiorentino et al., 1991b, Maynard and Weaver, 2008). We have recently 
demonstrated that while IL10 deficient mice have increased proportions of Treg cells throughout early 
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and mid-pregnancy, these Treg cells are highly unstable after PMA/ionomycin stimulation (Prins et al., 
2015), explaining why these mice have increased vulnerability to inflammatory insults in pregnancy and 
fetal loss (Murphy et al., 2005, Robertson et al., 2006, Robertson et al., 2007, Thaxton et al., 2009, 
Prins et al., 2015).  
In an attempt to understand the impact of IL10 deficiency on the Treg population, we examined the Treg 
transcriptome in the presence or absence of IL10. Interestingly, while IL10 deficiency leads to an 
elevation of Treg cell numbers throughout early and mid-gestation in the PALN in mice (Prins et al., 
2015), the Affymetrix microarray analysis demonstrated that IL10 deficiency altered the gene expression 
profile in Treg cells isolated from the PALN in mid-gestation. Amongst the genes differentially regulated,  
cathepsin E (Ctse) is a key factor contributing to Treg cell suppressive function independently of IL10. 
The upregulation of Ctse observed may reflect a compensatory effect to help sustain pregnancy, 
consistent with effects observed in IL10/IL35 double deficient mice where elevated Ctse rescues Treg 
cell suppressive activity (Pillai et al., 2011).  
In addition to Ctse, upregulation of Ifng and a trend towards elevation in Il17 expression may contribute 
to the instability of Treg cells in IL10-/- females observed after inflammatory stimulation (Prins et al., 
2015). Cytokine receptors Il1r1 and Il12rb2 as well as T cell marker Ctla2 were also elevated. IL12rb2 is 
required for TGFB-dependent stimulation of Treg cell development, and signalling via this receptor is 
thought to regulate the number and functional maturity of Treg cells (Zhao et al., 2008). These 
dysregulated pro-inflammatory genes in Treg cells in the absence of IL10 may contribute to the 




Figure 7.4. Il10 null mutation alters the transcriptome in Treg cells, with an elevation in Ctse and other  
pro-inflammatory genes. In Il10+/+ mice, the expression of Ctse and the other pro-inflammatory genes are  
well-regulated in the Treg cell population (A). In the absence of IL10, an elevation of Treg cell population is 
evident in the PALN, with upregulated expression of Ctse and other pro-inflammatory genes (B).  
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7.4 The impact of altered Treg cells on pregnancy outcomes 
Clinical studies have revealed that an altered immune environment impacts pregnancy quality. It has 
been demonstrated that shorter duration of sexual cohabitation is associated with elevated risk of 
pregnancy pathologies including preeclampsia and a small-for–gestational age fetus (Kho et al., 2009). 
In addition, women who have a new conceiving partner are more likely to develop preeclampsia 
(Klonoff-Cohen et al., 1989, Einarsson et al., 2003) suggesting that the protective effects following 
longer periods of cohabitation are partner specific. The serum IL10 level is diminished in women with 
preeclampsia, compared to normal pregnancy (Hennessy et al., 1999), and in mouse models, IL10 
deficiency resulted in pre-term labour when mice were challenged with LPS (Robertson et al., 2006). 
miR-155 and miR-223 are identified as markers to predict adverse pregnancy outcomes (Winger et al., 
2015). We postulated that the compromised immunological environment in the mouse models used in 
this study are likely to have impaired pregnancy quality. This was confirmed by elevated susceptibility to 
fetal loss after challenge with LPS, which is a model for the elevated inflammatory insult of preeclampsia.  
Previous studies have demonstrated that following LPS challenge in mid-gestation, Il10 null mutation 
results in an elevated rate of fetal loss in syngeneic pregnancies (Robertson et al., 2007). In the current 
study, we have expanded the knowledge that IL10 in the maternal compartment is crucial in protecting 
allogeneically pregnant mice from excess inflammatory damage in mid-gestation. It is notable that the 
maternal compartment is not entirely IL10 deficient as the fetuses were heterozygous for the IL10 gene. 
Maternal IL10 deficiency does not impact the capacity to sustain pregnancy in steady-state conditions, 
as PBS injection does not cause fetal loss. The requirement of IL10 is more apparent when pregnant 
IL10 deficient females were challenged with low dose LPS, which results in fetal loss, indicating that 
IL10 has a key function in protecting fetuses from an excess inflammatory response (Murphy et al., 
2005, Robertson et al., 2006, Robertson et al., 2007).  
Similar to the IL10 mouse model, male alloantigens or number of copulation times showed no effect on 
fetal outcomes in steady-state, indicating that the number and stability of Treg cells, and whether Treg 
cells are induced by allogeneic mating or syngeneic mating does not impact on pregnancy competence. 
However, the number and stability of Treg cells become apparent as a limiting factor when pregnant 
females were challenged with a low dose of LPS. In particular there was a difference between females 
mated 4x to Balb/b and females mated 4x to Balb/c. Compared to females mated 4x to Balb/b, the 
further expanded Treg cell pool with more stabilised phenotype in females mated 4x to Balb/c, was 
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more likely to suppress the inflammatory challenge in mid-gestation. These data reinforce the 
importance of prior seminal fluid exposure in the induction of a sufficient Treg cell response prior to 
implantation, and also the critical role that robust Treg cells play in protecting the fetus from 
inflammatory insults.  
As there was a diminished Treg cell population and altered number and phenotype of DCs and 
macrophages observed in miR-155 deficient and miR-223 deficient mice, we also examined the effect of 
miR-155 and miR-223 deficiency on the pregnancy outcomes after an inflammatory challenge in  
mid-gestation in these strains. Like the IL10 deficient mouse model and repeated mating mouse model,  
miR-155 and miR-223 deficiency had no impact on the maternal immune tolerance towards the  
semi-allogeneic fetuses in an unchallenged context, as no significant changes in fetal loss were 
observed in steady-state. However, a low dose LPS challenge led to greater fetal loss and reduced fetal 
to placental weight ratio, highlighting the importance of miR-155 and miR-223 in limiting excess 
inflammatory responses via the control of antigen presenting cell and Treg cell function. This is the first 
study addressing the impact of miRNA deficiency in pregnancy outcomes and further highlights that a 
consequence of changes to the immune population in the peri-conception period can impact on later 
fetal outcomes in pregnancy.  
7.5 Clinical implications 
Given that there is close similarity between mice and human in many immune regulatory factors, these 
findings are relevant to understanding which regulatory factors targeting Treg cells may be important in 
establishing maternal immune tolerance. Further studies are required to determine the extent to which 
repeated seminal fluid contact, IL10, and miRNAs are important in regulating the Treg cell response, 
including population expansion and phenotypic stability, in women. Defining the roles of these and other 
regulatory factors is likely to ultimately contribute to elucidating the pathology of preeclampsia and 
related complications of human pregnancy, where a less robust Treg cell response (Santner-Nanan et 
al., 2009) and altered regulation of placental IL10 (Hennessy et al., 1999) are both implicated in the 
underlying inflammatory aetiology.  
Prior seminal fluid exposure contributes to Treg cell expansion, and this study is the first to demonstrate 
that the benefit from prior seminal fluid exposure requires both sperm and seminal plasma and is  
partner-specific, which can explain the clinical observation that women with a new conceiving partner 
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have a higher incidence of preeclampsia (Dekker et al., 1998), and why pregnancies conceived with 
donor eggs or sperm where no prior antigen priming has occurred, also have a higher risk of 
preeclampsia (Salha et al., 1999). Additionally, since miR-155 and miR-223 are involved in the 
regulation of human Treg cell expansion, and DC and macrophage expansion and maturation, our 
findings provide an explanation for how dysregulation in these miRNAs may contribute to pregnancy 
pathologies in women, including implantation failure, preeclampsia, recurrent miscarriage (Bidarimath et 
al., 2014). 
7.6 Conclusion 
The microenvironment and immune cells present in the peri-implantation period are crucial to successful 
pregnancy. The current study has identified events and regulators that play an important role in 
controlling this immune environment. IL10, male alloantigens, miR-155 and miR-223 are all critical 
factors in the generation of a robust Treg cell response, influencing antigen presentation, cell 
proliferation to drive population expansion, and imparting stability – all of which are crucial in the 
success of pregnancy. Further studies will expand on these findings and examine the function of these 
immune cell populations in the presence and absence of these factors. These findings provide evidence 
to demonstrate a key role for IL10, repeated seminal fluid exposure, miR-155 and miR-223 in the 
immune responses at peri-conception period. If similar roles are identified in women, this could 
eventually contribute to addressing the underlying reasons for why preeclampsia and other  
immune-related complications originate, and these regulators might even prove to be useful targets for 
improving the Treg cell response to protect women from these prevalent conditions.  
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8.1 Chapter 4 
8.1.1 Treg cell expansion and stability in the mouse mLN, spleen and peripheral blood 
 
 
Figure 8.1 The effect of repeated exposure to male alloantigens on the number of Treg cells and stability 
of Foxp3 expression in CD4+ T cells in the mLN. B6 females were left unmated, mated 1x with Balb/c, 4x with 
Balb/c, 1x with Balb/b, 4x with Balb/b or 3x with Balb/b and 1x with Balb/c, and on DPC 3.5, mLN was analysed 
by flow cytometry for Treg cell parameters. Data presented as mean ± SEM and are the total cell number of 
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CD4+CD25+ Foxp3+Treg cells in the mLN (A), the expression of Foxp3 immediately after cell collection or 4h 
after strong polyclonal PMA/ionomycin stimulation in vitro (B), the expression of IL17A immediately after cell 
collection or 4h after strong polyclonal PMA/ionomycin stimulation in vitro (C), and the ratio of CD4+IL17+ to 
CD4+CD25+Foxp3+ cells from mLN after stimulation (D). The effect of PMA stimulation was evaluated using a 
paired T test in B and C, and the effect of mating was evaluated using Kruskall-Wallis and Mann-Whitney test in A 
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Figure 8.2 The effect of repeated exposure to male alloantigens on the number of Treg cells and stability 
of Foxp3 expression in CD4+ T cells in the spleen. B6 females were left unmated, mated 1x with Balb/c, 4x 
with Balb/c, 1x with Balb/b, 4x with Balb/b or 3x with Balb/b and 1x with Balb/c, and on DPC 3.5, spleen was 
analysed by flow cytometry for Treg cell parameters. Data are presented as the mean ± SEM are the total cell 
number of CD4+CD25+ Foxp3+Treg cells in the spleen (A), the expression of Foxp3 immediately after cell 
collection or 4h after strong polyclonal PMA/ionomycin stimulation in vitro (B), the expression of IL17A 
immediately after cell collection or 4h after strong polyclonal PMA/ionomycin stimulation in vitro (C), and the ratio 
of CD4+IL17+ to CD4+CD25+Foxp3+ cells from spleen after stimulation (D). Data are the mean ± SEM from 
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unmated or mated B6 mice. The effect of PMA stimulation was evaluated using a paired T test in B and C, and 
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Figure 8.3 The effect of repeated exposure to male alloantigens on the number of Treg cells and stability 
of Foxp3 expression in CD4+ T cells in the peripheral blood. B6 females were left unmated, mated 1x with 
Balb/c, 4x with Balb/c, 1x with Balb/b, 4x with Balb/b or 3x with Balb/b and 1x with Balb/c, and on DPC 3.5, 
peripheral blood was analysed by flow cytometry for Treg cell parameters. Data presented as mean ± SEM and 
are the total cell number of CD4+CD25+ Foxp3+Treg cells in the peripheral blood (A), the expression of Foxp3 
immediately after cell collection or 4h after strong polyclonal PMA/ionomycin stimulation in vitro (B), the 
expression of IL17A immediately after cell collection or 4h after strong polyclonal PMA/ionomycin stimulation in 
vitro (C), and the ratio of CD4+IL17+ to CD4+CD25+Foxp3+ cells from peripheral blood after stimulation (D). 
 
ZHANG                                                        Chapter 8                                                           168 
Data are the mean ± SEM from unmated or mated B6 mice. The effect of PMA stimulation was evaluated using a 
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8.2 Chapter5 
8.2.1 T cell profile in distal lymph nodes and peripheral blood 
 
 
Figure.8.4 The effect of miR-155 deficiency on populations of T cells in the mLN. miR-155+/+ and  
miR-155-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the 
mLN were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. 
Data are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the 
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total number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of Treg cells (D), the total number of Treg 
cells x106 (E), and the MFI of Foxp3 (F). Differences between groups were evaluated using Kruskal-Wallis test 
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Figure 8.5 The effect of miR-155 deficiency on populations of T cells in the spleen. miR-155+/+ and  
miR-155-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the 
spleen were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. 
Data are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the 
total number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of Treg cells (D), the total number of Treg 
cells x106 (E), and the MFI of Foxp3 (F). Differences between groups were evaluated using Kruskal-Wallis test 
and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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Figure 8.6 The effect of miR-155 deficiency on populations of T cells in the peripheral blood. miR-
155+/+ and miR-155-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and 
Foxp3+ cells from the peripheral blood were analysed by flow cytometry to quantify T cells. Virgin oestrus mice 
were used as non-mated controls. Data are presented as mean ± SEM and are the percentage of CD4+ T cells 
within the CD3+ population (A), the total number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of 
Treg cells (D), the total number of Treg cells x106 (E), and the MFI of Foxp3 (F). Differences between groups 
were evaluated using Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
 
ZHANG                                                        Chapter 8                                                           173 




ZHANG                                                        Chapter 8                                                           174 
 
 
Figure 8.7 The effect of miR-155 deficiency on population of macrophages and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in the mLN. miR-155+/+ and miR-155-/- B6 mice were mated with 
Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the mLN were analysed by flow cytometry to quantify 
proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as 
non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ macrophages within 
viable cells (A), the total number of macrophages x 106 (B), the percentage of activated macrophages (MHCII+ 
macrophages) (C), the total number of activated macrophages x 106 (D), the percentage of CD80+ macrophages 
(E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ macrophages (G) and the total 
number of CD86+ macrophages x 106 (H). Differences between groups were evaluated using Kruskal-Wallis test 
and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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Figure 8.8 The effect of miR-155 deficiency on population of macrophages and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in the spleen. miR-155+/+ and miR-155-/- B6 mice were mated with 
Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the spleen were analysed by flow cytometry to quantify 
proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as  
non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ macrophages within 
viable cells (A), the total number of macrophages x 106 (B), the percentage of activated macrophages (MHCII+ 
macrophages) (C), the total number of activated macrophages x 106 (D), the percentage of CD80+ macrophages 
(E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ macrophages (G) and the total 
number of CD86+ macrophages x 106 (H). Differences between groups were evaluated using Kruskal-Wallis test 
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Figure 8.9 The effect of miR-155 deficiency on the population of DCs and expression of MHCII, CD80, and 
CD86 by CD11C+ DCs in the mLN. miR-155+/+ and miR-155-/- B6 mice were mated with Balb/c males, and on 
DPC 3.5, CD11C+ F4/80- cells from the mLN were analysed by flow cytometry to quantify proportion of DCs and 
the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total number of 
DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of MHCII+ DCs x 106 (D), the 
percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ DCs (G) and 
the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using Kruskal-Wallis test 
and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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Figure 8.10 The effect of miR-155 deficiency on the population of DCs and expression of MHCII, CD80, 
and CD86 by CD11C+ DCs in the spleen. miR-155+/+ and miR-155-/- B6 mice were mated with Balb/c males, 
and on DPC 3.5, CD11C+ F4/80- cells from the spleen were analysed by flow cytometry to quantify proportion of 
DCs and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. Data 
are presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total number 
of DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of MHCII+ DCs x 106 (D), 
the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ DCs (G) 
and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using Kruskal-Wallis 
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8.3 Chapter 6 
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Figure 8.11 The effect of miR-223 deficiency on T cell populations in the mLN. miR-223+/+ and miR-223-/- 
mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the mLN were 
analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the total 
number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of CD3+ CD4+ CD25+ Foxp3+Treg cells (D), 
the otal number of CD3+ CD4+ CD25+ Foxp3+ Treg cells x106 (E), and the MFI of Foxp3 (F). Differences 
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Figure 8.12 The effect of miR-223 deficiency on T cell populations in the spleen. miR-223+/+ and  
miR-223-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the 
spleen were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-mated controls. 
Data are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ population (A), the 
total number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of CD3+ CD4+ CD25+ Foxp3+Treg cells 
(D), the total number of CD3+ CD4+ CD25+ Foxp3+ Treg cells x106 (E), and the MFI of Foxp3 (F). Differences 
between groups were evaluated using Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05). 
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Figure 8.13 The effect of miR-223 deficiency on T cell populations in the peripheral blood. miR-223+/+ and 
miR-223-/- mice were mated with Balb/c males, and on DPC 3.5, CD3+, CD4+, CD25+ and Foxp3+ cells from the 
peripheral blood were analysed by flow cytometry to quantify T cells. Virgin oestrus mice were used as non-
mated controls. Data are presented as mean ± SEM and are the percentage of CD4+ T cells within the CD3+ 
population (A), the total number of CD4+ T cells x106 (B), the CD4 MFI (C), the percentage of CD3+ CD4+ 
CD25+ Foxp3+Treg cells (D), the total number of CD3+ CD4+ CD25+ Foxp3+ Treg cells x106 (E), and the MFI of 
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Foxp3 (F). Differences between groups were evaluated using Kruskal-Wallis test and Mann-Whitney U test. 
(a,b,c,d indicates p<0.05). 
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8.3.2 Macrophage profile in the distal lymph nodes
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Figure 8.14 The effect of miR-223 deficiency on the macrophage population and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in the mLN. miR-223+/+ and miR-223-/- B6 female mice were mated 
with Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the mLN were analysed by flow cytometry to 
quantify the proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were 
used as non-mated controls. Data are presented as mean ± SEM and are the percentage of F4/80+ 
macrophages within viable cells (A), the total number of macrophages x 106 (B), the percentage of activated 
macrophages (MHCII+ macrophages) (C), the total number of activated macrophages x 106 (D), the percentage 
of CD80+ macrophages (E), the total number of CD80+ macrophages x 106 (F), the percentage of CD86+ 
macrophages (G) and the total number of CD86+ macrophages x 106 (H). Differences between groups were 
evaluated using Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05) 
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Figure 8.15 The effect of miR-223 deficiency on the macrophage population and the expression of MHCII, 
CD80, and CD86 by F4/80+ macrophages in the spleen. miR-223+/+ and miR-223-/- B6 female mice were 
mated with Balb/c males, and on DPC 3.5, CD11B+ F4/80+ cells from the spleen were analysed by flow 
cytometry to quantify the proportion of macrophages and the expression of MHCII, CD80, and CD86. Virgin 
oestrus mice were used as non-mated controls. Data are presented as mean ± SEM and are the percentage of 
F4/80+ macrophages within viable cells (A), the total number of macrophages x 106 (B), the percentage of 
activated macrophages (MHCII+ macrophages) (C), the total number of activated macrophages x 106 (D), the 
percentage of CD80+ macrophages (E), the total number of CD80+ macrophages x 106 (F), the percentage of 
CD86+ macrophages (G) and the total number of CD86+ macrophages x 106 (H). Differences between groups 
were evaluated using Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05) 
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8.3.3 Dendritic cell profile in distal lymph nodes
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Figure 8.16 The effect of miR-223 deficiency on the DC population and expression of MHCII, CD80, and 
CD86 by CD11C+ DCs in the mLN. miR-223+/+ and miR-223-/- B6 female mice were mated with Balb/c males, 
and on DPC 3.5, CD11C+ F4/80- cells from the mLN were analysed by flow cytometry to quantify the proportion 
of DC and the expression of MHCII, CD80, and CD86. Virgin oestrus mice were used as non-mated controls. 
Data are presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total 
number of DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated DCs x 
106 (D), the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ 
DCs (G) and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using 
Kruskal-Wallis test and Mann-Whitney U test. (a,b,c,d indicates p<0.05) 
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Figure 8.17 The effect of miR-223 deficiency on DC population and expression of MHCII, CD80, and CD86 
by CD11C+ DCs in the spleen. miR-223+/+ and miR-223-/- B6 mice were mated with Balb/c males, and on DPC 
3.5, CD11C+ F4/80- cells from the spleen were analysed by flow cytometry to quantify proportion of DCs and the 
expression of MHCII, CD80, and CD86. Unmated virgin oestrus mice were used as non-mated controls. Data are 
presented as mean ± SEM and are the percentage of CD11C+ DCs within viable cells (A), the total number of  
DCs x 106 (B), the percentage of activated DCs (MHCII+ DCs) (C), the total number of activated DCs x 106 (D), 
the percentage of CD80+ DCs (E), the total number of CD80+ DCs x 106 (F), the percentage of CD86+ DCs (G) 
and the total number of CD86+ DCs x 106 (H). Differences between groups were evaluated using Kruskal-Wallis 
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